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THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND 
ENHANCING RESPONSE TO TARGETED EGFR THERAPY 
The introduction of tyrosine kinase inhibitors (TKI) targeting the epidermal growth 
factor receptor (EGFR) inhibitors to the clinic has resulted in an improvement in the 
treatment of non small cell lung cancer (NSCLC).  However, many patients treated with 
EGFR TKIs do not respond to therapy.  The burden of failed treatment is largely placed 
on the healthcare field, limiting the effectiveness of EGFR TKIs.  Furthermore, 
responses are hindered by the emergence of resistance.  Thus, two questions must be 
addressed to achieve maximum benefit of EGFR inhibitors: How can patients who will 
benefit from EGFR TKIs be selected a priori? How can patients who respond achieve 
maximal benefit?  To answer these questions, two hypotheses were formed.  First, the 
EGFR-dependent phenotype, which is displayed by the tumors cells of those patients 
who respond clinically to EGFR TKIs, can be captured by genomic profiling of NSCLC 
cell lines stratified by sensitivity to EGFR TKIs.  This gene signature may be used to 
predict the outcome of EGFR TKI therapy in unknown samples.  Secondly, the predictive 
signature of response to EGFR TKI could provide insights into the underlying biology of 
the phenotype of EGFR-dependency. This information could be exploited to identify 
inhibitors which could be combined with EGFR inhibitors to elicit a greater effect, thereby 
minimizing resistance.  The work herein describes the testing of these hypotheses.   
Pharmacogenomics was utilized to define a signature of EGFR-dependency which 
effectively predicted response to EGFR TKI in vitro and in vivo.  Furthermore, the 
signature was analyzed by bioinformatic approaches to identify the RAS/MAPK pathway 
as a candidate target in EGFR-dependent NSCLC.   The RAS/MAPK pathway regulates 
expression and activation of EGF-like ligands.  Furthermore, the RAS/MAPK pathway 
modulates EGFR stability in the EGFR-dependent phenotype.   Further biochemical 
analyses demonstrated that the RAS/MAPK pathway mediates proliferation and survival 
of EGFR-dependent NSCLC cells.   Finally, combinatorial treatment of EGFR-dependent 
NSCLC cell lines with small molecules targeting EGFR and the RAS/MAPK pathway 
yielded cytotoxic synergy.  Thus, we have used pharmacogenomics methods to 
potentially improve NSCLC treatment by developing a method of predicting response 
and identifying an additional target to combine with EGFR TKIs to maximize responses. 
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CHAPTER 1  
A. LUNG CANCER OVERVIEW 
Cancer overview 
Cancer is the end-product of a series of genetic and epigenetic events within the 
cell and its environment that culminate in uncontrolled proliferation, survival, and 
eventually, malignant invasion into surrounding tissue.  Commonalities among all 
cancers are the loss of expression or functionality of tumor suppressors (genes involved 
in negatively regulating proliferation and survival), as well as the gain of function of 
oncogenes.  Tumor suppressors include genes which regulate apoptosis, such as p53, 
and those that control critical cell cycle checkpoints, such as retinoblastoma-1 (RB1), 
among others.  Similarly, gain-of-function mutations in or increased expression of proto-
oncogenes, such as the small GTPase RAS, also contribute to the formation of 
malignancy (1).  Activated oncogenes such as RAS promote survival or drive cell 
proliferation by establishing self-sufficiency of growth signals.  With few exceptions, 
multiple genetic and epigenetic events are required to fully transform normal into 
neoplastic tissue.  However, it is likely that acquiring early lesions increases the 
probability of developing cancer by fostering an environment for additional cancer-
promoting events.  For instance, autosomal aberrations in BRCA1, a DNA repair 
enzyme, reduce the ability of the cell to correct errors in DNA replication, greatly 
increasing the likelihood of further mutations (2). Thus, those patients inheriting one or 
more of such genetic lesions are often diagnosed with cancer at a relatively early age.  
As cancer progresses, tumor cells gain the ability to survive independently of the 
stroma.  As a result, neoplastic cells enter the circulatory system and metastasize to 
distant tissues (1).  Multiple organ involvement and ultimate failure is a hallmark of late-
stage disease, typically resulting in death.  Traditional treatments for cancer include 
resection of the malignant tissue, radiotherapy, and systemic chemotherapy.  
Importantly, resection is typically a useful approach in localized disease only.  Thus, 
early detection is critical in cancer, as surgical resection is the only treatment modality 
which is considered potentially curative (3).  Unfortunately, many aggressive cancers, 
including those of the lung, are characterized by a late stage of presentation resulting in 
high mortality rates (4).  
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Lung cancer epidemiology and etiology 
Cancers of the lung and bronchus pose a major health issue in the United States 
as well as in other developed nations.  Since the early 20th century, a rise in 
industrialization and smoking has significantly increased the prevalence of lung cancer 
(5).  Pulmonary cancer ranks first among all cancers in mortality, comprising over 28% of 
neoplastic-related deaths (4).  In 2008, over 215,000 new cases of lung cancer are 
expected to have occurred (4). A close correlation exists between incidence and 
mortality of lung cancer, reflecting the reality that approximately 80% of lung cancer 
patients ultimately die of their disease.  The Commonwealth of Kentucky reports one of 
the highest incidence rates of lung cancer of any state in the US, presumably due to high 
smoking rates and the local dependency on tobacco as an agricultural crop.  The 
predominant contributing factor to the development of lung malignancy is exposure to 
tobacco smoke.    Radon progeny, asbestos, arsenic, chloromethyl ethers and outdoor 
pollution are other exposure risks for the development of lung cancer (5).   
Lung cancer typically presents as one of several different histological subtypes.  
The broad categorization of lung carcinoma is typically stratified into small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC), which includes adeno-, 
bronchioalveolar, squamous cell, and large cell carcinomas.  Small cell and squamous 
cell carcinomas exhibit the strongest correlation to smoking.  Adenocarcinoma, which 
arises from glandular tissue, is the most commonly occurring lung cancer subtype (6).  
The heterogeneity of lung cancer coupled with the diversity and multitude of underlying 
genetic alterations results in a highly complex disease state.  Recent advances in our 
molecular and genetic knowledge of the disease have elucidated aspects of lung cancer 
biology that may be exploited through targeted biological and small molecule therapy.   
Lung cancer genetics 
Familial genetics plays a significant role in the development of lung cancer.  The 
majority of people who smoke never develop lung cancer suggesting that genetic risk 
factors may predispose certain smokers to disease (6). In support of this, after adjusting 
for age, smoke exposure, occupation, and gender, first-degree relatives of lung cancer 
patients have a two-fold risk of developing lung cancer (7).  On occasion, lung cancer 
can develop in nonsmokers at an early age, often fitting a Mendelian co-dominant 
inheritance model (8, 9).  Further evidence for the role of genetic predisposition for 
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development of lung cancer is found in homozygous and heterozygous carriers of 
inactivating mutations in tumor suppressor genes such as RB1 or p53 (10, 11).  
However, these genes are involved in the development of a variety of cancers, and a 
lung cancer-specific gene has not yet been conclusively identified (12). 
Aside from familial predisposition to the development of lung cancer, 
environmental factors such as tobacco smoke can facilitate the formation of a variety of 
genomic lesions directly resulting in pathogenesis (13).  Although lung cancer is a highly 
heterogeneous disease, many of the common genetic and epigenetic events that 
comprise the general pathological course have been elucidated.  Large scale genomic 
analyses demonstrate that a large number of somatic mutations are present in a typical 
lung tumor (14).  Additional events such as chromosomal aberrations and epigenetic 
alterations frequently coincide with mutations (15).  Constituents of tobacco smoke, such 
as polycyclic aromatic hydrocarbons, form DNA adducts which, when unrepaired, lead to 
apoptosis in normal cells.  However, if repair or apoptotic mechanisms fail, the mutations 
are retained in the genome (13).   Critical genetic lesions in p53, RB1, or RAS are 
present in a large number of lung cancers and correlate strongly with smoking (15).  
Their presence has been suggested to play a significant role in the initiation or 
progression of disease. A number of other genetic events have been shown to occur 
commonly in lung cancer and are reviewed elsewhere (15, 16). Among these are c-Kit 
mutations, amplification of MYC family members, and amplification of the pro-survival 
BCL2 protein.  Although clearly important in the pathogenesis of lung cancer, the 
specific roles of these genes are less well-studied than p53, RB, RAS and EGFR. 
The p53 transcription factor is one of the most frequently mutated genes in 
human cancers.  Wildtype p53 is a DNA-binding protein that is regulated through 
transcriptional, translational, and post-translational events, including degradation 
targeted by the MDM family of ubiquitin ligases (17).  Various stimuli, such as oncogenic 
signaling, hypoxic events, free radicals, and DNA damage activate wildtype p53 resulting 
in cell cycle inhibition at G1 and induction of apoptosis through both transcription-
dependent and transcription-independent mechanisms (18, 19).  Thus, p53 maintains a 
critical function in determining cell fate (i.e. repair or apoptosis)(19).  Loss of p53 
functionality promotes the progression of cancer by fostering an environment where 
additional lesions are more likely to occur.  As many as 90% of SCLCs and 50% of 
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NSCLCs harbor mutationally-inactivated p53, correlating to tobacco use (18).  Thus, loss 
of p53 activity is clearly an integral step in the development of lung cancer. 
Lung cancer is also commonly associated with aberrations in RB1.  Loss of RB1 
was one of the first tumor suppressor genes linked to the formation of lung cancer.  RB1 
regulates an imperative checkpoint in cell cycle progression and its inactivation by 
hyperphosphorylation and subsequent dissociation from E2F is required for E2F-
mediated S-phase entry (20, 21).  Inactivating mutations in RB1 or in other components 
of the RB pathway, such as P16INK4A, are present in almost all cases of lung malignancy 
(22).  Interestingly, mutations in RB1 or loss of heterozygosity at the RB1 locus is 
present in almost all small cell lung cancer cases, while inactivation of the upstream 
pathway component P16INK4A is more common in NSCLC (22).  Loss of RB pathway 
activity provides a means by which the tumor cell can avoid the regulatory constraints of 
cell cycle progression. 
Another important genetic event in the pathogenesis of lung cancer is mutation of 
the RAS oncogene.  The RAS family consists of three independently translated proteins: 
NRAS, KRAS, and HRAS. Under normal cell conditions, these proteins function as 
GTPases that are bound to GDP in their inactive state.  Activation by upstream 
mitogenic stimuli results in the formation of GTP-bound RAS.  Activated RAS binds 
downstream effector molecules and drives cell proliferation and survival.  GTPase 
activating proteins facilitate the hydrolysis of GTP to GDP, restoring RAS to its inactive 
form (23).  Of the three RAS family members, KRAS is most commonly studied in the 
context of lung cancer due to the frequency of observed aberrations.  Mutations in codon 
12 of exon 1 and codon 61 of exon 2 result in constitutive activation of KRAS and self-
sufficiency of growth signals, culminating in uncontrolled cell proliferation and survival.  
KRAS lesions are highly oncogenic, as demonstrated by the observation that 
introduction of the mutant protein is sufficient to transform fibroblasts (24).  Mutations in 
KRAS correlate with smoking status and occur in 40-50% of lung adenocarcinomas, but 
are relatively rare in other histological subtypes (25).   
A final gene receiving increasing scrutiny that is involved in lung cancer is the 
epidermal growth factor receptor (EGFR) oncogene, and is the focus of this body of 
work.  In the last decade, deregulation of EGFR through over expression, mutation, and 
various other mechanisms, has been shown to play a major role in a subset of NSCLC 
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tumors.  This population of tumors comprises only 10-20% of all lung cancer, but tumors 
harboring activated EGFR represent an important and intriguing phenotype to study.  
Patients harboring EGFR-deregulated lung tumors are often highly responsive to EGFR 
tyrosine kinase inhibitors.  Thus, our increasing understanding of both EGFR and the 
role of EGFR inhibitors in lung cancer represent a major breakthrough in therapy. 
Patients who respond to EGFR inhibitors tend to be non-smokers and have no overt 
etiological cause for disease.  Thus, it is unclear what the pathologic causes and 
consequences are in tumors harboring activated EGFR.  A thorough discussion of EGFR 
as it relates to lung cancer is presented below.    
B. THE BIOLOGY OF EGFR 
The epidermal growth factor receptor (EGFR/ErbB1/HER1) is a 170 kilodalton 
transmembrane receptor tyrosine kinase (RTK).  EGFR is one of four structurally related 
RTKs known as the ErbB family and consists of three primary domains: an extracellular 
ligand-binding domain, a lipophilic transmembrane domain and a cytoplasmic tyrosine 
kinase domain (26, 27).  EGFR exists as a monomer that homo- or hetero-dimerizes 
with other ErbB family members upon activation by extracellular ligands (FIG 1.1).  Thus, 
heterodimerization presents a mechanism by which co-activation of different 
combinations of ErbB family receptors can modulate a diverse array of cell signals.   
ErbB family members can be activated by many extracellular growth factor 
ligands.  The ligands responsible for the activation of EGFR include epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-α), amphiregulin (AREG), 
betacellulin (BTC), epiregulin (EREG), and heparin-binding epidermal growth factor (HB-
EGF) (28).  Several of these ligands, including TGF-α, AREG, and HB-EGF, are 
synthesized as inactive pro-ligands tethered to the cell membrane.  Processing of these 
ligands requires cleavage from the membrane by matrix metalloproteases (MMP) (29).  
Specifically, the ‘a disintegrin and metalloprotease’ (ADAM) family of MMPs is primarily 
responsible for this activity (30, 31).   Following the release of ligand from the 
membrane, ligand binding to EGFR induces a conformational change in the receptor that 
promotes dimerization.  Dimerization brings the cytoplasmic tails of the receptor 
monomers in proximity, resulting in autophosphorylation at tyrosine residues and 
activation of the kinase domain (26, 27).  These phosphorylated residues serve as 
docking sites for a variety of second messengers, such as PI3K, STAT3, PLCγ, SRC, 
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SHC, and GRB2, which in turn can be activated or facilitate the activation of other 
molecules via the kinase activity of EGFR.  The downstream effectors that can be 
activated by EGFR are diverse and are often cell type and/or context-specific.  The 
resulting series of transduced signals largely culminate in the nucleus, modulating gene 
expression and driving cell cycle progression (32). 
EGFR internalization and degradation 
EGFR is a regulator of cell cycle progression and is involved in normal epithelial 
cell renewal and remodeling (33).  Since control of cell cycle progression is a function 
that is frequently hijacked in the context of cancer, it is not surprising that EGFR 
signaling is a tightly regulated event.  EGFR signaling can be negatively regulated by the 
activity of phosphatases, transcriptional and translational control, and post-translational 
processing.  In addition to these regulatory events, degradation of the activated receptor 
is an important mechanism by which the cell can control the extent of signaling.   
Once EGFR has been activated by ligand binding, the receptor is internalized in 
the endosome and either recycled to the membrane or ubiquitinated and degraded 
through the proteosomal pathway (33).  Internalization is not required for receptor 
signaling, but is instead believed to be a mechanism by which the extent of signaling can 
be regulated (34).  Phosphorylation at tyrosine 1045 (Y1045) activates the docking site 
for the Cbl protein, which along with E2 ligase, binds and facilitates the mono- and/or 
poly-ubiquitination of EGFR.  Ubiquitinated EGFR is sorted to lysosomes where receptor 
degradation takes place (35).  Interestingly, some ligand-EGFR complexes, such as 
EGF-EGFR are more likely to result in receptor degradation than other ligand-EGFR 
complexes (36).  This has been suggested to be the result of a tighter binding efficiency 
of EGF in the acidic conditions of the endosome.  In contrast, TGF-α dissociates from 
the receptor at the endosomal pH, deactivating the receptor and reducing ubiquitination 
before lysosomal sorting can occur.  The dissociation and insufficient ubiquitination 
results in recycling of both the receptor and the ligand to the cell surface (36). Thus, 
differences in post-activation dynamics demonstrate one of the many diverse levels at 
which EGFR signaling and functionality can be modulated. 
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EGFR pathway activation 
The activation of EGFR results in downstream signaling through a number of 
pathways such as RAS/MAPK, AKT, and STAT.  Initial characterization of many of these 
pathways spawned a relatively naïve linear model for transduction of signals from the 
cell membrane to the nucleus (37).  However, advancement in knowledge of the 
complexity of these pathways has produced a much more elaborate ‘network’ model 
where many downstream pathways participate in significant ‘cross-talk’ among 
themselves (Figure 1.2) (38-40).  Additionally, many of these pathways can be activated 
by other receptor tyrosine kinases in response to a wide array of growth factors (38).  Of 
the complex network of downstream signaling modules that emanate from EGFR, 
several pathways have been studied extensively.   
The RAS/RAF/MEK/ERK (RAS/MAPK) pathway is a well-characterized signal 
transduction cascade activated by EGFR.  EGFR can activate the small GTPase KRAS 
through several known mediators, including GRB2, SHC, and SOS (41).  KRAS can also 
be activated through phosphorylation by other RTKs such as the insulin-like growth 
factor receptor (IGFR), MET, and the platelet-derived growth factor receptor (PDGFR) 
resulting in pathway cross-talk (38).  GTP-bound KRAS transduces signals through a 
chain of phosphorylation events activating each successive kinase in the chain (RAF-
MEK-ERK).  These signals are transmitted from the cell membrane to the nucleus, 
ultimately modulating gene transcription (42).  The ultimate kinase of the RAS/MAPK 
pathway, ERK, is translocated to the nucleus upon phosphorylation and activates 
transcription factors such as ETS and ELK (43). The genes regulated by RAS/MAPK 
activation, such as FOS, JUN, and MYC, drive cell proliferation and survival, two 
important oncogenic processes (44-46). Two components of this cascade, KRAS and 
BRAF, are oncogenes that are frequently mutated in a variety of cancers (47-57).   
Inhibitors of the RAS/MAPK pathway, specifically those targeting RAS, RAF, and MEK 
have been developed and tested clinically, but have yet to gain FDA approval.  Only the 
multi-targeted kinase inhibitor sorafenib, which targets RAF, has entered into clinical 
use. 
The second well-characterized pathway, phosphoinositol-3-kinase (PI3K)/AKT, 
also lies downstream of EGFR.  The PI3K/AKT pathway is of significant interest in the 
context of cancer due to its role in protein translation and inhibition of apoptosis.  
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Stimulation of RTKs such as EGFR can activate AKT via PI3K which in turn 
phosphorylates the BCL-2 family protein BAD, dissociating it from the BXL2/BCL2 
complex and inhibiting intrinsic pro-apoptotic mechanisms such as the release of 
cytochrome C from mitochondria and caspase activation (58, 59).  Importantly, AKT also 
feeds through the mammalian target of rapamycin (mTOR) pathway (60).  The mTOR 
pathway plays an integral role in regulation of protein translation, and is a validated 
target of the FDA-approved anti-cancer drug, temsirolimus, in renal cell carcinoma (61, 
62).   Currently, no small molecule AKT inhibitors have obtained FDA approval although 
one is currently navigating clinical trials and shows promise (63).  Several inhibitors are 
available for in vitro research, including wortmannin and LY294002, and these inhibitors 
demonstrate some activity in NSCLC cell lines (64). 
A third effector pathway that may play a role in EGFR-mediated oncogenicity is 
the signal transducers and activators of transcription (STAT) module.  STAT family 
members can be activated by direct EGFR-mediated phosphorylation or indirectly via 
SRC-mediated phosphorylation (65).  Upon EGFR or SRC activation, STAT is 
phosphorylated at Y701, Y705, or Y694 (STAT1, STAT3, or STAT5 respectively)(65).  
Phosphorylation induces homodimerization, which results in transport of STAT3 to the 
nucleus where it binds DNA, promoting or repressing gene transcription activity.  STATs, 
particularly STAT1, STAT3, and STAT5 have been extensively studied in cancer due to 
their role in regulating the expression of genes known to promote survival, cell 
proliferation, immune response, angiogenesis, and wound healing (66-68). STAT3/5 
target genes include cyclin D, VEGF, and BCL2 among others (68).   Interestingly, 
STAT1 has reduced expression in malignant tissue and transformed cells suggesting 
activity as a tumor suppressor, possibly through enhancement of p53 mediated 
apoptosis (69).   In contrast, STAT3 and STAT5 frequently transmit oncogenic signals 
and are potential therapeutic targets in lung cancer (68, 70-74).  However, no selective 
small molecule inhibitors of STAT3 or STAT5 have been extensively validated to date. 
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C. EGFR IN LUNG CANCER 
EGFR can be oncogenic by a variety of mechanisms in cancer, including 
mutations, over expression of EGFR, over expression of ligands, defective down-
regulatory mechanisms, and co-expression of other erbB family members (Figure 1.3).  
Somatic mutations in EGFR are frequently observed in solid tumors such as 
glioblastoma multiforme (GBM) and NSCLC.  The location and nature of EGFR 
mutations are diverse, but primarily occur in one of three regions of the receptor.  
Mutations in the extracellular and intracellular domains are common in GBM and result 
in truncated receptors, many of which display ligand-independent activation (75, 76).  
The most frequent of these mutations, EGFR variant III (EGFRvIII) has also been 
reported to occur sporadically in NSCLC (77).  EGFRvIII lacks extracellular amino acid 
residues 2-273, resulting from an in-frame deletion of exons 2-7 (78).   Although the 
EGFRvIII mutant has lost the ability to bind ligand, the receptor displays ligand-
independent activation of downstream pathways and impaired regulatory mechanisms, 
resulting in prolonged receptor activation (78, 79).  EGFRvIII mutations often coincide 
with EGFR gene amplification and have been estimated to occur in approximately 3% of 
NSCLCs, usually in squamous cell carcinomas (77). 
The most relevant EGFR mutations to NSCLC occur in the putative tyrosine 
kinase domain (exons 18-24) located in the cytoplasmic tail of the molecule (Figure 1.1).  
These mutations were only recently identified and occur in 10-20% of NSCLCs (80-88).  
Deletions in exon 19 (usually del746-750) and point mutations in exons 18 (G719A/C), 
20 (T790M), and 21 (L585R) result in increased and prolonged activation of the receptor 
(89-93).  Genes carrying these mutations, when ectopically expressed, are capable of 
transforming mouse fibroblasts. Additionally, lung-specific transgenic expression of 
EGFR del746-750 and L858R induce tumors in mice (90, 94).  Clinically, these 
mutations have been found in higher prevalence in adenocarcinomas and 
bronchioalveolar carcinomas, women, patients of Asian descent, and nonsmokers (87, 
95-97).  Interestingly, many NSCLC tumors that harbor these mutations in EGFR are 
uniquely responsive to EGFR-targeted small molecule inhibitors (83, 95).   In contrast, 
those tumors that contain the EGFR T790M mutation are resistant to EGFR inhibitor 
treatment (98-100).     
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EGFR (chromosome 7p12) can also be over expressed, usually the result of 
genomic amplification.  Increased EGFR copy number is found in the tumors of as many 
as 50% of lung cancer, GBM, and colorectal cancer patients (101-103).   Over-
expression of EGFR via genomic amplification leads to increased EGFR activation, likely 
due to spontaneous dimerization of the receptor at high density levels on the cell 
membrane (78, 104, 105).  Aside from genomic amplification, EGFR over-expression 
may be the result of increased promoter activity or decreased regulation of transcription 
or translational mechanisms (78).  
Activation of the EGFR receptor in the context of lung cancer can also result from 
increased expression and/or cleavage of ligands (106).  Ligand-dependent EGFR 
activation can result in a feed-forward autocrine loop, further inducing the expression 
and/or activation of ligands (107).  Increased ligand activity has been shown to promote 
oncogenesis in a number of models.  One of the most well studied EGFR ligands in 
cancer is TGF-α.  It has been known for more than a decade that transgenic mice 
(C57BL/6) engineered to over-express TGF-α develop a variety of hyper-, meta-, and 
neoplasias, demonstrating a possible role for TGF-α in the pathogenesis of cancer (108).  
The expression of EGFR ligands is required to achieve the oncogenic potential of 
wildtype-EGFR, as mouse fibroblasts over-expressing EGFR require TGF-α or EGF for 
transformation (109).  Tumors that have been engineered to ectopically express EGFR 
ligands such as TGF-α demonstrate a significant growth advantage suggesting that 
TGF- α expression may drive the growth of more aggressive tumors.  In one study, 
stable transfection of lung adenocarcinoma cells with TGF-α prior to orthotopic growth in 
nude mice produced lung tumors that were approximately 2-3 times the size of tumors 
grown from control lung adenocarcinoma cells (i.e. those not transfected with TGF-α  
(110). Other EGFR ligands, such as amphiregulin, promote additional oncogenic 
processes such as invasion and migration in normal and malignant mammary epithelial 
cells (111).   As such, the combinatorial effects of over expression of many ErbB1 
ligands could result in complex phenotypic interactions in cancer, promoting and 
maintaining oncogenic processes.  Thus, over-expression of EGFR ligands can play an 
important role in some cancers. 
Impairment in downregulatory mechanisms is yet another way that EGFR 
signaling can be deregulated in cancer.   Defective downregulation of EGFR has been 
observed in tumors cells that harbor activating mutations in the tyrosine kinase domain 
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of EGFR (93).  Cells harboring EGFR del746-750 or L858R demonstrate reduced 
ubiquitination in response to ligand binding, prolonging signaling (93).  Although it is 
presently unclear what the precise mechanism is for this impairment, it is hypothesized 
that mutant EGFR undergoes enhanced heterodimerization with ErbB2, thus blocking 
the Y1045 site required for interaction with Cbl, the enzyme responsible for mediating 
ubiquitination of EGFR (93).     
Finally, EGFR heterodimerization with other ErbB family members has been 
hypothesized to contribute to oncogenic properties of the tumor cell (78).  Receptor 
heterodimerization is an important aspect of ErbB family signaling in normal cells.  
ErbB2 has no known ligand while ErbB3 lacks a putative kinase domain underscoring 
the necessity of heterodimerization of these proteins to effectively transduce 
extracellular signals.  ErbB family members are over expressed in various cancer types 
resulting in aberrant oncogenic signaling (i.e. HER2/ErbB2 in breast cancer).  Because 
ErbB2 lacks a putative activating ligand and ErbB3 lacks a kinase domain, the 
importance of ErbB heterodimerization and crosstalk to convey oncogenic signals 
appears to be paramount (112). Of the various ErbB combinations that can be 
expressed in tumor cells, EGFR-ErbB3 heterodimerization has been suggested to play a 
primary role in driving NSCLC tumor cell growth and mediating resistance to EGFR-
targeted therapy (113, 114).  Due to the potentially large number of combinatorial over-
expression patterns of ErbB receptors in lung cancer, the role of receptor 
heterodimerization is not yet fully understood.  
EGFR oncogene addiction 
The term ‘oncogene-addiction’ originated from the finding that the tumor cells of 
greater than 90% of patients with chronic myelogenous leukemia (CML) harbor the 
t(9;22) translocation resulting in expression of the BCR-ABL fusion gene (115).  BCR-
ABL is a tyrosine kinase that is constitutively active in CML and drives cancer cell 
proliferation.  Inhibition of BCR-ABL function by treatment with the BCR-ABL inhibitor 
imatinib in CML patients results in rapid and sustained remission in an overwhelming 
proportion of patients, suggesting that BCR-ABL is essential for tumor proliferation (115).  
This finding contradicted the hypothesis that all cancers are highly heterogeneous and 
are the end product of deregulated redundant and compensatory oncogenic signaling 
pathways.    
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Similar to CML, in NSCLC tumors displaying amplified or mutated EGFR, cell 
proliferation and survival appear to be dependent on the EGFR pathway.  Cell culture 
models have demonstrated that cell lines harboring EGFR mutations undergo apoptosis 
when treated with EGFR-targeted agents or siRNA targeting the mutant receptors, much 
like that observed in CML patients treated with imatinib (83).  Furthermore, animal 
models have demonstrated that EGFR activating mutations can transform lung epithelial 
cells, resulting in the formation of tumors when injected into immune-compromised mice, 
and inhibition of EGFR using small molecules results in dramatic regression of the tumor 
(90).  Most importantly, large clinical studies have reported that a minority of patients 
(e.g. women, Asian, non-smoking, and/or adenocarcinoma histology) treated with small 
molecules targeting EGFR demonstrate massive tumor regression in cancers that were 
previously unresponsive to highly active chemotherapy (95).  This population frequently 
displays some or all of the clinical or molecular characteristics described with respect to 
EGFR activation.  Given that these neoplasms respond to inhibition of a single kinase in 
cases where broadly active chemotherapy was ineffective, it has been suggested that a 
subset of NSCLC are uniquely ‘EGFR-dependent’ in growth and survival characteristics 
(83, 95, 116, 117).    
EGFR as a Target for Cancer Therapy 
The finding that EGFR was activated through amplification or mutation in a 
variety of human cancers prompted the development of targeted EGFR therapeutics. 
Furthermore, preclinical models suggested that EGFR may mediate resistance to 
chemotherapeutic agents, thus targeting EGFR concomitantly with the administration of 
chemotherapeutic agents could improve benefit  (118).  The first anti-EGFR therapeutic 
to be approved was the EGFR tyrosine kinase inhibitor gefitinib (Iressa®, AstraZeneca) 
in May of 2003 (119).  Gefitinib was approved by the FDA for the treatment of refractory 
NSCLC as an accelerated-track drug based on tumor response rates in phase III trials.   
However, when survival data became available for the trial, gefitinib failed to show 
benefit and was subsequently placed on restricted-use status.  During this time, a 
second EGFR-TKI, erlotinib (Tarceva®, OSI Pharmaceuticals), completed Phase III 
trials.  In contrast to gefitinib, erlotinib showed a 2-month improvement in median 
survival compared to placebo when used as monotherapy in previously-treated NSCLC 
(120).  Based on these data, erlotinib was approved by the FDA in November of 2004 
(121).  Since its approval, erlotinib has also gained an indication for pancreatic cancer.   
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Erlotinib is an orally available quinazolinamine compound with the formula 
C22H23N3O4 •HCl and a molecular weight of 429.9.  Erlotinib is metabolized in the liver 
predominantly by CYP3A4, CYP3A5, and CYP2D6, but also by CYP1A2 (122).  It has 
also been hypothesized that metabolism by CYP3A4 in the intestine, CYP1A1 in the 
lung, and CYP1B1 in tumor tissue could play a role in the metabolic clearance of erlotinib 
(122).  Since smoking history appears to influence the efficacy of erlotinib in NSCLC, 
some reports have suggested that tobacco use may increase metabolic clearance of 
erlotinib via upregulation of CYP1A1 and CYP1B1, thus reducing drug exposure (123-
126). The most common clinical adverse drug reactions to erlotinib include rash, 
diarrhea, and rarely, interstitial lung disease or liver toxicity.  Interestingly, patients who 
develop a rash while on erlotinib have improved response rates, suggesting a 
pharmacokinetic component to the heterogeneous responses observed clinically (127, 
128).   
It is unclear why erlotinib appears to be more clinically efficacious than gefitinib in 
similar NSCLC populations.  The two compounds are structurally related and 
metabolized by many of the same enzymes (122).  Furthermore, both inhibitors appear 
to be particularly effective in subpopulations of NSCLC, such as those with EGFR 
mutations in exon 19 or 21 (87, 95, 129-132).  Cross-resistance between the inhibitors 
has also been observed (133).  One possible reason for the discrepancy in outcomes of 
the Phase III clinical trials is that erlotinib may achieve therapeutic concentrations for 
longer periods of time during administration due to its higher potency and less extensive 
metabolism by CYP3A than gefitinib (122).   
EGFR-tyrosine kinase inhibitors in NSCLC 
The EGFR TKI erlotinib has a unique role in the treatment of NSCLC.  Typically 
advanced-stage patients who have been treated with multiple courses of chemotherapy 
are unable to tolerate additional toxic multi-drug regimens.  Therefore, reduced-toxicity 
single agent treatments or supportive care are utilized in the second or third line setting.  
However, oral EGFR-TKI use, which demonstrated improved toxicity profiles in 
comparison with even single agent treatments, remains a useful option in the care of 
refractory patients.   Erlotinib has been shown in a number of independent trials to 
demonstrate improved quality of life, observable responses and modest but significantly 
improved survival (120, 134-138).   
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The treatment paradigm for use of erlotinib was affected by post-hoc analyses of 
the clinical characteristics of patients treated with EGFR TKIs which suggested that 
female gender, adenocarcinoma/bronchioalveolar carcinoma histology, and lack of 
smoking history were independent predictors of response to therapy (81, 132, 139).  
Furthermore, genetic analysis of the responding tumors identified the presence of novel 
EGFR tyrosine kinase domain mutations (L858R, del746-750 and other in-frame deletion 
mutations in this region) in the tumors of many of the responding patients (83, 87, 95).  
These mutations were subsequently found to result in constitutive activation of the 
receptor, and were proposed to be a positive predictor of EGFR-TKI response (83, 95).  
Both cell culture and mouse models of EGFR-mutated NSCLC reinforced this finding 
and suggested the presence of an oncogene-addicted phenotype in a subset of tumors 
(94, 140-142).  
EGFR monoclonal antibodies 
The second class of EGFR-targeted agents developed clinically was the IgG1 
chimeric monoclonal antibody cetuximab.  Monoclonal antibodies differ from small 
molecules in that they bind the extracellular domain of the target, and can elicit a wider 
array of cytotoxic effects, including inhibition of ligand binding, antibody-directed cell 
mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).  
Cetuximab was first approved by the FDA in February of 2004 for the treatment of 
colorectal cancer.  Since its approval, cetuximab has also gained indications for head 
and neck malignancies and and sought approval for use in NSCLC.  Although cetuximab 
has demonstrated efficacy in NSCLC, it has yet to enter routine clinical use, possibly 
because pivotal clinical studies were completed later than those of erlotinib, and 
cetuximab must be administered parentally versus erlotinib, which is administered orally. 
Cetuximab elicits anti-cancer effects through direct steric inhibition of the ligand binding 
domain, inhibiting downstream signaling.  Additionally, ADCC is proposed to play a role 
in cetuximab activity, although the contribution of CDC is unclear (143-145).  Thus, it is 
possible that cetuximab may have a different response profile than erlotinib in NSCLC. 
Resistance to EGFR inhibitors 
Resistance is a significant issue impairing the use of anti-EGFR therapies, 
particularly erlotinib, in NSCLC (99, 100, 146, 147).  Resistance to EGFR-targeted 
agents can be primary or secondary in nature.  Primary, or intrinsic, resistance to EGFR 
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inhibitors presents as rapidly progressing disease despite treatment and is seen in ~70% 
of patients treated with erlotinib. Secondary, or acquired, resistance to erlotinib typically 
appears in responding NSCLC patients within 12 months of initiation of therapy (99, 
148).  It is unclear whether secondary resistance to erlotinib arises from the selection of 
resistant tumor subclones that are present from treatment initiation, or whether it 
develops de novo in response to the offending agent.  Multiple lesions have been shown 
to contribute to resistance to EGFR inhibitors in NSCLC, including somatic KRAS 
mutations, the EGFR T790M escape mutation, and amplification of MET (98, 146, 147, 
149).    
Primary resistance to EGFR targeted therapy is likely the result of lack of tumor 
cell dependency on the EGFR signaling pathway.  Due to the genetically unstable nature 
of NSCLC, redundant pathways may be activated and are thus sufficient to maintain 
oncogenic signaling in the absence of EGFR activation (98, 113, 117, 150-154).  One 
important mechanism of intrinsic resistance to EGFR inhibitors is the presence of 
mutations in the KRAS oncogene (147, 155).  Mutations in KRAS, which occur primarily 
in exons 1 and 2 of the gene, are prevalent in a variety of cancers including lung, 
pancreatic, colorectal, lymphoma, and leukemia (48, 51, 52, 57).  In particular, KRAS 
mutations are a regular event in the pathologic progression of colorectal cancers in 
familial adenomatous polyposis (156). Activating mutations in KRAS correlate with more 
aggressive tumors and poorer prognosis in both lung and colorectal carcinomas (157-
161). More recently, the presence of KRAS mutations has been shown to be a strong 
negative predictor for response and benefit to anti-EGFR therapies in cancer patients 
(131, 147, 155).  Although this finding was originally documented in NSCLC treated with 
erlotinib, more substantial data has supported this finding in colorectal cancers treated 
with the anti-EGFR monoclonals panitumumab or cetuximab (155, 162-170).       
Acquired, or secondary resistance, is also a significant hurdle in the clinical use 
of EGFR inhibitors.  Uncovered in clinical trials of erlotinib in NSCLC, a common 
mechanism of acquired tumor resistance is the development of the T790M lesion in exon 
20 of EGFR.  Substitution of threonine for methionine at this residue results in an 
increase in catalytic activity of EGFR through an increase in the ATP binding affinity at 
the tyrosine domain (91, 100).  The presence of the T790M mutation was first noted to 
correlate with clinical resistance to erlotinib and gefitinib.  However, the exact 
mechanism by which this mutation inhibits activity of EGFR-TKI is unclear.  One 
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hypothesis suggests that steric inhibition of the drug binding site by the 
threonine/methionine substitution prohibits drug binding (171).  An alternative hypothesis 
suggests that, due to the ATP-competitive nature of erlotinib binding, the increase in the 
ATP binding affinity of the mutant shifts the equilibrium in favor of ATP-induced 
activation, despite the presence of drug (100).  Although T790M lesions are considered 
to be a secondary mechanism of resistance, detectable T790M mutations in the tumors 
of erlotinib-naive patients have been observed. The incidence of such findings is higher 
in studies that utilize detection methods with improved sensitivity, such as the 
SCORPION-ARMS method which incorporates real-time amplification of a mutation-
specific allele with a fluorescence-labeled hairpin primer (172-177).  These findings 
suggest that the lesion may be intrinsic to many EGFR-dependent tumors, although only 
in a small subpopulation of tumor cells (146, 178, 179).  Thus, treatment results in 
selection of the resistant clones. 
The distinct clinicopathologic and molecular characteristics of EGFR-dependent 
NSCLC suggest that there is a consistent underlying biology to the phenotype.  
However, single biomarkers such as mutation status and amplification (ie. either KRas or 
EGFR) and clinical characteristics such as gender, smoking status and histology are 
unable to adequately capture all patients harboring EGFR-dependent tumors.  Therefore 
it is conceivable that using tools that integrate many pieces of biological information, 
such as pharmacogenomics, may offer better opportunities for defining the EGFR-
dependent phenotype.    
D. PHARMACOGENOMICS IN CANCER THERAPY 
The advent of DNA microarray technology has enabled the high throughput 
analysis of gene expression data from nanogram quantities of RNA.  A single tumor may 
harbor many genetic abnormalities that contribute pathologically to the manifestation of 
the disease (1).  Single-gene or ‘candidate gene’ approaches, while useful scientifically, 
do not usually capture the true scope of clinical disease.  Thus, our growing 
understanding of the heterogeneity of cancer has lead to the hypothesis that integration 
of many pieces of biological information will yield improved insight into tumor biology.  
This insight could facilitate the development of better mechanisms for making objective 
treatment decisions and determining which patients will benefit most from particular 
therapies.  This global hypothesis is largely based on the seminal observation by Golub 
ADAPTED FROM: Balko et al, BMC Genomics (2006) 7:289 
 
20 
 
and colleagues that hierarchical clustering of microarray data from the cancer cells of 
leukemia patients can be used in an unsupervised manner to identify coordinated 
patterns in the expression of genes.  The individual clusters were shown to correspond 
to known clinical classifications of leukemias (i.e. acute lymphoblastic leukemia and 
acute myeloid leukemia) (180).   The resulting gene signature was then used to 
accurately predict the status of unknown leukemias.  This revelation opened the door to 
a number of scientific endeavors with the intention of using genomic data to diagnose, 
classify, prognose, and predict response to treatments and interventions.  
In addition to providing multivariate data which can be used for classification and 
predictive purposes, gene expression data allow for the functional characterization of a 
biological system using annotation of gene sets associated with a phenotype.  Routinely 
curated bioinformatics databases are widely available with which gene sets found to be 
altered or deregulated under specific experimental conditions can be explored.  These 
databases support gene expression analyses by providing a framework for determining 
commonalities among perturbed genes. Specifically, gene ontology (GO) databases 
interweave known protein-protein interactions, biological functions, transcription factor 
binding sites, and biochemical pathway membership (181-183). Thus, new hypotheses 
and broader insights into affected processes and pathways can be formed (181, 184, 
185).  
High-throughput genomics can significantly advance clinical cancer therapy using 
both supervised and unsupervised means of analysis.  The Vogelstein model for the 
progression of hereditary colorectal cancer suggests that progression from dysplastic to 
neoplastic disease is a molecularly-defined process (156).  Therefore, each molecular 
step of pathologic progression may yield an identifiable genomic profile and this 
information could be used to differentially diagnose precancerous lesions from 
carcinomas or normal tissue, improving cancer detection.  Alternatively, the metastatic 
and/or recurrence potential of a tumor can be identified from gene expression profiles 
(186-188).  An excellent example of this is the OncotypeDx™ assay which is based on 
the expression levels of 21 genes (189, 190).  The expression levels, along with the 
associated algorithm yields a ‘recurrence score’ that correlates with the probability of 
recurrence following resection of ER positive, node negative, HER2 negative breast 
cancers.    This information can be used to determine whether a breast cancer patient 
undergoing surgical intervention should receive adjuvant cytotoxic chemotherapy.  Since 
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the toxicity associated with therapy is high, the recurrence score provides valuable 
information on which to base clinical decisions.  Thus, the OncotypeDx™ assay, which 
has entered routine clinical use, demonstrates that genomic data can be successfully 
incorporated into patient care. 
Yet another way in which genomics can be used to improve clinical practice is in 
the prediction of drug sensitivity.  Nevins and colleagues have shown that cell line and 
tumor sensitivity to chemotherapy can be extracted from gene expression data and 
developed into a predictive algorithm of response (191-193).  Further, this group has 
demonstrated that gene expression profiles of ectopic signaling pathway activation can 
likewise be developed into a signature of sensitivity to targeted agents (194).  When 
these predictive profiles are used for classification of unknown samples, a prediction of 
sample sensitivity can be made.  The potential clinical utility of these predictive 
signatures is obvious.  A number of clinical trials have been initiated to validate this 
predictive power of the signatures, although prospective clinical data has not yet been 
reported. 
Despite the obvious need for discerning patients that will respond to certain 
therapies, developing tests for clinical practice using predictive genomics faces a 
number of hurdles.  In particular, high dimensional data is generated when using 
microarray technology, creating a statistical dilemma.  The resulting data are often 
described as ‘tall data’, referring to the large number of outcome variables compared 
with the number of individual experiments or replicates.  Therefore, large samples sizes 
are necessary to minimize the inclusion of false-positive genes (i.e. those which are not 
truly influenced by or associated with the controlled variable (195-197).  However, 
accumulating the number of samples needed to develop predictive signatures is 
frequently cost-prohibitive due to the high cost of the technology. 
Also problematic is the identification of an appropriate model in which to 
determine the number of features, or ‘signature’ genes, which may be predictive (198).  
Certainly, in vitro models are the easiest and least costly to perform. Another advantage 
of in vitro models is the relative ease for manipulation of experimental conditions.  
However, the resulting data may not be useful in vivo due to the potential for substantial 
differences in expression patterns in two-dimensional cell culture versus three-
dimensional tumor growth in vivo.  Another complicating factor is one of tissue 
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procurement from clinical samples. While human tissue is perhaps most useful, it is 
subject to difficult regulatory requirements and is significantly more expensive.  Further, 
gene expression data from tumors contain more noise (i.e. technical variability) as a 
result of procurement processes, net tumor content of the sample, and confounding 
biological and patient-specific variables (i.e. concomitant therapy, age, gender, etc).  
Therefore, the best method to develop a genomic profile of a disease or condition is 
unclear, with both in vivo and in vitro models demonstrating advantages and 
disadvantages.   
In order to contend with the data- and cost-intensive nature of performing 
pharmacogenomic studies, a defined strategy for generation and validation of the 
predictive model must be decided upon and implemented a priori.  When dealing with 
supervised methods of analysis ( i.e. situations where the classification status of the 
samples are known and integrated into the analysis), the available starting data is 
typically stratified into ‘training’ and ‘test’ sets.  The training data is used to generate the 
model based on the classification of a known response (e.g. sensitive or resistant).   
Thus, the features are selected and weighted based on the training data.   
Internal validation is the next step in the development of a predictive model.  One 
of the most commonly used internal validation methods is the leave-one-out cross 
validation (LOOCV) (199, 200).  This method, which is a variation of bootstrapping or 
jack-knifing principles, requires iterative model rebuilding by removing one of the 
experiments from the training set, reselecting and weighting the features, and then 
applying the resulting model to the experiment that was excluded.  The procedure is 
repeated with each of the training set experiments.   A high LOOCV classification 
accuracy demonstrates robustness of the training data and model building method (i.e. 
discriminant analysis, partial least squares, principle component analysis, etc).  Once a 
satisfactory model-building procedure is internally validated, the model is rebuilt using all 
of the training set data and applied to the test set.  This initial form of external validation 
ensures that the final model can accurately predict group classification on external data 
that has not been used to build the model and provides an estimation of the expected 
predictive accuracy.   
A more robust external validation, however, requires an extensive analysis of 
samples which are not part of the original dataset in order to obtain a better estimation of 
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the true predictive accuracy and to determine if a systematic bias (i.e. ‘batch effect’, or a 
non-biological difference) exists.  Batch effects are frequently observed in microarray 
data due to within-set homogeneity relative to between-set heterogeneity; potential 
sources of these biases include tissue procurement methods, RNA isolation techniques, 
microarray hybridization protocols and equipment, and geographical and clinical 
population (201, 202).  Batch effects can be corrected using a variety of methodologies 
when necessary, such as distance weighted discrimination (DWD) (202).  External 
validation is particularly important if the original data was built using in vitro data, as the 
model must be validated on clinical samples, assuming this is the overall goal of the 
study.       
While ascribing known biological importance to the genes comprising the 
predictive model is not required for utility of the predictive signature as a biomarker, a 
high accuracy rate of the predictive algorithm increases the confidence that the gene 
components of the model may be important to the phenotype (203).  Therefore, it is of 
great interest to explore the genes comprising the model in order to mine information 
that may identify additional therapeutic targets or gain otherwise biologically useful 
knowledge.  Working from a genomic signature backward, the ‘candidate gene’ 
approach may be useful in identifying a single relevant gene that biologically contributes 
to the phenotype (204).  Further experimental testing of the importance of the gene in 
the biological system of interest could therefore yield a new target for cancer therapy or 
an as yet undefined signaling pathway component.  As an alternative to the candidate 
gene approach, a systems biology approach can be applied to the gene signature in its 
entirety, gleaning commonalities in the genes with respect to signaling pathway 
membership, biological process, miRNA targeting, protein binding partners, common 
chromosomal aberrations and transcription factor binding sites (205).  These methods of 
analysis could be used to infer an underlying deregulation within the system that can be 
exploited for new therapeutic endeavors. 
E. PROJECT OVERVIEW 
Pharmacogenomics offers both a mechanism to learn about a disease state from 
the analysis of high density genomic data and to utilize these data to directly influence 
clinical care.  In this body of work, these approaches have been combined in order to 
achieve the overall goal of improving the utilization of EGFR-targeted therapy in NSCLC.  
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Since the initial FDA approval of the EGFR TKI gefitinib for NSCLC in 2003, it has been 
relatively well-established that EGFR and KRAS genotyping can be of value in 
determining candidate patients for EGFR-targeted therapy (87, 88, 95, 99, 131, 147, 
155, 163, 165-167, 206).  However, single biomarkers are unlikely to capture the true 
heterogeneity of lung cancer.  Multivariate biomarkers, while subject to increased 
statistical and logistical considerations, may offer improved predictive accuracy.  
Moreover, these data offer a means for exploring the underlying disease processes 
through systems biology approaches.  Additional insights into the disease state can 
improve understanding of the disease and direct new therapeutic paradigms. 
Although the introduction of EGFR inhibitors to the clinic has resulted in an 
improvement of in the treatment of NSCLC, the true potential of EGFR TKIs has yet to 
be realized.  Many patients treated in clinical trials with erlotinib and gefitinib did not 
respond to therapy and therefore realized little benefit (134-137, 207-213).  The costly 
burden of failed treatment is largely placed on the healthcare field, limiting the 
effectiveness of EGFR TKIs.  Furthermore, clinical responses are frequently hindered by 
the rapid emergence of resistance (99, 100, 113, 146, 179, 214).  Using knowledge 
gained from both responding and non-responding patients, as well as those who develop 
resistance, two questions must be addressed in order to achieve maximum clinical 
benefit of EGFR inhibitors: How can patients who will benefit from EGFR TKIs be 
selected a priori? How can patients who respond achieve maximal benefit and survival? 
To answer these questions, two primary testable research hypotheses were 
formed.  First, I proposed that the EGFR-dependent phenotype, which is displayed 
by the tumors cells of those patients who respond clinically to EGFR TKIs, can be 
captured by genomic profiling of NSCLC cell lines stratified by sensitivity to EGFR 
TKIs and the resulting gene signature may be used to predict the outcome of 
EGFR TKI therapy in unknown samples.  Secondly, I proposed that the predictive 
signature of response to EGFR TKI could aide in providing additional insights into 
the underlying biology of the phenotype of EGFR TKI sensitivity. This information 
could be exploited to identify inhibitors which could be combined with EGFR 
inhibitors to elicit a greater effect, thereby minimizing resistance.  This work 
documents the use of pharmacogenomics to improve the use of EGFR TKIs in lung 
cancer through patient selection and achieving combinatorial therapeutic benefit. 
Copyright © Justin M. Balko 2009
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CHAPTER 2  
A. OVERVIEW 
Small molecule tyrosine kinase inhibitors (TKI) of the epidermal growth factor 
receptor (EGFR) can induce both tumor regression and disease stabilization when used 
as second line therapy in patients with advanced non-small cell lung cancer (NSCLC) 
(86, 120, 215).  Mutations in the tyrosine kinase domain of EGFR were observed in 
patients that responded to EGFR TKIs. Cell lines harboring mutated EGFR are 
dependent on EGFR for survival since inhibition of EGFR using TKIs, monoclonal 
antibody C225 or RNAi knockdown results in apoptosis (87, 95, 129, 216, 217).     
While substantial data now exists that mutations in the tyrosine kinase domain of 
EGFR are associated with increased sensitivity to EGFR TKI, mutations in EGFR were 
not found to correlate with response to erlotinib in the BR.21 trial (218).   More recent 
reports have suggested that increased EGFR gene copy number, co-expression of other 
ErbB receptors and ligands, and epithelial to mesenchymal markers are important in 
determining sensitivity to EGFR TKI (106, 219-221).  There are conflicting reports about 
the role of RAS mutation and subsequent signaling in response to EGFR TKI (86, 106, 
220).  In addition, identifying patients who may clinically benefit from EGFR TKI other 
than through overt tumor response remains unclear. Importantly, tumor regression has 
been observed with these agents in patients that did not have identifiable EGFR 
mutations, suggesting other mechanisms, such as activation of parallel signaling 
pathways, underlie responsiveness to these agents (217, 222-224).  Therefore, the 
clinical decision on how best to choose patients for EGFR TKI remains an important and 
ongoing dilemma.   
Development of molecular profiles as predictive measures of outcome or 
response to therapy has increased significantly since the advent of large-scale genomic 
and proteomic approaches for classification of cancers (225). Microarray technology 
allows for interrogation of large numbers of genes that encompass variability found in 
biological conditions.   However, methods of data analysis and modeling are hampered 
by the data itself in that it involves significantly more data points than experiments 
primarily due to the cost associated with performing many replicates (226, 227). Thus, 
building predictive profiles of clinical outcome or therapeutic response in non-small cell 
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lung cancers using large-scale genomic data is a daunting process, but may be 
necessary for improving patient-targeted therapy. 
We developed a novel methodology using both bioinformatics approaches and 
supervised learning methods to model sensitivity to EGFR inhibitors with gene 
expression data from lung cancer cell lines. Cell lines were chosen as tumor surrogates 
for ease of handling, the ability to assay EGFR and downstream signaling events by 
biochemical methods, and the capacity to test inhibitors in a controlled environment. The 
predictive models were subjected to extensive leave-one (or a group)-out cross-
validation. Out-of-sample validation using gene expression data from additional cell lines 
and human tumors were also employed.  The predictive models described herein are 
both robust and accurate predictors of response that exceed the capacity of single 
parameters alone in NSCLC cell lines.  Our data suggest that this finding may be 
translated to patient tumors with similar value, as sensitivity to erlotinib in a small cohort 
of clinical tumors was accurately predicted using our model. 
B. METHODS 
Cell Culture 
A549 cells were grown in RPMI 1640 (Invitrogen) with 2 mM L-glutamine 
containing 10% fetal bovine serum (FBS) (BioWest), 1.5 g/L sodium bicarbonate, 4.5 g/L 
glucose, 10 mM HEPES, and 1 mM sodium pyruvate (Whittaker). H460 and UKY-29 cell 
lines (228) were generous gifts from Dr. Val Adams and Dr. John Yannelli, respectively, 
(University of Kentucky) and grown in DMEM (Invitrogen) + 10% FBS. H3255 cells were 
a gift from Dr. Frederick Kaye (NCI/Naval Medical Oncology, Betheseda, MD) and were 
grown in ACL4 media as described previously (87). K562 cells were a gift from Dr. Rina 
Plattner (University of Kentucky) and were cultured in suspension in RPMI 1640 and 
10% FBS. Human cancer cell lines H1650, H1975, PC9, H358 and A431 were cultured 
as described (97, 229). 
Cell Line RNA Isolation and Microarray Analysis 
Cells were grown to subconfluence and passaged every three days. On the 
second day after passage, cell were harvested from a 150 mm plate and lysed in Trizol 
(Invitrogen). Total RNA was isolated and used for probe generation and hybridization to 
Affymetrix U133A DNA microarrays.   Signal intensity values generated from Affymetrix 
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MAS v5.0 software was used for statistical analysis, described below.  Independent 
replicates of A549 (n=8), UKY-29 (n=3), H3255 (n=3), PC-9 (n=5), and H1650 (n=6) 
were generated by using sequential passages of the cell populations.  These replicates 
were treated as independent samples by the subsequent algorithms to identify 
differentially expressed genes and build the discriminatory training model.  One replicate 
of each A431, H358, H460, H1975, and K562 was used for validation of the training 
model and a single replicate of each of the training lines omitted from the original 
models.  Microarray analysis was carried out by the University of Kentucky Microarray 
Core Facility according to standard operating procedures.   The microarray data are 
available on maduk.uky.edu. 
External Cell Line Microarray Analysis 
Two external datasets of NSCLC microarray data were extracted from Gene 
Expression Omnibus (GEO): GSE4824 and GSE8332.  These datasets were comprised 
of panels of lung cancer cell lines which had previously been assessed for sensitivity to 
erlotinib (221, 230).  The MAS5 normalized data were used to predict sensitivity using 
the 180-gene model developed in this study.  IC50 values of ≤ 2 µM were considered 
sensitive in our analysis.   
Tumor Acquisition and Microarray Analysis  
Duke cohort: After appropriate informed consent and Duke IRB approval, the 
analysis used an initial cohort of 91 tumor samples obtained from patients with local and 
locally advanced (stage I-IIIa) NSCLC.  From the resected lung specimens, percentage 
of tumor content and histological type of each tumor was ascertained before RNA 
extraction. Of the 91 RNA samples, 89 were of sufficient quality for gene expression 
analysis. Of the 89 samples, 40 were clearly identified as adenocarcinoma. Gene 
expression data was generated using an Affymetrix U133 2.0 plus array and processed 
as described previously (194).  The Affymetrix data for these samples is deposited on 
GEO under accession number GSE3141. EGFR mutational status (for exon 19 deletion 
and L858R) was determined using previously described techniques (95). 
Moffitt cohort: Patients undergoing surgical resection of adenocarcinoma of the 
lung were consented to have tumor tissue stored and banked through a University of 
South Florida IRB approved protocol.  Processing of the samples was performed as 
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previously described (231).  The data were obtained through personal communication 
with Dr. Eric Haura, M.D. from the H. Lee Moffitt Cancer Center, Tampa Fl. 
University of Kentucky cohort: After appropriate informed consent and University 
of Kentucky IRB approval, samples were collected from patients in one of two manners:  
Retrospective collection of samples banked at the University of Kentucky Biospecimen 
Core was performed following identification of patients who were later treated with 
erlotinib.  Patients were identified using an Honest Broker system which was supervised 
by the University of Kentucky IRB (see Appendix I).  Chart review to identify RECIST 
response, patient demographics, and treatment history was completed by the treating 
oncologists and data was relayed to the investigators.  Snap-frozen banked tumor and 
normal tissue was used for RNA isolation with RNEasy mini columns (Qiagen, Valencia, 
CA) according to the manufacuturer’s supplied protocol and downstream microarray 
analysis.  DNA was also isolated for EGFR and KRAS mutational assessment (see 
below).  Also, in a prospective manner, patients with recurrent NSCLC who were 
initiating erlotinib therapy were enrolled in a trial to assess the feasibility of tumor sample 
collection in a true clinical setting (see Appendices II and III).  Briefly, CT-guided core 
needle biopsy or dissection of the primary tumor or metastatic site was performed.  
Cores or bulk tumor tissue were RNA-extracted for microarray analysis and DNA was 
sequenced for EGFR and KRAS mutations.  Patient response and survival was recorded 
for 9 months following the initiation of erlotinib therapy.  Five patients were evaluable (4 
retrospective, 1 prospective). 
DNA Content Analysis 
Cell lines were plated to 60 mm dishes in 10% media.  Cells were starved in 
0.5% media for 24 hr before treatment with 1uM erlotinib (provided by Genentech, South 
San Francisco, CA) or DMSO for 72 hr. Floating and adherent cells were collected by 
trypsinization and centrifugation. Cell pellets were washed in 1X phosphate-buffered 
saline (PBS) and fixed in 70% ice-cold ethanol. Pellets were washed in 1X PBS,1% 
bovine serum albumin (BSA), and resuspended in 1X PBS, 1% BSA, 50 ug/ml propidium 
iodide (Roche), and 0.5 mg/ml RNase A (Sigma) at 4oC. Cells were sorted by 
fluorescence activated cell sorting (FACS) (University of Kentucky core facility).  Data 
was analyzed using ModFit LT (Verity Software, Topsham, ME).  Apoptosis was 
recorded as the integrated sub-G1 peak. 
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K-Ras and EGFR Sequencing 
Actively growing cells were scraped into 1X phosphate buffered saline (PBS) and 
pelleted by brief centrifugation. The cell pellets were lysed in 100 mM Tris HCl, pH 8.5; 5 
mM EDTA; 0.2% SDS; 200 mM NaCl and 100 ug/mg proteinase K in a 500ul volume at 
55oC for several hours and the debris was pelleted by high speed centrifugation. 
Genomic DNA was precipitated from the supernatant, and the nucleic acid pellet was 
resuspended in 10 mM Tris-HCl, 1 mM EDTA. K-Ras exons 1 and 2 and EGFR exons 
18-21 were independently sequenced as previously described (99, 232).  Sequencing 
was carried out by the University of Kentucky Advanced Genetics Technology Center 
(AGTC) according to standard operating procedures. 
Gene Selection  
EGFR TKI-sensitive and resistant cell line expression data was filtered to remove 
probesets with less than 6 ‘present’ calls (<1/2 smallest n) between groups. Probesets 
with no single unique sequence by BLAST alignment were removed from the list. The 
remaining genes were compared using Significance Analysis for Microarrays (SAM) 
(233).   Those genes that were determined to be differentially expressed between 
sensitive and resistant cell lines were annotated using GATHER (205, 234); and only 
those genes that annotated to signal transduction at level 4 (GO:0007165) were included 
in the discriminant analysis.  Duplicate genes (i.e. different probesets that annotate to 
the same gene) were filtered by removing the least significant probeset(s) as determined 
by a 2-sample, equal variance t-test. 
Diagonal Linear Discriminant Analysis 
The genes in the final dataset were ordered by p-value in a two sample equal 
variance t-test.  Diagonal linear discriminant analysis (DLDA) was performed using the 
top 10, top 50, and the complete gene signature (180 genes) in order to assess the 
stability and robustness of the model.  A leave-one-out cross validation and external 
validation was performed on additional cell lines and adenocarcinomas.  
Adenocarcinomas hybridized to U133 Plus 2.0 arrays were filtered to remove genes not 
present on the U133A chip and mean chip intensities were standardized to the complete 
training data set.  
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C. RESULTS 
Identification of sensitive and resistant cancer cell lines 
Using lung cancer cell lines as tumor surrogates, we sought to find gene 
expression patterns that can predict the sensitivity to EGFR tyrosine kinase inhibitors. 
Published data, and our own, demonstrate that lung cancer cell lines are differentially 
sensitive to EGFR inhibitors, likely reflecting dependency upon EGFR or related 
signaling pathways (97).  We identified lung adenocarcinoma cell lines sensitive to a 
representative EGFR TKI, erlotinib, by DNA content analysis using propidium iodide 
staining. Apoptosis was assayed by quantifying the sub-G1 peak following propidium 
iodide staining and FACS analysis in cells treated with 1 µM erlotinib for 72 hours or 
DMSO control (Figure 2.1).  Several cell lines tested were sensitive to treatment with 1 
µM erlotinib and these data are consistent with the findings of others (97, 221). We 
selected the A549 and UKY-29 cell lines for the drug-resistant training group, and the 
H1650, H3255, and PC-9 cell lines for the drug-sensitive training group. 
Sequence analysis of EGFR and K-Ras genes 
Since EGFR and K-Ras mutational status are thought to correlate with sensitivity 
and resistance to EGFR TKIs, respectively (147), we characterized the mutational status 
of  EGFR and K-Ras in the cell lines.  The status of K-Ras and EGFR has been 
previously determined in all of the cell lines used, except lung adenocarcinoma cell line 
UKY-29, isolated at the University of Kentucky.  We performed direct DNA sequencing 
on PCR amplicons to identify mutations in EGFR exons 18-21 and K-Ras exons 1 and 2 
in the UKY-29 cells as previously described (99, 131).   The UKY-29 cells are wildtype 
for EGFR and harbor a mutation (G61H) in exon 2 of K-Ras, which has been observed 
in other NSCLC tumors and cell lines. A summary of the cell line data is shown in Table 
2.1. 
  
ADAPTED FROM: Balko et al, BMC Genomics (2006) 7:289 
 
31 
 
 
Figure 2.1: Sensitivity to erlotinib in cell lines  
Sensitivity to EGFR tyrosine kinase inhibitors was determined by treating cells with 1 µM 
erlotinib for 72 hr under serum-starved conditions.  Apoptosis was assessed by 
integration of the sub-G1 peak and compared to cells treated with equal volume of 
vehicle (DMSO).  Experiments were repeated in triplicate with error bars representing 
SD. * denotes statistical significance (p<0.05, two sided t-test for unequal variances)  
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Table 2.1: Characterization of cell lines used in training and validation 
 
 Cell Line Type 
Sensitivity to 
EGFR TKI K-Ras Status 
Affymetrix U133A 
chips 
EGFR Status 
(n) in 
training 
(n) in 
validation
Tr
ai
ni
ng
  
A549 AC No Mutant (Codon 12) 8 N/A Wt 1 
UKY-29 AC No Mutant (Codon 61)1 3 N/A Wt 1 
H1650 AC Yes Wt 6 N/A 
Mutant (DelE746-
A750)1 
PC-9 AC Yes Wt 5 N/A 
Mutant (DelE746-
A750)1 
H3255 AC Yes Wt 3 N/A Mutant (L858R) 1 
V
al
id
at
io
n 
H358 AC Yes Mutant (Codon 12) 0 1 Wt1 
H460 Large Cell No Mutant (Codon 61) 0 1 Wt1 
H1975 AC No Wt 0 1 
Mutant (L858R, 
T790M) 1 
K562 CML No Wt 0 1 Wt1 
A431 Epidermoid Yes Wt 0 1 Wt (Amplified) 1 
 
1 Assayed in this study 
AC: Adenocarcinoma 
CML: Chronic Myelogenous Leukemia 
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Microarray analysis and feature selection 
Based on the observation that cancer cell lines and tumors are selectively 
susceptible to inhibition of the EGFR signaling pathway and that sensitivity may not be 
directly correlated to EGFR mutation or amplification in all cases, we sought to identify a 
gene expression signature that is predictive of EGFR TKI sensitivity.  Using independent 
replicates of drug-resistant cell lines (n=11) and drug-sensitive cell lines (n=14), we 
generated gene expression data, and using both bioinformatics and statistical analyses 
identified a set of genes that predict sensitivity to EGFR TKI, outlined in Figure 2.2.   
Specifically, gene expression data generated from Affymetrix U133A arrays was 
filtered based on present/absent calls and BLAST sequence alignment. The 12,019 
remaining probe sets were analyzed by Significance Analysis for Microarrays (SAM), 
resulting in 1495 differentially expressed genes between the two groups, with a very low 
false discovery rate (0.025%) (233). We wished to focus on genes found primarily to 
function in signaling transduction in order to minimize noise from genes that are less 
likely to be responsible for differences in EGFR TKI sensitivity. To accomplish this, we 
annotated the list of 1495 differentially expressed genes using GATHER, a web-based 
gene ontology algorithm that detects enrichment of GO terms at all levels within a 
submitted list of genes (205).  In the GATHER algorithm, p-values represent the 
probability of the term being similarly enriched in a randomly generated list of genes of 
identical size.  A number of GO terms were significantly enriched within the 1,495 gene 
list, including signal transduction (GO:0007165, level 4, p<0.0001), G-protein coupled 
receptor protein signaling pathway (GO:0007186, level 6, p<0.0001) and cell surface 
receptor linked signal transduction (GO:0007166, level 5, p<0.0001), consistent with the 
hypothesis that altered signaling cascades may represent a significant proportion of the 
variability in EGFR TKI response.  We selected only those genes that were annotated 
under signal transduction (GO:0007165, level 4) to constitute the signature of EGFR 
sensitivity. 
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After GATHER annotation, 223 probesets remained, and several of these 
probesets were redundant with respect to their target gene.  To minimize bias in 
subsequent analyses, we kept only the most significant of the redundant probesets.  
When all filtering steps were complete, we identified a 180-gene signal transduction-
oriented expression signature of EGFR sensitivity (see APPENDIX IV).  The genes 
contained within the signature were re-annotated on higher levels of GO to more 
precisely characterize the biologic roles of these genes that are differentially expressed 
in EGFR TKI sensitive cells. Using GATHER’s GO pathway analysis, we found 
significant deregulation of the NFkB/IkB signaling cascade (15 genes, GO:0007249, 
level 7, p<0.0001).  Interestingly, Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway analysis of the 180-gene predictor revealed significant enrichment of pathways 
known to act downstream of EGFR, including the MAPK signaling pathway (16 genes, 
p=0.0001) and the phosphotidylinositol signaling pathway (9 genes, p=0.0006).  We also 
queried for significant enrichment of transcription factor binding sites among the 180-
gene signature using TRANSFAC via GATHER. The genes clustered into three 
interesting and significant classes of DNA-binding domains: c-Myc/Max complex binding 
sites (112 genes, p<0.0005), E2F1 sites (143 genes, p=0.003) and Tax/CREB sites (22 
genes p=0.0002). 
Internal and external validation using diagonal linear discriminant analysis  
Diagonal linear discriminant analysis (DLDA) was performed on the 180-gene 
signature of EGFR sensitivity because this methodology performs well in classification 
problems concerning gene expression data (235). For each unknown subject, DLDA 
calculates the distance of the unknown to the average of the subjects in each group of 
the training set with respect to the common diagonal covariance matrix. The unknown is 
then classified into the closest group.   
The model was trained using the H1650 (n=6), PC-9 (n=5), and H3255 (n=3) cell 
line samples as the sensitive group and the UKY-29 (n=3) and A549 (n=8) samples as 
the resistant group. The replicate measurements from each cell line were treated as 
independent samples by the subsequent algorithms to identify differentially expressed 
genes and build the discriminatory training model. We tested multiple predictive models, 
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including the 10 and 50 most significantly deregulated genes of the 180-gene signature 
to determine the robustness of the predictor (see APPENDIX IV).  
We also performed a leave-one-out cross validation of the DLDA function.  We 
assumed that one chip in the training set was an unknown, and then performed the 
complete analysis based on the remaining chips, beginning with the initial filtering steps.  
This was performed for each chip of the initial training set in turn. Specifically, each time 
a chip was removed from the training set the following steps were performed; 
presence/absence call filtering, SAM analysis on the newly filtered data set, with the 
same delta-threshold used in the complete analysis training set, gene ontology filtering, 
redundant probesets were removed, the diagonal linear discriminant function was fit 
from the remaining 24 chips, and then EGFR TKI sensitivity of the removed chip was 
predicted based on the newly fit diagonal linear discriminant function.  This was 
performed using the top 10 and 50 genes in each iteration, as well as the full gene list 
(range: 171-208 genes). Leave-one-out cross validation yielded a 0% misclassification 
rate.  Likewise, we also performed a leave-a-group-out cross-validation in which an 
entire cell line set was removed and the model was iteratively rebuilt. This approach 
resulted in correct predictions for PC-9, H3255, UKY29, and H1650 samples but 
incorrectly classified 3 of the 8 replicates of A549 (88% accuracy).  
The models were then externally validated using a set of cell lines not used in 
training the model of EGFR TKI sensitivity as well as a single replicate for each of the 
training cell lines that were not incorporated into the training data (see Table 2.1). The 
K562 line was chosen as a negative control as it is a cancer cell line dependent on BCR-
ABL expression to test if our predictor was recognizing non-specific dependence on any 
activated kinase. The 10-, 50-, and 180-gene models were used to classify all cell lines.  
The models classified all samples correctly, with the exception of the UKY-29 sample in 
the 10-gene model and the H1975 cell line in all 3 models.   Additionally, we compared 
our genomic predictor (gene signatures and DLDA) to predictions based on mutational 
status alone, assuming sensitivity in the presence of exon 19 or 21 mutations, or 
resistance in the absence of EGFR mutations, or presence of an exon 20 mutation.  
Results are shown in Table 2.2. 
To further assess the predictive accuracy of our model using external validation, 
we analyzed two independent NSCLC cell line datasets also assayed on Affymetrix 
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microarrays.  The first dataset was from Girard and colleagues (GEO#GSE4824).  
These data include 14 lung cancer cell lines, of varied histologies, which were not 
included in our training model-Calu.3, H1299, H157, H1648, H2009, H2126, H820, 
HCC15, HCC2279, HCC4006, HCC44, HCC78, HCC827, and HCC95.  Because 
NSCLC cell lines have a broad range of sensitivity to EGFR TKI, we chose an IC50 
threshold of 2 µM to EGFR TKI as determined in Bunn et al for these 14 cell lines(230). 
Our genomic model of EGFR TKI sensitivity correctly classified 64% of the lines. 
Increasing the threshold to 3 µM added an additional correctly predicted sample (71%).    
The final external NSCLC cell line dataset used was comprised of 42 NSCLC cell 
lines (GSE8332).  These cell lines were assessed for sensitivity to erlotinib by Yauch et 
al (221).  Again, using an erlotinib IC50 threshold of 2 µM (the same used by the authors 
in that study), we assessed the capacity of the 180-gene model to predict sensitivity.  
Using this threshold, the model correctly classified 34/42 cell lines, for a predictive 
accuracy of 81%.  
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Table 2.2: Diagonal linear discriminant analysis of NSCLC cell lines 
Predictions of EGFR TKI sensitivity are denoted for ten cell lines used in 
training/validation.  Column 2 demonstrates experimental sensitivity to erlotinib. Column 
3 demonstrates prediction of sensitivity using mutational status of EGFR. Columns 4-6 
denote prediction of sensitivity of the cell lines using the 10, 50, and 180 gene signatures 
in DLDA. √: denotes correct prediction based on experimental sensitivity to EGFR TKI. *: 
Leave-a-group-out cross-validation incorrectly predicts 3 of 8 replicates of this cell line. 
 
 
Cell Line 
Experimental 
Sensitivity to 
EGFR TKI 
(erlotinib) 
Predicted sensitivity to EGFR TKI 
Prediction based 
on analysis of 
mutational status 
alone (Exons 18-
21) 
Genomic signature / 
DLDA 
10- 
genes 
50-
genes 
180- 
genes
Training  A549 No √ √* √ √ 
UKY-29 No √  √ √ 
H1650 Yes √ √ √ √ 
PC-9 Yes √ √ √ √ 
H3255 Yes √ √ √ √ 
Validation  H358 Yes  √ √ √ 
H460 No √ √ √ √ 
H1975 No √    
K562 No √ √ √ √ 
A431 Yes  √ √ √ 
  % Correct 80% 80% 90% 90% 
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Independent external validation on resected lung adenocarcinomas 
Given the accurate classification of the cell line data, we hypothesized that the 
signature of EGFR sensitivity should correctly classify resected tumors, and would result 
in appropriate predictions of response to EGFR TKIs in vivo.   Two collections of 
resected adenocarcinomas, previously subjected to microarray analysis, were used to 
validate the predictive models of 10, 50, and 180 genes.  The first set of tumor samples 
used for external validation of the model was obtained from H. Lee Moffitt Cancer Center 
and Research Institute (Tampa, Fl).  RNA was prepared from those tumors and was 
used for hybridization to Affymetrix U133A arrays. Tumors were also assayed by 
immunohistochemistry (IHC) methods, scoring for phosphorylated EGFR (pEGFR) as 
previously reported (229).   Since persistently activated EGFR (pEGFR) may reflect 
underlying tumor reliance on EGFR and therefore sensitivity to EGFR TKI (229), we 
explored the relationship between classification by DLDA and pEGFR staining.  Of the 
19 tumors, 5 were either pEGFR-negative or exhibited very low pEGFR signal (<10 on a 
scale of 0-300) by IHC staining, while the remaining 14 stained with higher intensity of 
pEGFR.  When the Moffitt tumors were predicted by DLDA, 4, 13, and 10 tumors 
classified as sensitive in the 10-, 50-, and 180-gene predictors respectively.  Of the 
tumors that classified as sensitive, 100%, 92%, and 90%, respectively displayed higher 
degrees of pEGFR staining (>10).  Of those tumors that were predicted to be resistant, 
33%, 66% and 44% exhibited low levels or no pEGFR staining (<10), respectively. 
Tumor classification for the three models as well as IHC scoring is presented in Figure 
2.3, panel A. 
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Figure 2.3: Classification of two independent collections of resected adenocarcinomas 
(A) Tumors samples banked at H. Lee Moffitt Cancer Center and Research Institute 
were used for extraction of total RNA for probe preparation and hybridized to U133A 
arrays.  IHC scoring was performed as previously described (229).   Thatched boxes 
represent predictions of sensitivity.  (B) Tumors samples banked at Duke University 
were used for extraction of total RNA for probe preparation and hybridized to U133 2.0 
arrays.  pEGFR scoring is reported on a 4 point scale (0-3+).  The presence of activating 
mutations within EGFR is also reported.  Sensitive predictions are represented by a 
thatched box. 
 
 
ADAPTED FROM: Balko et al, BMC Genomics (2006) 7:289 
 
41 
 
Because mutational status of EGFR has been shown in select studies to 
correlate with tumor response to erlotinib and gefitinib (223, 236), we chose to further 
validate our model on a series of resected adenocarcinomas for which mutational status, 
as well as pEGFR status was known. Adenocarcinomas from the Duke lung cancer 
cohort were used as a second test of our model. RNA from the samples was used for 
hybridization to Affymetrix U133 Plus 2.0 arrays, and these data were imported into our 
models (194).   We were able to make predictions of EGFR TKI sensitivity of the Duke 
tumors using DLDA.   We found that the 10-, 50- and 180-gene predictors identified 1/6 
(17%), 5/6 (83%), and 5/6 (83%) of the tumors with EGFR mutations as sensitive, 
respectively.  Of those tumors that classified as sensitive in the 10-, 50-, and 180-gene 
models, 82%, 78%, and 77% displayed positive staining for pEGFR, respectively.  Of 
those tumors that were classified as resistant in the 10-, 50-, and 180- gene models, 
24%, 33%, and 25% displayed no pEGFR staining, respectively.  Classification of the 
data are shown for the Duke lung adenocarcinoma dataset in Figure 2.3, panel B. 
Finally, to directly test the hypothesis that the 180-gene model could accurately 
predict response of lung tumors to erlotinib, we initiated a pilot clinical study and 
collected both retrospective and prospective data from patients at the University of 
Kentucky who were treated with erlotinib (see Appendices I, II, and III).  Frozen tumor 
and matched normal resected tissue (where available) was utilized for DNA sequencing 
of KRAS and EGFR.  RNA was isolated for microarray analysis.  Radiographic response 
was recorded and compared with predictions using our 180-gene predictive model.  In all 
cases, normal tissue predicted as ‘resistant’ to erlotinib.  Three of five tumor samples 
predicted as sensitive, and of these, two of three demonstrated clinical benefit (stable 
disease or partial response).  Two tumors predicted as resistant, and both of these 
patients demonstrated progression on erlotinib treatment.  Also, 3 of the 5 patients in this 
cohort had cytotoxic therapy between the time of resection and the time of erlotinib 
treatment, suggesting that the predictive signature may be stable through other 
treatments, such as platinum agents that are commonly used in adjuvant or first-line 
regimens.  We have assessed this hypothesis elsewhere, using ovarian carcinoma cell 
lines treated with platinum agents (237).  
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Table 2.3: Results of predictive analysis of University of Kentucky Cohort 
 
 
NS: non-smoker, FS: former smoker, CS: current smoker, BAC: bronchioalveolar 
carcinoma, AC: adenocarcinoma, WT: wildtype, PR: partial response, SD: stable 
disease, PD: progressive disease  
Sample  Sex  Eth  Smoking  Pack-
year  
Histology Tissue EGFR 
(ex19-
21)  
KRAS 
(ex1-2)  
RECIST  Tumor 
prediction  
L05-239  M  Ca  NS/FS  <1  BAC  Prim  L858R WT  PR  sensitive  
L06-312  F  Ca  FS  N/A  AC  Prim  WT  WT  SD  sensitive  
L06-298  F  Ca  CS  N/A  Poor diff  Prim  WT  WT  PD  sensitive  
L06-338  M  Ca  FS  25  AC  Prim  WT  WT  PD  resistant  
BLA-06-
ERL-02  
M  AA  CS  47  Poor diff  Node  WT  N/A  PD  resistant  
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D. DISCUSSION 
The EGFR TKI erlotinib was shown to increase survival in previous clinical trials 
when used as monotherapy in previously treated patients with advanced NSCLC (238).  
Toxicity to erlotinib is markedly lower than many alternative pharmacologic treatments, 
and would clearly be a preferred therapeutic option if survival were shown to be 
equivalent or better than treatment with other second line agents.  Since only a fraction 
of patients respond to such therapy, a priori identification of responders could have a 
vast effect on healthcare costs and patient survival.  Many clinical parameters that have 
been shown to correlate with response to EGFR TKIs, including smoking history, 
gender, ethnicity, and tumor histology.  Additionally, EGFR expression levels, 
phosphorylation status of EGFR, and mutations within the kinase domain (81, 131, 236) 
also correlate with sensitivity to some degree.  While each of these predictors of 
response result in some overlap, potential responders to EGFR targeted therapeutics 
may be overlooked.  In the same vein, a significant number of patients selected for 
treatment with EGFR TKI will fail therapy.  Therefore, we undertook this study with the 
hypothesis that a gene expression signature of response will capture more of the 
variability within the tumor and improve prediction of EGFR TKI sensitivity than currently 
preferred methods.  Furthermore, closer examination of the genes within this signature 
will allow for greater understanding of the effects of aberrant EGFR signaling, as well as 
potential elucidation of new drug targets. 
Using NSCLC cell lines as tumor surrogates and previous findings as guidance, 
we sought to train our model by stratifying cell lines by drug sensitivity. Three sensitive 
cell lines were chosen for training data: H3255, PC9, and H1650. A549 cell line and 
UKY-29 cell lines were resistant to treatment and used for training data.  The cell lines 
resistant to EGFR TKI harbor K-Ras mutations while the sensitive cell lines used in the 
training set all harbor EGFR mutations, as previously reported, and this finding is 
consistent with the hypothesis that K-Ras mutations and EGFR mutations are mutually 
exclusive in NSCLC (147).   
Our hypothesis is anchored in the concept that while many factors correlate with 
sensitivity to EGFR inhibition, distinct combinations of signaling pathway deregulation 
may underlie the observed phenotype.  Therefore, a gene expression signature 
capturing this complexity should be a more accurate predictor of response to EGFR TKI, 
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and we defined a gene expression signature that utilizes our knowledge of signal 
transduction to model the phenotype of sensitivity.   
Approximately 1500 genes were significantly different between our sensitive and 
resistant training cell lines, and while many of these genes may be important in our 
phenotype of response, we reasoned that a significant portion may be artifacts of two-
dimensional growth and cell culture conditions. We filtered the 1500 differentially-
expressed genes based on ontological annotation, allowing us to focus our signature on 
those genes that are important for cell signaling and are more likely to influence 
response to inhibition of the EGFR signaling cascade. To our knowledge, this is a novel 
approach to feature selection within a predictive gene signature study. A limitation of this 
approach is that genes that may contribute to pharmacokinetic variability such as 
transporters and metabolic enzymes would be omitted from the signature.   Furthermore, 
markers of epithelial to mesenchymal transition (EMT), which have been shown to 
correlate with sensitivity to EGFR TKI (220, 221) are not present in our final predictive 
signature due to the filtering by gene ontology.  It is of note that the SAM analysis 
identified several EMT genes as differentially expressed within the 1500-gene training 
data set, such as vimentin, E-cadherin, and β-catenin.   
We defined a set of 180 features that represent differentially expressed genes 
that exhibit enrichment in signal transduction functions between EGFR-inhibition 
sensitive and EGFR inhibition-resistant cell lines, including a number of previously 
identified oncogenes such as SRC, BRAF, and PI3K that function downstream of EGFR 
activation.  EGFR itself was identified as significantly deregulated and is consistent with 
the observation that EGFR expression may correlate with sensitivity (130).  
GATHER allowed us to interrogate KEGG pathways in analysis of the genes 
included in the 180-gene signature and identified deregulation within the PI3K and 
MAPK pathways between sensitive and resistant cell lines.  Interestingly, both of these 
pathways are downstream of EGFR, providing further evidence of their importance in 
NSCLC.  Consistent with this finding, several subunits of PI3K were found highly 
expressed in the EGFR TKI sensitive cells, including both the catalytic and regulatory 
subunits.  
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Analysis of transcription factor binding elements using GATHER also identified 
strong commonalities among the genes included in the signature.  The high proportion of 
the genes are likely regulated by the E2F-family of transcription factors and/or c-
MYC/MAX transcription factors suggesting common regulatory mechanisms may lead  to 
the phenotypic difference of EGFR TKI-sensitive and -resistant cells.  Importantly, both 
activating E2Fs and MYC are recognized as essential cell cycle regulators and bind to 
promoters of genes important for driving cell proliferation (239). 
Our EGFR signature represent 180 genes that were observed to have large 
differences with low variability in our system (see Appendix IV).  Since our leave-one-out 
cross-validation yielded a 0% misclassification error, there may be concern that over-
fitting of the model has occurred.  A full leave-one-out cross validation (i.e. features are 
reselected and model parameters are rebuilt at each iteration) is a stringent and 
relatively unbiased estimate of the model building algorithm error (240, 241).  However, 
to ensure that the treatment of replicate cell line samples as independent samples in our 
model did not result in cross-validation bias, we performed additional internal validation 
experiments.  Subsequent cross-validation was performed in which the entire data set 
from each cell line was removed (features were re-selected and weights were 
recalculated based on the data from only 4 cell lines, and the samples from the 5th cell 
line were predicted using the new model).  This method of cross-validation yielded a 
high degree of accuracy as well in that all cell lines predicted correctly, with the 
exception of 3 of 8 A549 samples (data not shown). We also constructed a second 
predictive model of EGFR TKI sensitivity using balanced numbers of replicates in both 
training classes (n=3 replicates/cell line). We found that although 111 genes of the 
resulting 169-gene model were common to the 180-gene signature the resulting model 
did not exactly replicate the classifications of the 10-, 50-, and 180-gene models. The 
differences could be due to a lack of statistical power in the second model.   
We assessed the ability of this model to predict additional sets of gene 
expression data.   To independently validate the signature, we used DLDA to classify 
cell lines that were not included in training the models. Additionally, we assessed the 
variability in predictive strength using multiple models.  We found that predictions based 
on the most statistically significant 10 or 50 genes were similar to those made with the 
full data set.  However, 10-gene model resulted in misclassification of both the UKY-29 
and H1975 samples.  This finding underscores the importance of including enough 
ADAPTED FROM: Balko et al, BMC Genomics (2006) 7:289 
 
46 
 
features in the model to account for variability found in the biological system of interest, 
a lung adenocarcinoma.  Interestingly, the H1975 sample is seemingly misclassified in 
the 50- and 180-gene models as well.  This cell line harbors a second mutation in exon 
20 that has been shown to confer resistance to the EGFR TKI gefitinib and erlotinib (99).  
Importantly, however, recent reports have shown that the irreversible inhibitors of EGFR 
such as CL-387, 785 overcome this resistance (242).  Therefore, the double-mutant 
H1975 cell line, although insensitive to gefitinib and erlotinib, retains reliance on EGFR 
signaling pathways, providing an explanation for its classification using our models (89).   
Furthermore, when compared to predictions based on mutational status alone, the 
genomic predictors (50- and 180-gene models) perform better in determining a priori 
sensitivity (see Table 2.3). 
We carefully selected the cell lines used as a validation set to ensure that our 
model was predictive of EGFR TKI sensitivity and not mutational status alone.  The 
H358 adenocarcinoma cell line harbors a K-Ras mutant and no EGFR mutations, yet our 
predictor and data of others (221) identify this cell line as sensitive to EGFR inhibition.  
Furthermore, the A431 cell line was not derived from a lung adenocarcinoma, has both 
wildtype EGFR and K-Ras alleles, and is exquisitely sensitive to EGFR inhibition. 
However, K562 cell line is derived from a CML blast crisis patient, is wild-type for both 
EGFR and K-Ras, and is highly resistant to EGFR TKI.  All three of these cell lines 
classify correctly and consistently among the 10-, 50-, and 180-gene predictors. 
To strengthen confidence in our 180-gene model, we tested an unpublished, 
independently-derived set of NSCLC cell line microarray data (Girard, GEO # 
GSE4824). Our signature correctly classified 64-71% of the cell lines, depending on IC50 
threshold selection of resistance to EGFR TKI as determined in Bunn et al (230). Of the 
four cell lines from the Girard set that were incorrectly predicted using our model, two 
were not of adenocarcinoma origin-H1299 (large cell carcinoma) and H157 (squamous 
cell carcinoma). Our predictor of sensitivity was trained using cell lines of 
adenocarcinoma origin and may then be more accurate when using similar data. 
Utilizing additional training data from cell lines of varied NSCLC histologies will likely 
improve the model for clinical use. 
We next assessed the ability of the predictive models to classify lung 
adenocarcinoma tumors.  Initially, in the absence of clinical outcome or survival data 
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from a prospective trial, we identified two datasets to which reasonable proxies for 
EGFR signaling and TKI sensitivity were available.  These data included a set of 19 
adenocarcinomas for which phosphorylated EGFR (pEGFR) was assessed using IHC 
and a set of 40 adenocarcinomas for which both pEGFR and EGFR mutational status 
was assessed.  Classification based on 50 or 180 genes remained relatively constant, 
demonstrating robust predictive power.   Furthermore, classification of the tumors using 
50- and 180-genes models identify a majority of the pEGFR positive samples in both 
datasets, as well as capturing 5 of 6 EGFR mutants in the Duke tumor dataset.  
We identified several tumors in both the Moffitt and Duke datasets that 
demonstrate no detectable expression of pEGFR but classify as EGFR TKI sensitive 
using the predictive gene expression model.  It is possible that IHC analysis is less 
sensitive than classification using the gene expression profile and is also dependent on 
sections stained and phospho-specific antibody used.  Alternatively, the tumors 
harboring low levels of pEGFR predicted to be sensitive to EGFR TKI might possess 
deregulation of parallel signaling pathways that result in a gene expression phenotype 
that closely resembles activation of EGFR, and accordingly, these patients classify as 
sensitive to EGFR TKI. 
We classified 83% (5/6) of the Duke cohort that were EGFR mutants as sensitive 
to EGFR by gene expression signature.  While the predictor seems to have misclassified 
one tumor that harbors mutant EGFR, we note that others have reported that cell lines 
with activating EGFR mutations are also insensitive to EGFR TKI, and our predictive 
models may have identified a tumor that will not respond to treatment (106).   Further, 
the Duke cohort lacked analysis of the T790M mutation and MET amplification, two 
markers of clinical resistance to EGFR inhibitors that are not mutually exclusive with 
sensitizing EGFR mutations (98, 99).  Thus, it could be that this EGFR-mutant sample 
contained one of the resistance-conferring lesions.  Additionally, in non- Japanese 
populations screened by EGFR mutational status prior to treatment with gefitinib, the 
response rate among those patients with either deletion or point mutation of EGFR was 
found to be 75% suggesting that mutation of EGFR is not sufficient for EGFR TKI 
sensitivity (211).  Thus, our tumor classifications accommodate the proportion of 
responders found in previous studies and while our approach may exceed those 
findings, future validation depends on comparing classification to response in a clinical 
study.  
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Because we did not have the EGFR TKI response data for the Moffitt and Duke 
tumor specimens, we used pEGFR staining and mutation status as surrogates for EGFR 
signaling, as described above. Combining both of the tumor data sets, our predictor of 
EGFR TKI sensitivity suggests that 80% of the tumors may be sensitive. Previous 
studies found that nearly 50% of patients with advanced stage IV NSCLC who had 
previously received cytotoxic chemotherapy had clinical benefit with EGFR TKI defined 
as either overt tumor response (shrinkage), stable disease, or symptomatic improvement 
(215). Since all the Moffitt and Duke tumors were of adenocarcinoma histology, a known 
clinical predictor of benefit to EGFR TKI, it is possible that the genomic predictor may 
accurately classify sensitivity in this group of tumors. 
Finally, we designed a pilot clinical study to gather tumor samples from patients 
prior to treatment with erlotinib.  Importantly, we were able to collect additional data in 
this study that was missing from the other clinical cohorts.  Specifically, we tested for the 
presence of KRAS and EGFR T790M mutations to gain additional insight into the 
performance of our predictor in these genetic backgrounds.  However, MET amplification 
was not tested in this study.  Our hypotheses were supported by the results of the 
University of Kentucky clinical cohort, where accurate predictions of erlotinib sensitivity 
were made in 4 of 5 tumors.  It is unclear whether there exists a difference in EGFR TKI 
sensitivity between early stage lung cancers and widely metastatic cancers that have 
previously received cytotoxic chemotherapy. However, our model appeared to perform 
well in predicting response in both early stage resected tumors and advanced disease.  
Studies are underway that address the sensitivity of early stage lung cancers to EGFR 
TKI. True assessment of the accuracy of our gene expression profiles to predict 
sensitivity of lung cancers to EGFR TKI will require more extensive prospective testing.  
E. CONCLUSIONS 
The gene expression signature of EGFR TKI sensitivity exhibits strong biological 
relevance as it encompasses many members of the EGFR signalling cascade. The 
prediction of sensitivity to EGFR inhibitors using DLDA models was accurate and robust 
within the cell line data.  Furthermore, the DLDA predictive models suggest improved 
prediction of EGFR TKI sensitivity of human lung adenocarcinomas compared to single 
biomarkers alone.  Clearly, the next step in assessing the ability of this signature to 
improve upon existing methods must be determined in a larger prospective clinical trial.  
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We anticipate that use of gene expression predictors could advance patient-targeted 
therapy in this area. 
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CHAPTER 3  
A. OVERVIEW 
The epidermal growth factor receptor (EGFR) is activated by ligand binding to the 
extracellular domain resulting in either homo- or hetero-dimerization of the receptor and 
subsequent auto-phosphorylation of the intracellular domain.  Activation of EGFR 
initiates a series of downstream signaling networks that integrate both proliferative and 
survival pathways (83, 97, 129, 232, 243, 244).   
Mutations within the EGFR kinase domain (exons 18-21) result in increased 
pathway activity, and occur in 5-20% of NSCLC patients (81, 83, 87, 129, 131, 223).  Of 
particular significance, NSCLC tumors harboring activating EGFR mutations rely upon 
constitutive pathway activation for survival, resulting in oncogene addiction (81, 83, 95, 
129, 131, 140-142, 147, 223, 245).  The inhibition of this pathway in NSCLC cell lines 
using EGFR tyrosine kinase inhibitors (TKI) or by siRNA-mediated knockdown of EGFR 
results in reduction in survival by colony-forming assays and reduction in proliferation by 
MTS assays (83, 97, 99, 232).   Xenograft models of many of the same NSCLC cell lines 
respond to EGFR TKI in vivo (246). Tumors induced in the lungs of mice by tissue-
specific expression of mutationally-activated EGFR also regress with EGFR TKI 
treatment (94).  Furthermore, clinical treatment of carcinomas harboring mutations in the 
EGFR gene with the EGFR TKIs erlotinib or gefitinib has been reported to elicit higher 
response rates than those observed in wild type EGFR tumors or unselected patient 
populations (86, 87, 95, 96).   
Interestingly, clinical response has been observed in NSCLC tumors with no 
identifiable EGFR mutation (218, 247).  In concordance with these findings, various 
NSCLC tumor cell lines lacking known activating EGFR mutations have been found to 
be highly sensitive to EGFR inhibition (117, 220).  As such, EGFR pathway addiction 
(reviewed in Chapter 1) may arise from other mechanisms in addition to activating 
mutations in EGFR (87, 93, 106, 114, 130, 207, 248).  One potential mechanism was 
described by Fujimoto et al, who demonstrated that EGFR ligands are up regulated in 
adenocarcinomas that are sensitive to EGFR inhibition, suggesting the presence of an 
autocrine loop (106).   
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A number of ligands have been identified that are capable of binding EGFR, 
including epidermal growth factor (EGF), heparin-binding EGF-like ligand (HB-EGF), 
transforming growth factor–α (TGF-α), epiregulin (EREG) and amphiregulin (AREG).  
Deregulated expression and/or activation of these ligands may serve to potentiate an 
autocrine loop that contributes to EGFR pathway addiction either independently or in 
concert with EGFR-activating mutations.   An autocrine loop involving TGF-α, EGFR, 
and the RAS/MAPK pathway has been suggested to exist previously, although its 
importance in EGFR-dependent lung cancer in unclear (107, 249, 250).  Our own work 
has identified genes deregulated in the EGFR-dependent phenotype, which included 
genes involved in the MAPK pathway (see chapter 2) (251).  Other epithelial cells, such 
as mammary and intestinal cells, also exhibit up-regulated EGFR ligands following RAS 
or RAF activation (252-254).  From our data and the data of others, we hypothesized 
that signaling cascades downstream of RAS activation may play a role in modulating an 
autocrine loop controlling EGFR ligand activity in NSCLC. 
In this study, we demonstrate that EGFR-dependent NSCLC cell lines display 
constitutive ERK1/2 activation.  RAS/MAPK signaling contributes to regulation of EGFR 
ligand expression and activation in EGFR-dependent lung cancer cells, as well as in 
primary small airway epithelial cells and immortalized bronchial epithelial cells.  Finally, 
we demonstrate that RAS/MAPK regulation of EGFR ligands is important for stabilization 
of EGFR protein levels.  Antibody-mediated inhibition of ligand binding to EGFR results 
in degradation of the receptor, phenocopying the effects of small molecule-mediated 
RAS/MAPK inhibition.  Our results demonstrate that EGFR-dependent NSCLC cell lines 
utilize RAS/MAPK activity to drive expression/activation of EGFR ligands which may 
serve to stabilize EGF receptor levels.  These processes are potential contributors to 
oncogenic EGFR signaling in lung cancer. 
B. MATERIALS AND METHODS 
Cell culture  
RPMI 1640 (with 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 
4.5% glucose and 1.5% sodium bicarbonate) and DMEM were used as culture media 
and were supplemented with 10% fetal bovine serum (FBS) (Biowest, Miami, FL), 50 
µg/ml penicillin and 50 µg/ml streptomycin. The human NSCLC cell lines A549, H460, 
UKY-29, NCI-H1975, NCI-H1650, NCI-H358, and PC9 were obtained and maintained as 
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previously described (251). Immortalized human bronchial epithelial cells (hBEAS2b) 
were obtained and cultured as recommended by the ATCC.   
Adenoviral infections 
The v-AKT and constitutively active STAT3 (STAT3ca) adenoviruses were 
provided by Dr. Eric Haura, M.D. of the H. Lee Moffitt Cancer institute (255).  The 
constitutively active MEK-1 (MEK-1ca) adenovirus was generously provided by Dr. Janet 
Rubin of the University of North Carolina (256, 257).  hBEAS2b were plated in full growth 
media approximately 24 hr prior to infection.  Cell culture media was removed and cells 
were washed once in PBS prior to addition of adenovirus in infection media (basal 
growth media buffered with 25 mM HEPES).  Cells were infected at a multiplicity of 
infection of 50 ffu/cell for one hour in a minimal volume and full growth media was then 
replaced overnight.  Cultures were harvested 16 hr after infection for subsequent RNA or 
protein analysis. 
Inhibitors and neutralizing antibodies 
The MEK1/2 inhibitor U0126 was acquired from EMD Chemicals (Gibbstown, 
NJ).  MG-132 was obtained from Dr. Hsin-Hsiung Tai, Ph.D., University of Kentucky.  All 
inhibitors were solubilized in DMSO.  Anti-EGFR LA1 and anti-HB-EGF neutralizing 
antibodies were acquired from Upstate (Lake Placid, NY) and R&D Systems 
(Minneapolis, MN) respectively, and were utilized at a final concentration of 10 µg/mL.  
Microarray data 
The NSCLC cell line dataset was extracted from the Microarray Database of 
University of Kentucky (251, 258).  Small airway epithelial cell cultures infected with 
adenovirus, as described above, were used to purify RNA and generate probe for 
microarray hybridization as described in Chapter 2.  All data were MASv5.0 normalized. 
Quantitative real-time PCR 
Total RNA was extracted from cells using RNEasy Mini kits (Qiagen, Valencia, 
CA) according to the manufacturer’s supplied protocol.  cDNA was synthesized by 
reverse-transcribing 1 µg of purified RNA using iScript (BioRad, Hercules, CA) according 
to the manufacturer’s supplied protocol.   Quantitative real-time PCR (qRT-PCR) was 
performed using Taqman Assays On-Demand primer/probes (Applied Biosystems, 
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Foster City, CA) for GAPDH, TGF-α, HB-EGF, and EGFR.  PCR was performed on an 
ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA).  
Relative quantification was applied using a standard curve method and normalization to 
GAPDH expression.   
Immunoblotting 
Cells were plated in media containing 10% FBS and media was changed to 0.1% 
for a 24 hr incubation prior to collection.   Cells were washed in PBS, harvested and 
lysed in RIPA buffer (50 mM Tris (pH 7.4), 1% NP-40, 150 mM NaCl, 1 mM EDTA, 0.1% 
SDS, 0.25% sodium deoxycholate, 5 mM NaF, 5 mM Na3VO4, 10% glycerol, 1 mM 
phenylmethyl-sulphonylfluoride, and protease inhibitors) for 30 min on ice. Lysates were 
sonicated briefly on ice to disrupt membranes and then centrifuged at 13,200 rpm for 10 
min and the protein concentrations of the supernatants were determined by BCA assay 
(Bio-Rad, Hercules, CA). Samples were separated by SDS-PAGE and transferred to 
PVDF membrane. Membranes were blocked with 5% nonfat dry milk or 5% BSA in TBS 
for 1 hr at room temperature and then incubated overnight at 4oC with the appropriate 
antibody. Antibodies specific for phospho-MEK1, phospho-ERK1/2, total ERK1/2, 
phospho-EGFR (Tyr 1068), total EGFR, calnexin and PARP were all obtained from Cell 
Signaling Technology, Beverly, MA.  Antibody specific for total MEK-1 (Santa Cruz 
Biotechnology, Santa Cruz, CA) was also utilized. Following incubation with appropriate 
horseradish peroxidase-conjugated secondary antibodies, proteins were visualized using 
an enhanced chemiluminescence detection system.  Immunoblots were scanned at a 
resolution of 600 dpi and quantified by integrated density using ImageJ (National 
Institutes of Health) where applicable.  Data were normalized to a loading control protein 
(actin or calnexin).  
MEK inhibition assays  
Cells were plated in 12-well plates (Costar, Corning, NY) at a density of 1x105 
cells per well. After 16 hr, the growth media was replaced with media containing 0.1% 
FBS and the cells were incubated for a further 24 hr. Subsequently, cells were treated 
with 10 µM UO126 for 24 and 48 hr by direct addition of the drug to the culture media. 
Control cells received an equivalent volume of DMSO. Following treatment, adherent 
and non-adherent cells were collected by centrifugation, washed in PBS, and lysed as 
previously described.  For time-course analyses of ligand expression, cells were treated 
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as above, but were harvested at 0, 4, 8, 16, and 24 hr in RLT buffer (Qiagen, Valencia, 
CA).  Total RNA was isolated using RNeasy mini kits according to manufacturer’s 
instructions.   
Determination of EGFR ligand concentration in conditioned media 
Cells were plated at a concentration of 2x105 cells/well of a 12 well dish and 
allowed to adhere overnight in full growth serum.  The following morning, media was 
changed to media containing 0.1% FBS.  Twenty-four hours later, cells were treated by 
adding U0126 to a final concentration of 10 µM to the existing media.  Following this 
treatment, conditioned media was collected from wells at 0, 2, 6, and 24 hr post-
treatment.  Media was cleared by centrifugation at high speed for 10 minutes at 4°C and 
the supernatant was removed and transported to new tubes.  Samples were snap-frozen 
and transported to Raybiotech® (Norcross, GA) for analysis by Quantibody Array.  
Concentrations of HB-EGF and TGF-α were determined and reported.  The experiment 
was performed and analyzed in triplicate. 
C. RESULTS 
EGF-like ligands HB-EGF and TGF-α are constitutively expressed in EGFR-
dependent NSCLC cell lines 
We explored our previously published gene expression data from a panel of 
NSCLC cell lines which was used to identify genes from the genomic signature of 
sensitivity to EGFR inhibitors that are important for mediating EGFR-dependency in 
NSCLC (251).  The dataset included both lung cancer cell lines with and without EGFR-
activating mutations (see Table 2.1).  The data explored in this analysis were the pool of 
1495 genes that were differentially expressed between EGFR-dependent and EGFR-
independent cell lines, of which a subset of 180 signal transduction genes were found to 
be predictive of response to EGFR inhibition.   Gene ontology trees are organized in a 
hierarchical manner, and we opted to utilize the entire 1495-gene dataset to include 
genes that are associated with cell signaling, although at a lower gene ontology level 
than that used to define the 180-gene subset. Therefore, using the entire 1495-gene 
dataset, we explored genes that appeared to be specifically deregulated in EGFR-
dependent cell lines.   
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Interestingly, the EGFR ligands, heparin binding EGF-like ligand (HB-EGF) and 
transforming growth factor-alpha (TGF-α), were identified as significantly up regulated in 
the microarray experiments using EGFR-dependent NSCLC cells (Figure 3.1, panels A 
and B).  These data were generated from cells actively proliferating in high-serum (10% 
FBS) containing media, which provides cells with exogenous survival factors.   
To explore the effects of survival factors on ligand expression, HB-EGF and 
TGF-α mRNA levels were evaluated in three of these cell lines using qRT-PCR following 
24 hours of serum-deprivation (0.1% FBS-containing media) (Figure 3.1, panels C and 
D).  We chose these cell lines as they represent a variety of EGFR genotypes (see 
Table 2.1).  We also included the H358 cell line as a representative EGFR-wt, EGFR-
dependent cell line, and the EGFR-wt, EGFR-independent A549 cell line as a reference 
for a total of 5 cell lines.  Relative expression levels of HB-EGF and TGF-α were 
consistent with the microarray data, with the exception of the EGFR-dependent PC-9 cell 
line.  The PC-9 cell line demonstrated reduced expression of the ligands relative to the 
other tested cell lines by qRT-PCR in low serum conditions. 
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Figure 3.1: HB-EGF and TGF-α are constitutively expressed in EGFR-dependent 
NSCLC 
Affymetrix MASv5.0 signal intensity values for (A) HB-EGF and (B) TGF-α, respectively, 
were extracted from the microarray data presented in Chapter 2. Only cell lines with data 
from at least 3 experiments were included.  Bars represent average + SD. qRT-PCR 
analysis of expression of (C) HB-EGF and (D) TGF-α, respectively, in A549, H358, 
H1650, H1975, and PC-9 cells following 24 hours of serum-deprivation (0.1% FBS-
containing media). Expression was determined by use of ABI TAQMAN probes and 
normalization of individual samples to GAPDH expression.  Relative quantification was 
performed using a standard curve method.  Bars represent mean + SD of three 
replicates. 
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Ras/MAPK pathway activation induces expression of alternate EGF-like ligands 
Analysis using TRANSFAC (234) and MAPPER (259) of the HB-EGF and TGF-α 
promoters identified the presence of ELK-1 and ETS-1 binding sites.  These transcription 
factors are downstream of and controlled by ERK1/2, a member of the RAS/MAPK 
module (260-262).  It is well established that EGFR can trans-activate the RAS/MAPK 
pathway (23).  Additionally, both HB-EGF and TGF-α have previously been shown to be 
regulated via oncogenic RAS and/or RAF expression in intestinal and mammary 
epithelial cells (252, 253, 263).   Finally, Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis of the components of our 180-gene predictive signature 
identified enrichment of genes involved in the RAS/MAPK pathway (see Figure 2.2) 
(251).  Therefore, both biochemical and bioinformatic analyses intersected at the 
RAS/MAPK pathway as a potential regulator of EGF-like ligand expression, and further 
exploration of this pathway in the context of EGFR-dependent NSCLC was warranted. 
EGFR signaling is mediated through at least three downstream pathways in 
NSCLC: the RAS/MAPK pathway, the STAT3 pathway, and the PI3K/AKT pathway (78).  
Therefore, we next determined if the RAS/MAPK pathway could specifically regulate 
gene expression of HB-EGF and TGF-α in normal lung cells.  We chose small airway 
epithelial cells (SAECs) as a model system because they are a primary cell line thought 
to be the precursor to adenocarcinoma and bronchioloalveolar carcinoma (264, 265).  To 
isolate the effects of deregulation of downstream pathways of EGFR, we infected these 
cells with adenoviruses expressing either green fluorescent protein (GFP) as a control, 
v-AKT (Ad-v-AKT), constitutively active STAT3 (Ad-STAT3ca), or constitutively active 
MEK-1 (Ad-MEK-1ca), a penultimate kinase of the RAS/MAPK pathway.  Uninfected 
cells were also analyzed as an additional control for the infection process.  After 16 
hours of virus infection, RNA was harvested for microarray analysis.  We specifically 
analyzed the probesets corresponding to HB-EGF and TGF-α, and found that only Ad-
MEK-1ca infection resulted in marked increase in expression of these EGFR ligands 
(Figure 3.2, panel A).  To confirm these results, we repeated the ectopic expression of 
MEK-1ca in human bronchial epithelial cells (hBEAS-2B), a lung cell line which has been 
immortalized by SV40 large-T antigen.  After 16 hours of infection, we confirmed ectopic 
expression (Figure 3.2, panel B) and isolated RNA to assess gene expression of both 
ligands by qRT-PCR.  Again, gene expression of both ligands was significantly 
increased following infection of MEK-1ca (Figure 3.2, panels C and D).  
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EGFR-dependent NSCLC cell lines exhibit constitutive ERK1/2 activation  
To determine whether HB-EGF and TGF-α expression correlates with activation 
of the Ras/MAPK pathway, we next assessed the level of activation of this pathway in 
the panel of NSCLC cell lines that we previously screened by microarray analysis.  To 
determine baseline activity of this pathway, all cell lines were plated and cultured for 24 
hr in low serum (0.1% FBS) containing media prior to lysis and western analysis for 
phospho-MEK-1 (pMEK-1) and phospho-ERK1/2 (pERK1/2) (Figure 3.3).  The EGFR-
dependent cell lines, which had the highest mRNA expression of HB-EGF and TGF- α, 
also demonstrated constitutive activation of ERK1/2.   
MAPK inhibition disrupts expression and activation of HB-EGF and TGF- α in 
EGFR-dependent NSCLC cells 
To confirm that the RAS/MAPK pathway drives expression of HB-EGF and TGF-
α in EGFR-dependent NSCLC, we assayed mRNA expression by qRT-PCR of these 
genes for 24 hr following MEK1/2/5 inhibition with U0126 in three of the EGFR-
dependent cell lines, as well as the EGFR-independent cell line, A549, as a reference 
(Figure 3.4, panel A and B).  In the H358 and H1975 cell lines, U0126 significantly 
decreased expression of HB-EGF and TGF-α.  For HB-EGF, this effect lasted the entire 
course of the experiment.  However, TGF-α expression was decreased transiently, 
returning to baseline by 24 hours.  In contrast, no decrease in the expression of either of 
the ligands was observed following MEK1/2/5 inhibition in the EGFR-independent A549 
cell line or the EGFR-dependent H1650 cell line. 
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While inhibition of gene expression represents one mechanism by which ligand 
activity may be controlled by the RAS/MAPK pathway, it is also important to assess 
ligand activation and shedding from the plasma membrane.  Alternate EGFR ligands, 
such as HB-EGF and TGF-α, are synthesized as pro-peptides and remain tethered to 
the cell membrane in an inactive form.  Shedding and activation of these molecules 
requires the action of the ADAM family of matrix metalloproteinases (114).  Vero-H cells 
(a monkey kidney epithelial line) have been previously utilized to demonstrate that 
shedding of HB-EGF is induced following constitutive RAS/MAPK activity (266). To 
evaluate the contribution of the Ras/MAPK pathway on ligand shedding and activation in 
NSCLC cells, we quantified both HB-EGF and TGF-α protein in conditioned media from 
each of these cell lines following MEK1/2 inhibition with U0126 (Figure 3.4, panel C and 
D, respectively).  We found that in H1975 cells, the concentration of HB-EGF was rapidly 
depleted to approximately 30% of baseline levels within 2 hr, and was maintained at 
approximately 50% of baseline levels for the remainder of the 24 hr experiment.  In 
H1650 cells, no change was observed in HB-EGF concentration in the supernatant.  In 
H358 cells, HB-EGF levels were consistently below the level of quantification.  The 
patterns observed in H1650 and H1975 cells were consistent with HB-EGF mRNA 
expression profile from the previous experiment (see Figure 3.4, panel A and B).  In 
contrast, TGF-α concentrations decreased quickly in both H1650 and H358 cells and 
remained at approximately 50% baseline for the remainder of the 24 hr period.  TGF-α 
was below the limit of quantification for all time points in the H1975 cell line.  Overall, the 
patterns of TGF-α concentration observed for the cell lines did not reflect mRNA 
transcription, suggesting additional control of TGF-α shedding or activation through a 
MAPK-dependent mechanism.    
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Figure 3.4: Characterization of the effects of MEK inhibition on HB-EGF and TGF-α 
expression and shedding in EGFR-dependent NSCLC cell lines  
Cells were plated and allowed to adhere overnight in 10% FBS-containing media.  Media 
was then changed to 0.1% FBS-containing media for 24 hours before direct addition of 
U0126 to the culture supernatant.  Cells were harvested at 0, 4, 8, 16, and 24 hours after 
addition of drug and RNA was used for downstream qRT-PCR analysis of (A) HB-EGF 
and (B) TGF-α expression.  Values are reported as mean expression, normalized to the 
expression of the internal standard GAPDH and set to an arbitrary value of 1 for each 
cell line at the 0 hr.  □ : H358 ○: H1650 Δ: H1975. Cells were treated as above, but 
supernatant media was collected and analyzed by the ELISA-based Quantibody ® array 
system to determine concentrations of (C) HB-EGF and (D) TGF-α, respectively.  Values 
are reported as the mean of 3 experiments, with error bars representing the SEM.  HB-
EGF was below the limit of quantification for all time points in H358 and is not reported.  
TGF-α was below the limit of quantification for all time points in H1975 and is not 
reported.   □: H358 ○: H1650 Δ: H1975. 
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MAPK inhibition modulates EGFR stability through a transcription independent 
process  
In order to determine the effects of decreased ligand expression and activity on 
EGFR signaling in each cell line following MEK inhibition, we performed western blot 
analysis to assess the phosphorylation of EGFR at tyrosine 1068 (one site which 
regulates RAS/MAPK pathway activity) following 24 and 48 hours of MEK1/2/5 inhibition 
with U0126 (Figure 3.5 panel A and B, respectively) (267).  In each cell line, ERK1/2 
phosphorylation was effectively inhibited by U0126 over the 48 hour period.  A decrease 
in phospho-Y1068 was also observed in the U0126 treated cells compared to the 
DMSO-treated controls in each cell line tested.  However, a decrease in total EGFR 
protein occurred concurrently in each of the cell lines, suggesting that the effects of MEK 
inhibition on EGFR-dependent survival may be due to a combination of decrease in 
ligand expression/activation and a down regulation of the EGF receptor itself.  Down-
regulation of EGFR was not observed in several EGFR-independent cell lines treated 
with U0126 (Figure 3.5, panel C), suggesting that this effect may be specific to the 
EGFR-dependent phenotype. 
To further dissect these changes in EGFR stability, we assessed expression of 
EGFR by qRT-PCR over 24 hr following MEK1/2/5 inhibition, and did not observe a 
significant decrease in receptor gene expression in the H1975 or H1650 cell lines 
(Figure 3.5, panel D).   The H358 cell line demonstrated a transient reduction in EGFR 
mRNA expression by ~ 70%.  EGFR gene expression returned to baseline by 24 hr, 
failing to explain the prolonged reduction in EGFR protein.   
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Inhibition of ligand binding induces EGF receptor down regulation in the T790M, 
L858R EGFR mutant 
Given these findings, we sought to identify a mechanism by which MEK inhibition 
could down regulate EGFR protein levels.  EGFR can be ubiquitinated and degraded in 
the proteosome following ligand binding (268, 269).  However, significant differences 
exist in the dynamics of endosomal EGFR sorting and subsequent proteosomal 
degradation following binding of the two most extensively studied EGFR ligands, TGF-α 
and EGF.  TGF-α dissociates from EGFR at lower endosomal pHs more readily than 
EGF, and results in enhanced receptor and ligand recycling. EGF-EGFR interactions are 
more stable and result in degradation of the receptor-ligand complex (36, 268, 269).  
Thus, specificity of ligand binding could modulate EGFR turnover, depending on the 
ligands available in the tumor cell microenvironment.   
We therefore hypothesized that the persistent presence of alternate EGFR 
ligands, those other than EGF, such as HB-EGF or TGF-α could protect the receptor 
from degradation.  To test this hypothesis, we utilized the EGFR double mutant 
(L858R/T790M) H1975 cell line.  In previous experiments, the H1975 cell line responded 
the most dramatically to MEK inhibition in terms of EGFR down regulation.  To 
determine if U0126-mediated down regulation of EGFR occurs via enhanced 
proteosomal degradation, we treated H1975 cells with either U0126 or the combination 
of U0126 and MG-132, a proteosomal inhibitor.  U0126 treatment down regulated EGFR 
by approximately 30-40% at 24 hours, while the combination of U0126 and MG-132 
treatment abrogated this effect.  These results indicate that, in part, U0126 down 
regulates EGFR via enhanced proteosomal processes (Figure 3.6, panel A).    
We have shown that H1975 cells express high levels of HB-EGF, but not TGF-α 
in cell culture supernatant and that U0126 treatment depletes HB-EGF and EGFR in 
these cells. Therefore, we treated H1975 cells with neutralizing HB-EGF targeted 
antibody or neutralizing EGFR ligand-binding domain antibody for 2, 6, or 24 hr to 
determine if interruption of HB-EGF binding to EGFR could produce a similar phenotype 
to MEK inhibition.  We found that EGFR levels were significantly depleted after 24 hr in 
both neutralizing antibody treatment groups compared to control (Figure 3.6, panels B 
and C).   Interestingly, this phenotype following EGFR-neutralizing antibody treatment 
was even more pronounced than U0126 treatment in this cell line.  These data suggest 
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that persistent ligand binding of endogenous HB-EGF and/or other alternate EGFR 
ligands may protect the receptor from turnover, and could offer an additional explanation 
for the persistent EGFR levels observed in EGFR mutant NSCLC cell lines (93, 270). 
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D. DISCUSSION 
Understanding EGFR expression, activation, and turnover in the context of 
NSCLC is a subject of great significance and interest to both the basic science and 
clinical fields.   Substantial research has been aimed at elucidating the relative 
contribution of downstream pathways to the phenotype of EGFR-oncogene addiction.  
Our results indicate that the Ras/MAPK pathway, through the expression and activation 
of EGF-like ligands, may serve to stabilize EGFR levels resulting in autocrine activity.   
The work presented here demonstrate that EGFR-dependent cell lines express 
high levels of EGF-like ligand mRNA, regardless of culture conditions. Furthermore, 
constitutive activation of ERK1/2 correlates with expression of these ligands.  
Interestingly, phosphorylation of MEK-1 and its immediate downstream effectors ERK1/2 
did not correlate in the NSCLC cell lines tested. Induction of the RAS/MAPK pathway by 
ectopic expression of constitutively active MEK-1 in non-malignant lung cells also 
induces ligand expression, mimicking the presence of an autocrine/paracrine loop in 
lung epithelial cells that is likely deregulated in EGFR-dependent NSCLC.  
Loss of MAPK activity in EGFR-dependent lung cancer cell lines results in 
decreased expression and/or activation of EGF-like ligands, leading to reduced EGFR 
activation.  Thus, in the absence of exogenous survival factors, the MAPK pathway is 
likely necessary for survival of EGFR-dependent lung cancer cells.  This hypothesis will 
be tested in Chapter 4.  The importance of the production and activation of EGF-like 
ligands in the EGFR–dependent phenotype is the subject of scrutiny. However, our work 
suggests that the mechanism of EGFR oncogene addiction may encompass either 
paracrine and/or autocrine signaling involving these ligands. 
We have observed that activation of the EGFR pathway may also be modulated 
by inhibition of the RAS/MAPK cascade through a transcription-independent down 
regulation of the EGF receptor itself.  Recent reports have suggested that EGFR 
mutations result in impaired degradation of the receptor following EGF activation (93, 
271).   This finding has been partially attributed to enhanced EGFR-HER2 interactions 
arising from constitutive phosphorylation of the mutant EGFR receptor.  HER2-EGFR 
heterodimerization blocks the Cbl docking site on EGFR, thus interrupting Cbl-mediated 
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ubiquitination, and enhancing receptor recycling (93, 270).  Similarly, EGFR-ligand 
interactions may also protect the receptor from degradation in EGFR-dependent cells. 
A second mechanism that may be altered in EGFR-dependent NSCLC is EGFR 
turnover driven by inappropriate levels of EGF-like ligands. While EGF was utilized to 
stimulate EGFR in the aforementioned cell culture models, we were unable to detect 
endogenous EGF by ELISA in any of the NSCLC cell lines tested here (data not shown), 
suggesting that EGF may not be the most relevant stimuli in these cell lines.   In contrast 
to EGF,  TGF-α stimulation has been demonstrated to result in reduced degradation of 
the ligand-receptor complex via increased receptor recycling (36).  Thus, TGF-α 
expression and activation may protect EGFR from degradation via shunting the receptor 
into recycling pathways.   Although significantly less is known regarding the ligand-
receptor dynamics of HB-EGF-EGFR, one could hypothesize that expression of 
alternative EGF-like ligands such as HB-EGF could similarly protect the receptor from 
degradation.  Reduction in ligand activity by inhibition of the RAS/MAPK pathway might 
then restore normal receptor degradation rates, resulting in reduced EGFR protein 
levels.  We have directly tested this hypothesis in H1975 cells by neutralizing HB-EGF 
as well as blocking the ligand binding domain of EGFR under conditions free of 
exogenous growth factors.  Both neutralizing antibodies caused a substantial decrease 
in EGFR expression, similar to that observed with U0126.  Interestingly, we were unable 
to achieve similar results in full-serum media, suggesting that growth factors contained in 
the media, such as EGF-like ligands, could supplement the loss of ligand activity 
induced with MEK1/2/5 inhibition or neutralizing antibody treatment. The results of this 
experiment suggest that RAS/MAPK-mediated expression of EGFR ligands, such as 
HB-EGF and TGF-α, may contribute to sustained EGFR expression and signaling in 
EGFR-dependent NSCLC. 
Interestingly, an alternative and potentially contributing effect of ERK1/2 
activation is phosphorylation of T669 of EGFR.  Reconstitution experiments in CHO-
GHR cells, which lack expression of EGFR, performed using stable expression of a 
T669A EGFR mutant, demonstrate that phosphorylation of this residue delays receptor 
trafficking, ubiquitination, and degradation (272).  Furthermore, MEK inhibition 
phenocopied this effect in EGFR T669 expressing cells, but not in cells expressing the 
T669A mutant (272).  Therefore, these results offer an additional explanation for how 
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RAS/MAPK activity in EGFR-dependent NSCLC cells may stabilize EGFR protein levels.  
The contribution of this mechanism remains to be studied in EGFR-dependent NSCLC. 
Although each of the EGFR dependent cell lines demonstrated common trends 
when treated with MEK1/2/5 inhibitors, mRNA expression of HB-EGF and TGF-α was 
resistant to changes induced by MAPK inhibition in the H1650 cell line.   Therefore, the 
H1650 cell line may utilize additional signaling pathways to maintain expression of these 
ligands.  Interestingly, the H1650 cell line does not express the tumor suppressor PTEN, 
a primary mediator in PI3K/AKT pathway activity (273).  PTEN deletion results in 
constitutive AKT activation and has been suggested to also play a role in mediating 
erlotinib resistance (154).  In accordance with this observation, the H1650 cell line has 
been reported to be insensitive to EGFR inhibitors in some cell culture models (274).   
Therefore, it is possible that AKT pathway activation may compensate for loss of ERK 
activity in this cell line, although PI3K inhibition in H1650 cells did not reduce ligand 
expression (data not shown). Despite the heterogeneity observed among the cell lines 
tested, MAPK-dependent shedding of TGF-α was observed in H1650 cells, possibly 
accounting for the modest induction of apoptosis observed in this cell line.  The ability of 
this cell line to evade some, but not all, of the effects of MEK inhibition on EGFR 
autocrine activity are intriguing and will be studied in the future. 
E. CONCLUSIONS 
The results of this study demonstrate that ERK activation is needed for EGFR-
ligand activity and may protect the receptor from degradation in EGFR-dependent cells.  
These data offer mechanistic detail explaining the role of autocrine/paracrine signaling in 
maintenance of EGFR levels and subsequent downstream pathway activity. Further, 
these findings could indicate important therapeutic roles for HB-EGF neutralizing 
antibodies and/or MEK inhibitors in the treatment of EGFR-dependent NSCLC.  It will be 
important to further these data by determining whether the effects of MEK inhibition in 
EGFR-dependent lung cancer cells translate to potential therapeutic benefit (i.e. 
decreased cell proliferation and/or survival).  Also, future studies will determine if 
chemical inhibitors of MEK1/2, which are currently navigating clinical trials, may be 
useful in combination with EGFR inhibitors in the EGFR-dependent NSCLC phenotype. 
Copyright © Justin M. Balko 2009
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CHAPTER 4  
A. OVERVIEW 
The formation of resistance to EGFR inhibitors represents a hurdle in 
progressing toward a sustainable cure in EGFR-dependent NSCLC patients.   
Generation of the T790M mutation in exon 20 of the EGFR gene is the most common 
mechanism of acquired resistance documented to date, although intrinsic resistance via 
T790M has also been reported in clinical studies (91, 99, 178, 179).  The T790M 
mutation confers enhanced EGFR activity and results in increased ATP binding affinity, 
dramatically raising the IC50 of the inhibitor (91, 100). Additionally, amplification of the c-
MET gene has also been reported to facilitate resistance to EGFR inhibition, although it 
does not appear to occur as commonly as the T790M lesion (98, 113). 
One strategy to combat acquired resistance to EGFR inhibitors is the clinical 
testing of second generation EGFR-TKI which irreversibly inhibit the ATP-binding 
domain of EGFR (214, 242, 275).  Irreversible inhibitors could offer extended responses 
in patients with EGFR-dependent tumors when used front-line or may be used in 
salvage therapy for patients who initially respond to first-generation inhibitors and 
subsequently relapse.  However, pre-clinical studies suggest that the T790M mutation 
can still be selected by exposure to clinically relevant concentrations of the irreversible 
EGFR inhibitor HKI-272 (146), perhaps as the result of the ATP-competitive nature of 
HKI-272 coupled with a comparably lower binding affinity of the drug for the mutated 
binding pocket than ATP.  Therefore, the generation of T790M-mediated EGFR-TKI 
resistance could persist despite the irreversible mechanism of action of HKI-272, and the 
use of irreversible inhibitors of EGFR as a single-target treatment may not provide 
further benefit to patients harboring EGFR-dependent tumors. 
 Combinatorial therapy in cancer treatment results in improved response rates 
and reduced acquired resistance (276).  Such strategies are widely implemented in 
antimicrobial and antiviral therapy, most notably in HIV treatment (277).  When using 
traditional agents, combinatorial therapy in cancer often results in enhanced toxicity. 
However, combining EGFR inhibitors with traditional chemotherapeutic agents has not 
been successful in early clinical trials (135, 208-210).  Little data is available regarding 
the combination of erlotinib with other kinase inhibitors, which may result in improved 
ADAPTED FROM: Balko et al, Cancer Biology & Therapy (2009) 8:6 
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response rates with lower toxicity than traditional chemotherapeutics.  Identification of 
appropriate add-on therapeutics to EGFR inhibitors to improve therapy and combat 
acquired resistance requires an understanding of both the EGFR pathway and the 
effects of EGFR dependency on the lung tumor cell.  
EGFR transduces signals from the extracellular space to the nucleus via several 
downstream pathways.  The RAS/MAPK pathway lies downstream of EGFR, but can 
also be activated by other trans-membrane receptors, including c-MET (278).  MEK1 
and MEK2, the penultimate kinases of the classical Ras/MAPK pathway, activate ERK1 
and ERK2, and are targeted by a number of kinase inhibitors currently navigating clinical 
trials (23, 279, 280).  The more recently characterized MEK5 appears to activate ERK5 
downstream of EGFR and RAS, independently of the classical RAF-MEK1/2-ERK1/2 
pathway (281).  Many of the commercially available MEK1/2 inhibitors such as U0126 
and PD98059 have also been shown to affect MEK5, and therefore additional strategies, 
such as siRNA technology, are necessary to isolate the MEK1/2 pathway in 
pharmacological research.   
Our observations, as well as those of others, demonstrate that ERK1/2 are 
constitutively active in EGFR-dependent NSCLC cells and this phenotype is associated 
with EGFR dependency (97).  Furthermore, genomic profiling of EGFR-dependent 
NSCLC cells identified deregulation of the RAS/MAPK pathway (see Chapter 2).  
Inhibition of the RAS/MAPK pathway in EGFR-dependent NSCLC cells reduced the 
expression and/or activation of HB-EGF and TGF-α, two EGFR ligands (see Figure 3.4).  
These ligands were implicated in modulating the stability of EGFR protein levels, as 
MEK1/2/5 inhibition or inhibition of EGFR ligands with neutralizing antibodies resulted in 
decreased receptor levels in a transcription-independent process (see Figure 3.6).   
In this study, we show that MEK1/2/5 inhibition reduces EGFR-dependent tumor 
cell proliferation, and induces apoptosis depending on trophic conditions.  Importantly, 
MEK1/2/5 inhibitors are active in T790M mutant cell lines, supporting their use to reduce 
selective pressure for the T790M mutation in patients treated with EGFR inhibitors.   
Finally, combining MEK1/2/5 inhibitors with EGFR inhibitors resulted in synergistic 
activity, and the effect was the greatest in EGFR-mutant cells.  Parallel experiments 
utilizing AZD6244 (ARRY-142886), a selective MEK1/2 inhibitor, as well as depletion of 
ERK1/2 using siRNA followed by EGFR inhibitor treatment further supported these data 
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and suggest that inhibition of MEK1/2 and not MEK5 drives the sensitive phenotype.  
Therefore, we conclude that combining EGFR and MEK1/2 inhibitors warrants clinical 
testing to enhance response and reduce acquired resistance by coordinately inhibiting at 
least two oncogenic signaling pathways.  Overall these data support further research in 
evaluating the efficacy of combined MEK/EGFR inhibition in in vivo models of EGFR-
dependent tumors. 
B. METHODS 
Cell culture 
The human NSCLC cell lines A549, UKY-29, NCI-H1975, NCI-H1650, NCI-H358, 
and PC-9 were obtained and maintained as previously described (251).   PC-9#37 was 
kindly provided by Dr. Jeffery Settleman, M.D. and is a randomly mutagenized subclone 
of the PC-9 cell line which contains the T790M mutation in the EGFR gene (146).  This 
mutation is known to reduce the binding of EGFR inhibitors (99).  All cells were 
maintained in RPMI 1640 (with 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium 
pyruvate, 4.5% glucose, 1.5% sodium bicarbonate) containing 10% fetal bovine serum 
(FBS) (Biowest, Miami, FL), 50 µg/ml penicillin and 50 µg/ml streptomycin.   Serum 
content of the media was reduced for particular experiments where indicated.  Fraction V 
Bovine Serum Albumin (BSA, InVitrogen, Carlsbad, CA) was obtained at a stock 
concentration of 7.5% w/v.  BSA was added to cell culture experiments at a 1:10 (0.75%) 
or 1:100 (0.075%) concentration where indicated. 
Chemical compounds 
The MEK1/2/5 inhibitors U0126 and PD098059, as well as the irreversible EGFR 
inhibitor CL-387,785 were obtained from EMD Chemicals (Gibbstown, NJ).  The EGFR 
inhibitor erlotinib was provided by Genentech (San Francisco, CA).  AZD6244 (ARRY-
142866) was kindly provided by Astra Zeneca (London, UK). All inhibitors were 
solubilized in DMSO at a 1000X concentration such that the concentration of DMSO in 
treated cells did not exceed 0.1%. 
Western blotting 
Cells were washed in PBS, harvested and lysed in RIPA buffer (50 mM Tris (pH 
7.4), 1% NP-40, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 0.25% sodium deoxycholate, 5 
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mM NaF, 5 mM Na3VO4, 10% glycerol, 1 mM phenylmethyl-sulphonylfluoride, and 
protease inhibitors) for 30 min on ice. Lysates were sonicated for 2-3 seconds to shear 
DNA and cleared by centrifugation at 13,200 rpm for 15 min.  Protein concentrations of 
the lysates were determined by BCA assay (Bio-Rad, Hercules, CA). Samples were 
separated by SDS-PAGE and transferred to PVDF membrane. Membranes were 
blocked with 5% nonfat dry milk or 5% BSA in TBS for 1 hr at room temperature and 
then incubated overnight at 4°C with the appropriate antibody as indicated. Antibodies 
specific for phospho-ERK1/2, total ERK1/2, p-AKT (Ser473), total AKT, activated CASP3 
and total PARP were obtained from Cell Signaling Technology (Beverly, MA).  MEK-1 
and HA-tag antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  
Actin and calnexin antibodies were used as controls for equivalent protein loading and 
were obtained from Sigma-Aldrich (St. Louis, MO) and Cell Signaling Technology, 
respectively. Following incubation with appropriate horseradish peroxidase-conjugated 
secondary antibodies, proteins were visualized using an enhanced chemiluminescence 
detection system.  Immunoblots were scanned at a resolution of 600dpi and quantified 
by integrated density using ImageJ (National Institutes of Health) where applicable.   
Trypan blue exclusion assays 
Cells were plated in 24-well plates at a density of 2x104 cells per well and 
allowed to adhere overnight in full growth media.  The following morning, all cells were 
changed to media containing 0.1% FBS for 24 hours.  Cells were then treated in one of 
the following conditions: 0.1% DMSO in media containing 10% FBS, 10 µM U0126 in 
media containing 10% FBS, 0.1% DMSO in media containing 0.1% FBS, or 10 µM 
U0126 in media containing 0.1% FBS.  At 0, 24, 48, and 72 hr post-treatment, non-
adherent (floating) and adherent cells were collected.  Viable and non-viable cells were 
counted using trypan blue exclusion under light microscopy.  Cell growth was 
determined at each time point by the percent of viable cells in the well compared to the 
viable cells counted immediately following treatment (0 hr).  Cell viability was calculated 
as the number of viable cells counted at each time point as a percentage of the sum of 
non-viable and viable cells counted at that time point ([100% x viable ] / [non-viable + 
viable]).  Experiments were repeated at least 3 times to determine experimental 
variability.  Data were analyzed by JMP (SAS, Cary, NC) using ANOVA for repeated 
measures to determine treatment effects.   
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Clonogenic survival assays 
Cells were plated to 6-well dishes at a density of 1000 cells/well.  The following 
morning, media was changed to 5% or 0.1% serum-containing media, and cells were 
treated with 10 µM U0126 or DMSO control.  After 48 hr, media containing drug was 
removed, cells were washed once in PBS, and then cells were replenished with 10% 
serum-containing media.  After 7-14 days, cells were washed once in PBS and then 
fixed in ice cold methanol for 10 min.  Cells were then stained with 0.5% crystal violet in 
25% methanol for 10 minutes and excess dye was removed with multiple water washes.  
Colonies of greater than or equal to 10 cells were counted in 10 fields under light 
microscopy.  The average number of colonies per visual field was then multiplied by 
348.6 (number of fields calculated per well) to determine the number of surviving 
colonies.  Colonies were counted by two investigators, one of whom was blinded to the 
purpose and design of the experiment.  The average of the two counts was utilized for 
statistical analysis (two-tailed student’s t-test).  Each experiment was performed in 
triplicate. 
Cell cycle/FACS analysis 
Cells were plated on 60 mm dishes and allowed to attach overnight in full growth 
serum-containing media.  The following morning, media was changed to 0.1% serum-
containing media.  Twenty-four hours later, sufficient serum was added to achieve a final 
concentration of 5% serum and cells were treated with 5 µM U0126 or 0.1% DMSO.  
After 24 hr, adherent and floating cells were collected and fixed in ethanol overnight.  
Cells were stained with propidium iodide and analyzed by flow cytometry for DNA 
content.  
Adenovirus infection 
Cells were plated at a density of 5x104/well of 6-well plates and allowed to 
adhere for 6-8 hours.  Once cells had attached, media was aspirated and the cells were 
infected with replication-deficient recombinant adenovirus expressing GFP or HA-tagged 
constitutively active MEK-1 at a multiplicity-of-infection of 500.  The MEK-1ca construct 
was kindly provided by Dr. Janet Rubin, Ph.D. and the details regarding this construct 
are previously published (256).  The infection was carried out in 1 mL of serum-free 
RPMI media supplemented with 25 mM HEPES buffer.  The plates were returned to the 
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incubator and rocked every 15 minutes for 1 hr before the addition of 1 mL of full-serum 
media.  Sixteen hours later, cells were treated with inhibitors or DMSO control in 0.1% 
FBS-containing media for a period of 48 hr.  Floating and adherent cells were then 
harvested and analyzed by western blot as described. 
siRNA transfection 
Cells were plated and allowed to attach overnight in full growth serum-containing 
media.  The following morning, cells were transfected with siRNA using siQuest (Mirus 
Bio, Madison WI) transfection reagent according to the manufacturer’s protocol.  
Smartpool siRNA targeting ERK1 (MAPK3), ERK2 (MAPK1) or non-targeted siRNA was 
purchased from Dharmacon (Chicago, IL).  Cells were collected at 48 hr and harvested 
for western analysis or re-plated for additional experiments. 
Sulfarhodamine B assays 
Sulfarhodamine B (SRB) was used to measure cell proliferation and viability 
using total protein content as a quantitative metric and is widely used by the NCI to 
screen compounds and quantify cytotoxicity.  Cells were plated in 96 well plates at a 
density of 5x103 cells per well in 100 µL of full growth media and allowed to adhere 
overnight.  The following morning, media was changed to 100 µL 5% FBS-containing 
media and cells were treated with DMSO control or serial dilutions of U0126 in an 
additional 100 µL of 5% FBS-containing media.  After 24, 48, or 72 hr, media was 
aspirated and the cells were fixed for 30 minutes in 10% trichloroacetic acid at 4°C.  
Cells were then washed with tap water 5 times and allowed to air dry.  Cells were 
stained with 0.4% sulfarhodamine B in 1% acetic acid for 10 minutes, washed 5 times 
with 1% acetic acid to remove unbound dye, and then allowed to air dry.  Bound dye was 
then solubilized by the addition of 100 µL 10 mM Tris-HCl and shaking for 5 minutes.  
Absorbance was measured at 490 nM on a 96-well plate reader.  At the time of 
treatment, additional cells were analyzed to determine baseline (time zero) signal.  Blank 
wells and time zero signals were subtracted from the raw data, then normalized to the 
control (untreated) values.  Fifty-percent growth inhibitory (GI50) and total growth 
inhibitory (TGI) values were determined by fitting a sigmoidal dose-response curve to the 
data and interpolating the concentrations at which drug inhibited 50% and 100% of the 
growth relative to time zero, respectively.  Experiments were performed in quadruplicate 
and data was analyzed using Graphpad Prism (Graphpad Software, La Jolla, CA).  
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Synergy studies 
Cells were treated and analyzed by SRB as above.  The MEK inhibitor U0126 
and the EGFR inhibitor CL-387,785 were utilized at fixed (1:1) ratios of the IC50 as 
quantified in preliminary experiments.  IC50 values were calculated similarly to GI50 
values from SRB assays as described above, but without subtracting the time-zero 
signals.  Synergy was assayed using Calcusyn (Biosoft, Ferguson MO).  The 
combination index for the drug combination at the IC50 and IC75 was determined by the 
method reported by Chou and Talalay (282).  Degree of synergy is based on the 
combination Index (CI) and is reported in the following manner: CI < 1, synergy; CI=1, 
additive; CI > 1, antagonism.  The experiment was performed at least three times in all 
cell lines. 
C. RESULTS 
EGFR-dependent NSCLC cell lines display ERK-dependent growth 
A panel of adenocarcinoma-derived NSCLC cell lines representing a variety of 
EGFR genotypes was assessed to determine activation of effector molecules 
downstream of EGFR.  The characteristics of the cell lines used are presented in Table 
4.1.  Two signal transduction pathways downstream of EGFR that are known to 
contribute to the oncogenic phenotype include the RAS/MAPK pathway and the 
PI3K/AKT pathway.  We first assessed the status of the RAS/MAPK pathway in EGFR-
dependent cells.   The PI3K/AKT pathway was also interrogated because it has been 
implicated in mediating many of the oncogenic effects of activated or mutated EGFR in 
NSCLC.  
In order to evaluate constitutive activity of EGFR effector molecules, the cell lines 
were cultured for a period of 24 hr in low-serum (0.1% FBS) media prior to harvest and 
assessment by western blot of the activated effector proteins ERK1/2 and AKT (Figure 
4.1, panel A).  There was strong concordance between the EGFR-dependent phenotype 
and p-ERK expression relative to the reference EGFR-independent cell lines (UKY-29 
and A549) under the same conditions, while the degree of p-AKT observed in the cell 
lines was variable. 
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Table 4.1: NSCLC cell line characteristics 
Cell line 
EGFR-
dependent EGFR status KRAS status PTEN status 
UKY-29 No Wild-type G61H expressed 
A549 No Wild-type G12V expressed 
H358 Yes Wild-type G12V expressed 
PC-9 Yes Amplified, del746-750 Wild-type expressed 
PC-9#37 Yes Amplified, del746-750, 
T790M 
N/D expressed 
H1975 Yes L858R, T790M Wild-type expressed 
H1650 Yes del746-750 Wild-type deleted 
N/D: No data 
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To further explore the importance of ERK activity in these cell lines, the 
MEK1/2/5 inhibitor U0126 was used to determine the contribution of activated ERK on 
EGFR-dependent tumor cell growth.  In parallel experiments, the pure MEK1/2 
antagonist AZD6244 was utilized at a clinically achievable concentration (1 µM) to 
isolate the MEK1/2 pathway and confirm the findings (283).  Using an SRB assay to 
monitor proliferation in the presence of drug, MEK1/2 activity was important in at least 4 
of 5 cell lines tested (Figure 4.1, panel B).  AZD6244, but not U0126, significantly 
reduced proliferation in the H1650 cell line.  Additionally, we performed trypan blue 
exclusion assays on each of the cell lines under full serum conditions over a 72 hr period 
of 10 µM U0126 treatment and found that in 3 of the 4 EGFR-dependent cell lines tested 
(H358, PC-9, and H1975, but not H1650), a significant reduction in cell growth was 
observed by this method (see APPENDIX V, Figure V.1).  Western analysis of p-ERK 
confirmed that U0126-mediated down regulation of ERK activity was sustained for at 
least 48 hours in all of the cell lines tested.  
 In light of our results using the specific MEK1/2 antagonist AZD6244, we wished 
to confirm specificity of these results to the MEK1/2 targets ERK1 and ERK2.  To isolate 
this pathway, we performed siRNA-mediated depletion of ERK1, ERK2, and the 
combination (ERK1+ERK2).  Forty-eight hours after transfection, a portion of the cells 
were harvested and ERK knockdown was confirmed by western blotting (Figure 4.1, 
panel C).  Remaining cells were plated to 96-well dishes and cultured for an additional 
48 hr to measure cell proliferation by SRB.  ERK1 or ERK2 knockdown reduced cell 
proliferation considerably, although to varying degrees, depending on the cell line 
(Figure 4.1, panel D).  Overall, ERK2 knockdown resulted in a more consistent reduction 
in cell proliferation across the cell lines.  In 3 of 4 EGFR-dependent cell lines tested, 
combined ERK1/2 knockdown induced total growth inhibition (TGI).  
To determine whether the effect of U0126 treatment on cell proliferation was due 
to growth arrest, DNA content analysis was performed in the cell lines following 24 hr of 
5 µM U0126 treatment (Figure 4.1, panel E).  Only the H358 and H1650 cell lines 
demonstrated a significant increase in cells in the G0 /G1 phase.  Interestingly, although 
small molecule inhibition of MEK1/2 or siRNA-mediated knockdown of ERK1/2 resulted 
in reductions in cell growth in the H1975, PC-9, and PC-9#37 cell lines, we did not 
observe growth arrest by DNA content analysis in these cell lines. We hypothesized that 
the inhibition of cell growth due to loss of ERK1/2 activity observed in the EGFR-
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dependent cell lines could therefore be the result of contributing mechanisms such as 
cell death or apoptosis, as opposed to growth arrest. 
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A)  Cells were harvested following 24 hr of culture in low-serum media and lysates were 
assayed by western blot for the indicated proteins and phospho-proteins.  B)  Cells were 
treated with DMSO control, 10 µM U0126, or 1 µM AZD6244 in 5% media for 72 hr and 
assayed by SRB.  Bars represent mean of four experiments +/- SD.  * p<0.05, ** p<0.01, 
*** p<0.001.  C)  Cell lines were transfected with non-targeted (NT) siRNA, or  siRNA 
targeted for ERK2, ERK1, or the combination.  After 48 hr, the cells were harvested and 
lysates were analyzed by SDS-PAGE and western blot to confirm successful 
knockdown.  D)  Cells from panel ‘C’ were trypsinized and split to 96-well plates.  Cell 
proliferation was analyzed by the SRB assay at 0 and 48 hr.   Data are expressed as 
percent of the signal achieved at day 0 for each transfection group, +/- SD (three 
replicates).  E)  Cells were treated with U0126 (5 µM) or DMSO control in 5% serum 
containing media.  After 24 hr, cells were collected, fixed in ethanol, and stained with 
propidium iodide.  DNA content analysis was performed by FACS analysis.    Data are 
expressed as the percentage of cells in the G0/G1 phase. Bars represent mean of three 
experiments +/- SD. * p<0.05, ** p<0.01, *** p<0.001 
 
 
 
 
 
 
 
 
   
Figure 4.1: ERK1/2 is required for the proliferation of EGFR-dependent NSCLC cell 
lines  
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Loss of ERK activity inhibits survival and induces apoptosis in EGFR-dependent 
NSCLC cell lines during trophic stress 
We assessed whether EGFR-dependent NSCLC cell lines demonstrate reduced 
survival in response to MEK inhibition.  In order to measure survival, we performed 
clonogenic survival assays in the EGFR-dependent cell lines following 48 hr of treatment 
with U0126 or DMSO in low serum media (0.1% FBS).  A significant reduction in 
clonogenic potential was observed in each of the 4 cell lines tested (Figure 4.2, panel A, 
top).  However, when the cells were treated in serum containing media (5% FBS) for 48 
hr, this effect was largely abrogated (Figure 4.2, panel A, bottom).  To further these 
results, we treated the cell lines with U0126 in low serum media (0.1% FBS) and 
assessed viability from 0-72 hours by trypan blue exclusion.  The percent of viable cells 
was negatively affected by 10 µM U0126 treatment, particularly in the H1975 and H358 
cell lines (see APPENDIX V, Figure V.2).  The low serum conditions resulted in a 
considerable loss of viability in the PC-9 cell line regardless of U0126 treatment.  
However, as with the clonogenic assay, U0126 did not reduce viability when the 
experiment was repeated under full serum (10% FBS) conditions.  These data suggest 
the presence of either a trophic effect, which alleviates the cytotoxicity of MEK inhibition 
under full serum conditions, and/or a stress-response effect, which facilitates an 
enhanced response to MEK inhibition in low serum. 
We next characterized the cytotoxicity that was observed during MEK inhibitor 
treatment under low-serum conditions.  Three of the EGFR-dependent cell lines were 
assayed for PARP cleavage as an indicator of apoptosis following U0126 treatment for 
24 hr (Figure 4.2, panel B, top) and 48 hr (Figure 4.2, panel B, bottom) in low serum 
media.  Treatment with U0126 resulted in a significant upregulation of the cleaved 85kD 
band, suggesting apoptotic activity due to MEK inhibition under trophic stress.  These 
data were furthered by confirming the presence of a dose-response effect on PARP 
cleavage in H1975 cells following 24 hr of treatment with varying concentrations of 
U0126 (Figure 4.2, panel C).  Furthermore, ectopic expression of a constitutively active 
MEK-1 mutant rescued H1975 cells from PD098059-induced PARP cleavage, but not 
U0126-induced PARP cleavage (see APPENDIX V, Figure V.3).  In contrast to U0126, 
which inhibits the kinase activity of MEK1/2/5, PD098059 prevents the activation 
(phosphorylation) of MEK, thus genetically-modified MEK1 that is constitutively active 
would be expected to be refractory to inhibition by PD098059 (284).  These experimental 
ADAPTED FROM: Balko et al, Cancer Biology & Therapy (2009) 8:6 
 
84 
 
results confirm the role of MEK1 and not MEK5 in mediating the survival of EGFR-
dependent NSCLC cells. 
We found that supplementing low serum media with bovine serum albumin 
abolished the ability of U0126 to induce apoptosis in the H1975 cell line (see APPENDIX 
V, Figure V.4).  These findings suggest that drug binding to albumin may limit the effects 
of U0126, or alternatively, that albumin indirectly reduces low serum-mediated cell 
stress.  Regardless, loss of ERK1/2 by siRNA treatment of cells grown in full serum 
media resulted in only moderate upregulation of cleaved PARP (Figure 4.2, panel D).  
Taken together, these data suggest that loss of ERK activity can induce apoptosis in 
EGFR-dependent cell lines depending on the serum content of the media. 
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Loss of ERK activity synergizes with EGFR inhibition in EGFR-dependent non-
small cell lung cancer cell lines 
We next tested whether inhibiting both MEK1/2/5 and EGFR could result in 
enhanced activity over either inhibitor alone.  We first treated H358, PC-9, H1975 and 
H1650 cells with either erlotinib (500 nM), U0126 (5 µM), or the combination under low 
serum conditions to determine whether enhanced apoptotic activity could be achieved.  
After 24 hr, a statistically significant effect in PARP cleavage was observed in the 
combination treatment over either inhibitor alone, with two notable exceptions (Figure 
4.3, panel A).  First, the addition of U0126 to erlotinib in the PC-9 cell line did not result 
in a significant change in cleaved PARP, primarily because of the high sensitivity to 
erlotinib alone observed in this cell line.  Secondly, the addition of erlotinib to U0126 in 
the H1975 and PC-9 #37 cell line did not result in a significant change in cleaved PARP, 
presumably due to the presence of the T790M mutation in these cell lines, which 
prohibits the binding of erlotinib to the target site on EGFR.    
Given these results, we asked whether the combination of MEK1/2/5 and EGFR 
inhibitors could induce synergistic activity in EGFR-dependent NSCLC cells.  Cells were 
treated with U0126, CL387,785, or the combination in fixed ratios of the IC50 for 48 hr in 
5% serum containing media (Figure 4.3, panel B).  The CL-387,785 compound was used 
since several of the cell lines tested (PC-9 #37 and H1975) harbor the T790M mutation, 
which strongly desensitizes the cell lines to erlotinib.  A moderate level of serum was 
utilized to reduce trophic stress on the cells while limiting the presence of serum binding 
proteins such as albumin.  In the EGFR-dependent cell lines, and in particular, the 
EGFR-mutant cell lines, the drugs displayed considerable synergy at a variety of dose 
levels.  The drug effects in the EGFR-wt H358 cell line were additive at the IC75, but 
were synergistic at the IC50. In contrast, the effects in EGFR-independent, A549 cell line 
were moderate and appeared to be only additive (the 95% confidence interval includes 
‘1’) at both the IC50 and IC75.   
To isolate the effects of ERK1/2 loss in combination with EGFR inhibition under 
full serum growth conditions, we performed siRNA-mediated knockdown of ERK1, 
ERK2, or the combination in four of the EGFR-dependent NSCLC cell lines.  Forty-eight 
hours after transfection, cells were plated to 96-well dishes and treated with varying 
concentrations of erlotinib or the irreversible EGFR inhibitor CL-387,785 in 10% serum-
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containing media.  CL-387,785 was used only in those cell lines harboring the T790M 
mutation (PC-9#37 and H1975) as well as in the PC-9 cell line for direct comparison to 
the resistant (PC-9#37) clone.  After 48 hr of treatment, cell proliferation was assayed by 
SRB (Figure 4.3, panel C).  The concentration of EGFR inhibitor required for total growth 
inhibition (TGI) was interpolated from the dose-response curves, and was markedly 
reduced following either ERK1 or ERK2 knockdown (Figure 4.3, panel D).  TGI for the 
ERK1 + ERK2 combination could only be calculated in the PC9#37 cell line, as ERK1/2 
knockdown induced TGI without EGFR inhibitor treatment in the other cell lines tested 
(see Figure 4.1, panel D).  These data support the hypothesis that MEK1/2 pathway 
inhibition, not MEK5 pathway inhibition, is likely responsible for the cytotoxic effects 
observed with U0126 either in the presence or absence of EGFR inhibitors. 
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Figure 4.3: Loss of ERK activity synergizes with EGFR inhibition in EGFR-dependent 
non-small cell lung cancer cell lines  
A)  The indicated cell lines were cultured in low serum media (0.1% FBS) for 24 hr 
before addition of 5 µM U0126, 500 nM erlotinib, or the combination of both inhibitors.  
Following 24 hr of drug treatment, cells were harvested and lysates were assayed by 
western blot for PARP.  A representative blot is pictured at left.  Blots were scanned and 
analyzed by densitometry as described in Figure 4.2.  Bar graphs (right) represent the 
mean +/- SD from three experiments.  Means were compared using ANOVA with a 
Tukey’s post-hoc test to contrast the individual groups.    *p<0.05, **p<0.01, *** p<0.001  
B)  The indicated cell lines were treated for 48 hr in 5% FBS-containing media with fixed 
ratios of the IC50 of U0126, CL-387,785, or the combination before SRB analysis.  
Synergy was calculated using Calcusyn and the combination indices (CI) at the IC50 
and IC75 for both drugs was graphed along with the 95% confidence intervals from three 
to four experiments.  Interactions are reported as follows:  CI <1: synergism, CI=1: 
additive, CI>1: antagonism. C)  Cells were transfected with siRNA targeting ERK2, 
ERK1, or the combination, as described in Figure 4.1.  After 48 hr, cells were trypsinized 
and re-plated to 96-well dishes in full serum media.  After 16 hr, cells were treated with 
serial dilutions of erlotinib (H358 and H1650) or CL-387,785 (PC9, H1975, and PC9#37).  
Forty-eight hours later, inhibition of cell growth was assayed by SRB staining, and dose 
response curves were fit using Prism software.  D)  Using the data from panel C, the 
concentration of EGFR inhibitor required for total growth inhibition (TGI) was interpolated 
from the curves.  *** TGI was achieved without the addition of EGFR inhibitors (i.e. 
combined siRNA transfection alone of ERK2 and ERK1 induced TGI). 
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D. DISCUSSION 
EGFR-dependent NSCLC represents a significant group of lung cancer cases, 
and is perhaps the most clinically treatable molecular phenotype in this devastating 
disease at this time.  However, the outcomes of both preclinical and clinical studies 
suggest that improved strategies will be necessary to provide a sustainable systemic 
cure for patients harboring EGFR-dependent tumors.  In this study, we sought to 
determine whether MEK1/2 inhibitors present promise for use as an add-on therapy for 
EGFR inhibitors in this patient subpopulation.  The addition of a synergistic pathway 
inhibitor could enhance response rates, reduce acquired resistance, and prolong 
progression-free survival.  Several MEK inhibitors are currently being tested in clinical 
trials, including AZD6244, although none have been tested in a clinically or molecularly 
defined population of EGFR-dependent NSCLC. Importantly, these inhibitors are specific 
for MEK1/2 and do not inhibit MEK5.   
The MEK pathway is known to play a role in tumor cell survival and proliferation 
in a variety of cell culture and animal models (23).    The compound utilized throughout 
the majority of this study (U0126) inhibits MEK1/2 as well as MEK5, and thus we have 
also utilized siRNA to isolate the MEK1/2-ERK1/2 pathway.   Additionally, the selective 
MEK1/2 inhibitor AZD6244 phenocopied the growth inhibitory effects of U0126 and 
ERK1/2-directed siRNA, supporting our conclusions that the observed effects of U0126 
are predominantly related to its inhibition of MEK1/2 and not MEK5.   
We have demonstrated that EGFR-dependent NSCLC cells require the MEK1/2 
pathway for sustained growth and survival signals.  This dependence appears to 
correlate with the trophic conditions of the cellular environment.   In low serum 
conditions, the free concentration of U0126 may be greater, resulting in stronger MEK 
inhibition and pronounced reductions in both proliferation and survival.  However, in high 
serum conditions or low serum conditions with high concentrations of BSA, there may be 
reduced free drug due to serum-albumin binding. 
EGFR mutations are thought to selectively activate the pro-survival PI3K/AKT 
pathway and may be primarily responsible for the transduction of constitutive oncogenic 
signaling emanating from activating EGFR mutations in NSCLC (83, 129, 285).  
Retrospective clinical data suggest that EGFR/PI3K/AKT axis activation may predict 
response to EGFR-targeted agents (117, 285).  We have hypothesized that activation of 
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the PI3K/AKT pathway in EGFR-dependent tumors may override the importance of the 
MEK pathway in sustaining the anti-apoptotic phenotype and thus both pathways must 
be inhibited to most effectively induce apoptosis and elicit the strongest cytotoxic effects.  
In low serum conditions, only the H1650 cell line demonstrated pronounced AKT 
activation.  This is likely due to the deletion of the PTEN gene in this cell line, which 
regulates PI3K activity (273).  In concordance with this, we were not able to induce 
significant apoptosis in the H1650 cell line with a MEK inhibitor alone, suggesting that 
AKT activation could provide the necessary survival signals to sustain the anti-apoptotic 
phenotype.  In other experiments, we found that U0126 treatment further activated AKT 
in this cell line, possibly through a feedback loop (see APPENDIX V, Figure V.5).  
Interestingly, combining a MEK inhibitor with an EGFR inhibitor in the H1650 cell line 
abrogated the expression of p-ERK1/2 as well as p-AKT, although total AKT expression 
was also reduced.  Coordinate decreases in p-ERK1/2 and p-AKT corresponded to a 
significant induction of apoptosis, supporting the hypothesis that both MEK and AKT 
pathways must be inhibited to induce apoptosis.   
Synergism between MEK and EGFR inhibitors was evaluated based on the 
following observations: 1) tumors harboring EGFR mutations are likely to respond to 
EGFR inhibitors; 2) EGFR mutations are known to selectively activate the PI3K/Akt 
pathway; and 3) coordinate deactivation of both the RAS/MAPK pathway and the PI3K 
pathway has been shown to result in improved anti-cancer activity (273).   Our data 
show that synergistic cytotoxicity is achieved when combining MEK and EGFR inhibitors 
in EGFR-dependent lung cancer-derived cell lines.  Our conclusions are strongly 
supported by the observation that siRNA-mediated knockdown of ERK1 and/or ERK2 
sensitized the same cell lines to CL-387,785.  
Finally, of particular importance, several of the cell lines displaying synergy 
between EGFR and MEK inhibitors harbored a T790M mutation.  In clinical practice, a 
minority of EGFR-driven lung tumor patients present with detectable T790M prior to 
treatment, although most develop tumors harboring the T790M mutation during or 
following erlotinib treatment.  This phenotype presumably arises due to selection of pre-
existing subpopulations of cancer cells harboring T790M with erlotinib.  The findings of 
others have suggested that even the newer generation irreversible inhibitors of EGFR 
such as HKI-272 may not be able to achieve concentrations sufficient to fully inhibit the 
T790M mutation in vivo (146).  Thus, perhaps the observed synergistic interaction 
ADAPTED FROM: Balko et al, Cancer Biology & Therapy (2009) 8:6 
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between irreversible EGFR inhibitors and MEK inhibitors could reduce the selective 
pressure on the T790M mutation. 
E. CONCLUSIONS 
We have demonstrated that synergistic activity can be achieved with the 
combination of an irreversible EGFR inhibitor and a MEK inhibitor, suggesting that lower 
doses of both agents can be used to achieve an equivalent anti-cancer effect to either 
drug alone, reducing potential toxicity to these agents.  Through enhanced activity, the 
combination of a MEK inhibitor and an irreversible EGFR inhibitor could remove the 
selective advantage on cells harboring the T790M mutation, thereby lengthening 
response time while minimizing resistance. Quantitative models of acquired resistance 
will be necessary to fully test this hypothesis.  Additionally, in vivo animal model studies 
are warranted to determine if clinical trials should be targeted at the use of this 
combination in patients harboring EGFR-mutant NSCLC to enhance response and 
minimize acquired resistance.   
 
 
 
 
 
 
 
 
 
 
Copyright © Justin M. Balko 2009
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CHAPTER 5  
A. SUMMARY OF RESULTS 
We hypothesized that gene expression profiling could enhance treatment of 
EGFR-dependent NSCLC by two methods: 1) to implement predictive classification of 
NSCLCs for the purposes of stratifying patients to EGFR-inhibitor therapy and 2) to 
provide new insights into the EGFR-dependent phenotype which could be chemically 
exploited.   By coupling in vitro models with pharmacogenomic efforts, we have captured 
the phenotype of aberrant EGFR-dependent cell signaling in a gene expression profile.  
We conclude this work by demonstrating that these insights could be exploited using 
additional chemical inhibitors to enhance therapeutic outcome in EGFR-dependent 
NSCLC.  
The first hypothesis, explored in Chapter 2, was tested by utilizing bioinformatics 
and systems biology approaches to define the180-gene profile of EGFR-dependency, 
both of which are novel methods of feature selection in this stratum of experimentation.  
The defined signature is capable of predicting the status of unknowns and exhibits 
biological relevance.  The signature was validated in a panel of NSCLC cell lines with 
known sensitivity to EGFR inhibitors, and in NSCLC tumors stained for p-EGFR (a 
possible proxy of response to EGFR inhibitors) (251).  Finally, we collected tumor tissue 
from NSCLC patients treated with erlotinib and found that the signature performed well 
in predicting RECIST response in this small cohort.  Our results indicate that gene 
expression profiling could offer improved prediction over EGFR mutational status or 
immunohistochemical detection-based predictions alone, although additional validation 
will be required to robustly test this hypothesis.  It is anticipated that through further 
modification and validation, the profile will yield a predictive diagnostic to identify 
response in patients with EGFR-targetable malignancies. 
In Chapter 3, we explored the broader set of 1495 deregulated genes in EGFR-
dependent NSCLC cell lines and found that high expression of EGFR ligands HB-EGF 
and TGF-α appears to be associated with EGFR-dependent phenotype.  Further, we 
were able to identify at least three ways that RAS/MAPK activation could contribute to 
maintenance of the EGFR-dependent phenotype: 1) promoting expression of EGF-like 
ligands, 2) promoting shedding/activation of EGF-like ligands, and 3) modulating EGFR 
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protein stability and degradation (Figure 5.1).  The RAS/MAPK pathway is constitutively 
active in EGFR-dependent NSCLC cell lines and directs expression of HB-EGF and 
TGF-α, as small molecule inhibition of MEK1/2/5 reduced EGF-like ligand gene 
expression.   Importantly, redundant pathways may contribute to sustained expression of 
EGF-like ligands despite inhibition of the RAS/MAPK pathway, as was observed in the 
H1650 cell line.  Thus, combining targeted agents may be necessary to achieve full 
abrogation of EGFR signaling in heterogeneous epithelial tumors (273, 286-290).  We 
also discovered that proteolytic processing of TGF-α is mediated by the RAS/MAPK 
pathway, as MEK1/2/5 inhibition reduced the release of activated TGF-α from H1650 
cells while sustaining gene expression levels.  Finally, these results suggest that the 
availability of HB-EGF and/or TGF-α may be directly related to the stability of EGFR.  
Ligand activated EGFR is normally either recycled to the membrane or proteosomally 
degraded (78).  In our experiments, MEK1/2/5 inhibition down regulated EGFR by 
enhancing proteosomal degradation and/or by reducing receptor-ligand recycling.  To 
extend these results, the role of EGFR ligands in modulating EGFR stability was directly 
tested by neutralizing HB-EGF or the ligand binding domain of EGFR with antibodies.  
Both ligand-neutralizing antibodies phenocopied the effects of MEK inhibition in the 
H1975 cell line.  Therefore, neutralizing antibodies directed at the ligand binding domain 
of EGFR (such as cetuximab), those directed at specific EGFR ligands, or small 
molecule inhibitors of the RAS/MAPK pathway may all offer potential therapeutic benefit 
in EGFR-dependent NSCLC because of the role of RAS/MAPK and EGF-like ligands in 
maintaining the EGFR-dependent phenotype.  
Given our improved mechanistic understanding of the effects of RAS/MAPK 
pathway inhibition in EGFR-dependent NSCLC (see Figure 5.1), we tested the 
importance of this pathway in mediating tumor cell proliferation and survival (see 
Chapter 4).  MEK1/2/5 inhibitors as well as the specific MEK1/2 inhibitor AZD6244 
significantly inhibited the proliferation of EGFR-dependent NSCLC cell lines.  We 
confirmed these results using siRNA-mediated knockdown of the MEK1/2 targets, 
ERK1/2.  MEK inhibition also significantly impacted survival and induced apoptosis 
under low-serum conditions.  Combining the MEK1/2/5 inhibitor U0126 with the 
irreversible EGFR inhibitor CL-387,785 resulted in cytotoxic synergy.  Again, the role of 
the MEK1/2 pathway was isolated from the MEK5 pathway by combining EGFR 
inhibition with siRNA-mediated knockdown of ERK1/2.  Thus, the combination of 
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targeting the RAS/MAPK pathway and EGFR appears to be highly effective in inducing 
cell cycle arrest/cell death in EGFR-dependent NSCLC. 
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B. EXPERIMENTAL CONSIDERATIONS 
We combined pharmacogenomic and pharmacologic models to test our central 
hypothesis that gene expression profiles could be used to both select patients for EGFR 
inhibitor therapy and enhance therapy through the identification of additional molecular 
targets that could be exploited in combination with EGFR inhibitors.  Using 
pharmacogenomic approaches, we were able to make broad inferences about the 
underlying deregulation occurring in EGFR-dependent NSCLC cell lines.  Incorporating 
bioinformatics allowed us to then focus our results on candidate pathways and genes.  
Finally, the use of pharmacologic models allowed us to directly test the resulting specific 
hypothesis in a controlled experimental environment.  Nonetheless, it is important to 
carefully consider the aspects of the experimental design for limitations and 
assumptions. 
 The most obvious caveat to the data presented herein lies in the extensive use 
of cell culture models.  Cell culture models of cancer have the advantage of being 
malleable systems in which hypotheses requiring significant manipulation can be tested.   
However, cell culture models of cancer lack the heterogeneity and four-dimensional 
character of in vivo models, and therefore the conclusions that can be drawn from these 
models are limited.  The impact of the model choice varies between the genomic and 
biologic/pharmacologic experiments. 
Genomic models  
We used gene expression data from NSCLC cell lines with known sensitivity to 
EGFR inhibition to populate a genomic dataset and identify a signature of EGFR-
dependency.  An alternative approach would be to utilize human tumors with known 
clinical outcomes to EGFR inhibitors.  However, such data are not readily available and 
the cost of collecting and performing genomic analysis in a sufficient number of patients 
to confidently identify deregulated genes would be limiting, due to inter- and intra-sample 
heterogeneity (see Chapter 1 for a review).  The relative homogeneity of cancer cell 
lines, both in replicates samples from the same cell line (inter-sample) and in cells 
constituting the clonal culture population (intra-sample), allowed us to achieve statistical 
confidence in the selected genes, and to reserve clinical data for validation.  However, it 
is understood that this method may cause us to include features that may be artifacts of 
two-dimensional growth.  Thus, continued validation in human tumors and possibly 
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modification of the profile will be important in further development as a useful clinical 
diagnostic. 
Biologic and pharmacologic models   
Cell culture models were also utilized for the biologic and pharmacologic 
experiments performed herein.  Thus, there are important considerations associated with 
conclusions that were based on these models.   As stated, a cell culture model of cancer 
does not likely capture the heterogeneity of the human condition.  In order to reduce the 
impact of these limitations, we performed many of the experiments using a panel of cell 
lines representing different genetic backgrounds as opposed to a single representative 
cell line.  Thus, our results may hold additional external validity over experiments 
performed in a single cell line, but the described models are still limited in their ability to 
capture three-dimensional growth characteristics and the contribution of the stromal cells 
surrounding a tumor.  Additionally, pharmacokinetic and pharmacodynamic drug 
interactions between MEK inhibitors and EGFR inhibitors will be a crucial aspect of 
combinatorial therapy to explore before conducting clinical trials with this combination.  
As such, xenograft models will be important in validating and further exploring the 
findings of the biological experiments contained herein. 
Another experimental consideration in the biologic and pharmacologic models is 
the use of serum starvation conditions to assess cell survival and apoptosis.  We chose 
these conditions because we observed constitutive ERK activation that appeared to be 
uniquely associated with the EGFR-dependent phenotype under serum starvation.  
Importantly, serum starvation may not accurately reflect physiological conditions, since 
non-tumor cell derived growth and survival factors are likely to be present the tumor 
environment in vivo.  However, the tumor environment in vivo is often hypoxic, creating 
regions of tumor necrosis and apoptosis (291).  Therefore, the level of survival factors 
supplied to cells during culture in high serum medium, resulting in a low cell turnover 
rate in vitro, may conversely overestimate physiological conditions.  We believe that it is 
reasonable to utilize low-serum media since one hallmark of cancer is the ability to 
survive independently of external growth signals.  Growth and survival factors supplied 
under serum rich conditions may provide sufficient activation of alternative pathways to 
override the oncogenic self-sufficiency demonstrated by the EGFR-dependent cell lines.  
Furthermore, drug-binding plasma proteins may also play a role in reducing drug effects 
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on growth or survival at a given concentration, an effect that could be observed both in 
vivo and in vitro.  Reducing the serum content of the media could have the effect of 
increasing free drug concentrations, and thus the observed pharmacologic activity.  
Importantly, the effects of MEK inhibition on cell survival and apoptosis were variable in 
the NSCLC cell lines used, depending on the serum content of the culture conditions.  
Thus, the model utilized is likely to have impacted our results.  In the absence of in vivo 
data, it is unclear whether our low serum model is more or less representative of drug 
effects on cell survival than when a high serum model is used.  Therefore, in vivo models 
will be important for further substantiating our hypotheses. 
C. CONTRIBUTION TO THE FIELD 
This work makes a substantial contribution to an improved understanding of the 
EGFR-dependent phenotype.  The rising costs of health care require the identification of 
effective ways of minimizing non-beneficial medication use and maximizing outcomes.  
Predictive pharmacogenomics is a field that can meet these demands.  Our work and 
the work of others have identified genomic signatures that could underlie 
responsiveness to EGFR inhibitors in the EGFR-dependent phenotype (230, 251, 292, 
293) (see also Chapter 2).  Coldren et al also published a genomic signature of 
response to erlotinib developed from NSCLC gene expression data (230).  Their 
approach, while similar to our own utilized a larger number of cell lines in their model-
training set, but did not use statistical replicates of each cell line. Importantly, they 
stopped short of validating their profile in human tumors.  Fujimoto et al explored 
combinations of expression of ErbB family members and their ligands in EGFR-TKI 
sensitive NSCLC cell lines and mouse models of lung cancer (106).  However, they did 
not attempt to translate their findings into a useful predictive model for classification of 
human tumors.  Thus, the experiments contained in our work are the first to translate 
predictive signatures of EGFR-dependency successfully to human tumors.  However, 
the cohort that has been used for validation is small, and thus significant work lies 
ahead.   
Predictive gene expression signatures are being implemented in prospective 
clinical trials to guide the use of other cancer therapeutics (191-194).  Other signatures 
have already been well established to be useful in this context, such as the Oncotype Dx 
and Mammaprint assays, which can predict the probability of metastatic recurrence 
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following resection in early stage breast cancer (190, 294-296).  Thus, we provide an 
integral contribution to this movement.  Further development of clinical diagnostics by 
others based on gene expression data will pave the scientific and regulatory avenues for 
the translation of our predictive signature into a clinically useful diagnostic.  Likewise, 
successful clinical integration of our signature in EGFR-dependent NSCLC will further 
substantiate the approach of using genomic data to develop clinically predictive 
diagnostics. Thus, this outcome could facilitate a framework for the future development 
of gene expression predictors by others. 
The signature we have identified also provides a wealth of data to mine for 
additional insight into the EGFR-dependent phenotype and these data could be further 
exploited to investigate new targets for therapy.  These data are publicly available, and 
can be utilized by other researchers in the field to test their hypotheses or explore using 
candidate gene approaches.  Our own mining of this dataset was successful in 
identifying the RAS/MAPK pathway as a significantly deregulated pathway in the EGFR-
dependent phenotype.  We further found that the expression and/or activation of EGFR 
ligands are modulated by RAS/MAPK activity.  Regulation of ligand expression may be 
important for controlling EGFR receptor levels and this activity may be a factor in 
constitutive EGFR-mediated signaling.  This concept remains to be rigorously tested, but 
provides a hypothesis to be further explored by those in the field.   
Importantly, our work has restored focus on the RAS/MAPK pathway as an 
important target in EGFR-dependent NSCLC.  Significant bodies of research have 
recently focused attention on the PI3K/AKT pathway in this phenotype.  The PI3K/AKT 
pathway, downstream of EGFR and other growth factor receptors, has been shown to 
contribute to cell survival in EGFR-dependent cell lines and tumors (117, 129, 285, 297, 
298).  Furthermore, it has been suggested that inhibitors of the RAS/MAPK pathway 
may be more effective in tumors harboring mutant RAS or RAF that are mutually 
exclusive with tumors harboring EGFR mutations (23, 139, 147, 222, 299-303).  Our 
work re-examines the RAS/MAPK pathway in the EGFR-dependent phenotype as a 
result of knowledge gained from our genomic studies.  While inhibition of the RAS/MAPK 
pathway resulted in modest reduction of proliferation on EGFR-dependent NSCLC cells, 
significant synergy was observed when combined with EGFR inhibitors, enhancing 
apoptosis (see Chapter 4). Thus, based on the results of others in the field, our results 
obtained in combining EGFR and RAS/MAPK inhibitors were surprising.  These data will 
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hopefully guide the effective combination of targeted agents to impact EGFR-dependent 
NSCLC therapy. 
D. TRANSLATIONAL AND CLINICAL RELEVANCE 
The findings of the work herein hold significant translational and clinical 
relevance.  Each of the broad questions asked when formulating the hypotheses of this 
work were made with a particular concern for their impact on patient care.  Furthermore, 
the approaches used, particularly in construction and validation of the genomic signature 
of EGFR-dependency, bridged both basic science and clinical fields, thus being largely 
translational in nature. 
Improved methods of stratifying patients for targeted therapy in EGFR-dependent 
NSCLC are required to more appropriately utilize EGFR-targeted therapy in the clinic.  
The cost of erlotinib, estimated at over $3000 per month of therapy, underscores this 
need, as the impact of failed treatment on health care costs, quality of life, and outcome 
are driving forces in the focus on predicting response to cancer therapies.  We have 
made a significant effort to validate the signature of response in clinical samples, but 
more validation is clearly necessary.  Translating our findings in cell culture models to a 
clinically useful diagnostic is difficult, but addresses the broader clinical needs of the 
health care system.  Successful implementation of the model could significantly impact 
health care costs and outcomes associated with erlotinib use. 
Even those patients who achieve response or stable disease to EGFR inhibitors 
almost certainly progress through the development of resistance (98, 99, 113, 148).  
One well-established principle in anti-cancer therapy is the implementation of drug 
combinations to combat resistance.  This principle is based on the assumption that the 
probability of a tumor cell becoming resistant to a combination therapy is the product of 
the probabilities of the development of resistance to each individual agent alone, 
provided there is not a common mechanism of resistance to both agents (276, 287).  
Thus, identifying effective drug combinations for treating EGFR-dependent NSCLC is 
paramount.    
Combining MEK and EGFR inhibition could reduce resistance in EGFR-
dependent NSCLC by several mechanisms.  First, synergistic activity was observed 
between the agents in the cell culture models we utilized.  Thus, one would expect more 
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significant initial clinical responses to the combination, reducing tumor burden and 
minimizing the probability of a drug-resistant tumor cell emerging (276).  Second, 
common mechanisms of acquired resistance to EGFR inhibitors may result in 
reactivation of the RAS/MAPK pathway or reduction in the ability of the EGFR inhibitor to 
abrogate EGFR-RAS/MAPK signaling (98, 99, 147, 273).  Therefore, treatment with both 
inhibitors could reduce the selective pressure for the development these mechanisms of 
tumor resistance. We anticipate that in vivo models and further clinical testing will define 
the clinical utility of this drug combination in EGFR-dependent NSCLC.  Thus, the 
questions asked and approaches taken to answer those questions are translational and 
ultimately clinical in nature. 
E. CONCLUSIONS 
We conclude that the EGFR-dependent phenotype in NSCLC can be defined and 
captured in a gene expression profile.  This profile could aide in identifying and 
stratifying NSCLC patients who will benefit from EGFR-targeted therapy.  Enrichment of 
the treated population for responders will significantly impact the clinical utility of these 
agents.  Furthermore, we conclude that coupling inhibitors of the RAS/MAPK pathway 
with EGFR inhibitors such as erlotinib could offer the potential to maximize benefit from 
targeted therapy in EGFR-dependent NSCLC through enhanced responses and 
minimized acquired resistance to therapy.   
 
 
 
 
 
 
 
Copyright © Justin M. Balko 2009
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APPENDICES 
APPENDIX I: EXEMPT IRB SUBMISSION FOR RETROSPECTIVE CLINICAL STUDY 
1. Background:   
Gene expression signatures of objective response to anti-cancer agents are a 
novel approach to personalizing cancer medicine.  New targeted agents such as erlotinib 
(Tarceva ™) and trastuzumab (Herceptin ™) among others are effective agents for the 
treatment of cancer, but activity varies depending on particular tumor and patient 
characteristics.  Quantitative assessment of the expression of large numbers of genes 
may offer sufficient data to account for heterogeneity of disease in humans, and thus 
provide a way to predict response to targeted agents a priori.   
We have previously published a signature of erlotinib sensitivity that appears to 
predict response in human cancer cell lines and possibly tumors.  However, significant 
and vigorous validation of the ability of this signature to appropriately predict response is 
necessary.  Erlotinib is not used extensively to treat non-small cell lung cancer at the 
University of Kentucky, although it is one of several recommended treatment options at 
particular points in care.  The limited use of the agent precludes prospective collection of 
samples from lung cancer patients, as a large number would be required in order to 
obtain sufficient sample size to validate the ability of the signature to predict outcome.  
This is primarily because only 5-10% of all samples collected would likely be from 
patients who were later treated with erlotinib.  Collection by such a process could be 
very time consuming and costly and thus highly inefficient. 
Tissue banks nationwide represent a resource for acquiring retrospective 
samples in order to explore hypotheses in heterogeneous patient populations.  The 
University Of Kentucky Biospecimen Core Program (BCP) has a large number of 
samples procured from lung cancer patients in the Kentucky area.  Other publically 
available tissue banks include the Cooperative Human Tissue Network (CHTN).  The 
CHTN is an NCI sponsored program that collects and banks samples at a number of 
institutional ‘hubs’ from  myriad of disease states for distribution to academic 
investigators across the nation.  All patient identifiers will be removed prior to distribution 
to us, as per the requirements of the program.  More information on this program can be 
found at: http://chtn.nci.nih.gov/.  We intend to utilize tissue banking resources, 
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specifically the BCP and CHTN, to validate and improve our predictive algorithm in hope 
of making a positive impact on cancer care.   
2. Objectives:   
The study will be a retrospective analysis of existing human lung cancer 
specimens for the purpose of understanding activated signal transduction pathways 
present in the tumor and how this correlates to response to small molecule inhibitors of 
those pathways.  The goals of this work are to: 
1.  Determine the accuracy of a gene expression signature to predict response to 
the small molecule inhibitor erlotinib which targets the EGFR signal transduction 
pathway 
2.  Augment the predictive algorithm with additional gene expression data 
derived from human tumors  
3. Study Population:   
We will use samples that are available with no specific population of patients 
desired, other that those that had resected lung cancer and were treated with erlotinib.   
4. Subject Recruitment Methods:   
There will be no prospective recruitment. We will use the samples and 
associated clinical data provided by the BCP or the CHTN.  In either case, to obtain 
pertinent clinical data, independent chart review will be performed by non-study 
associated personnel qualified to complete such review.  For both of these tissue banks, 
patients signed a consent form stating the tumor tissue and clinical data could be used in 
a de-identified manner. 
5. Research Procedures:   
We plan to purify RNA from 5-10 milligrams of existing fresh frozen lung tumor 
tissue as provided by the Markey Cancer Center Biospecimen Core Program (BCP) or 
the Cooperative Human Tissue Network (CHTN).  For samples from the CHTN, chart 
review will take place under the supervision of site-specific IRBs and only lung tumors 
which were treated adjuvantly with EGFR inhibitors (gefitinib, erlotinib) will be acquired.   
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For samples from the BCP at the University of Kentucky, the approach outlined 
below for identifying appropriate samples for collection will be used: 
1)  Dr. Susanne Arnold, M.D. and Dr. John Rinehart, M.D. of the Markey Cancer 
Center will act as moderators to ensure that no de-identified PHI will be made available 
to the PI.  Since these are the two primary treating physicians at UK for non-small cell 
lung cancer, they will follow the procedures below to identify eligible samples for the 
study: 
a) The physicians will compile a list of the patients they have treated with erlotinib 
(names, DOB, medical record numbers). 
b) This list will be transferred to personnel at the UK BCP.  The BCP personnel will then 
identify which, if any, of the patients from the list have specimens available. 
c) The de-identified samples numbers will then be communicated to the PI and the 
samples will be delivered and analyzed by the PI laboratory. The RNA from the tumor 
samples will be used for hybridization to high-density DNA microarrays. Protein lysates 
may also be used to determine the activation patterns of particular pathways, including 
EGFR.  For microarray analyses, the resulting genomic data will be subject to statistical 
analyses, both supervised and unsupervised learning methods, for the purpose of 
validating a genomic test to predict response to EGFR inhibitors. The information 
derived from this study will allow us to validate our previous in vitro work (Balko et al, 
BMC Genomics 2006).   
d) The outcome of the analysis will be communicated to the physicians (Drs Arnold and 
Rinehart).  
e) The physicians will request that the de-indentified sample numbers be matched with 
the patient list and this list will be communicated from the BCP to the physicians.  The 
physicians will then match the analysis results with the patient data (see data collection), 
remove all identifiable patient information (i.e. MRN, DOB, and name) and forward the 
dataset back to the PI.   
6. Data Collection:  
Information to be collected by the oncologists, if available, will include:   
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a. Age, sex, race 
b. Smoking history 
c. Histology 
d. Previous treatments (chemotherapy, radiotherapy) 
e. Stage at erlotinib treatment 
f. Dose of erlotinib 
g. Length of treatment 
h. Response (RECIST) 
i. Progression free survival 
j. Overall survival  
7. Potential Risks:   
There are no significant risks involved in this research protocol.  No inheritable 
genetic information per se will be collected during the course of this research, and 
therefore the data collected will not be particularly sensitive data.  The PI will not be 
given any identifiable information.   
8. Research Materials, Records and Confidentiality:  
The data acquired will be maintained only on the secure UK server.  Specimens 
will not be linked to identifiable information and will be kept in locked facilities when not 
in use.  No identifiable information will be acquired or utilized by the PI, and therefore 
there is no risk to confidentiality.  The physicians functioning under the honest broker 
system will have access to identifiable information, but have access to this information in 
a regular basis since they are the treating physicians. 
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APPENDIX II: MEDICAL IRB SUBMISSION FOR PROSPECTIVE CLINICAL TRIAL 
Medical IRB Research Description 
1. Background  
Lung cancers account for 30% of cancer-related deaths and are the most 
common cause of cancer-related mortality in the U.S. The Commonwealth of Kentucky 
leads the nation in incidence and mortality due to lung cancer [1]. Non-small cell lung 
cancer (NSCLC) is a disease characterized by late stage of presentation and intrinsic 
resistance to cytotoxic chemotherapy. Furthermore, a majority of NSCLC patients fail 
treatment and experience toxicity to standard treatments. Clinical and pre-clinical studies 
strongly suggest that a patient’s tumor bears a molecular signature that can be 
predictive of response to targeted therapies [2].  We propose that the molecular 
signature of a patient’s tumor can be captured and translated into a predictor of 
response of that individual to therapy. Using a predictive profile of response, we can 
avoid patient exposure to toxic and ineffective chemotherapeutic agents.  
The majority of patients are diagnosed with NSCLC that is not surgically 
resectable, leaving systemic chemotherapy as their main treatment option. Platinum-
containing doublets (using a taxane, gemcitabine or vinorelbine as the second agent) 
are utilized in front-line therapy with reasonable efficacy.  Recently, bevacizumab has 
been added to platinum-containing doublets and has shown a survival improvement 
compared to chemotherapy alone in non-squamous histologies [3].  Unfortunately, many 
patients do not respond to initial treatment or relapse soon after cessation of 
chemotherapy. For patients with a performance status > 2, second line therapy with a 
single agent is the standard of care. As single agents, docetaxel and erlotinib have all 
been shown to improve survival compared to best supportive care and pemetrexed has 
been proven to be equally effective as docetaxel. Gemcitabine, which is approved as a 
first line therapy, has significant activity as a single agent in second line therapy. As 
second line therapy, these agents have been shown to generate responses in 
approximately 10 percent of patients and prolong survival by approximately 3 months [4-
7].  Patients who respond to therapy have a longer survival than those who do not 
respond, and the median duration of response ranges from 4-6 months while less than 
30% have responses that last more than a year.  While many patients experience 
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Table 1: Predictions of EGFR TKI sensitivity are 
denoted for ten cell lines used in training/validation.  
Checkmarks denote correct predictions. 
 
 
Cell 
Line 
Sensitivity to 
erlotinib 
Predicted sensitivity to EGFR TKI
Prediction 
based on EGFR 
exon 19‐21 
mutations 
Genomic signature / 
DLDA 
180‐ genes 
Tr
ai
ni
ng
A549  No  √  √
UKY‐ No  √  √
H165 Yes  √  √
PC‐9  Yes  √  √
H325 Yes  √  √
V
al
id
at
io
n
H358  Yes    √
H460  No  √  √
H197 No  √ 
K562  No  √  √
A431  Yes    √
    %Correct  80%  90%
toxicity with commonly used chemotherapeutic agents, erlotinib, a small molecule 
therapeutic, results in the least amount of grade 3-4 toxicity.  
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), 
erlotinib represents a novel class of compounds shown in clinical studies to improve 
survival over best supportive care when used as single agent in second-line therapy for 
NSCLC. Erlotinib monotherapy in patients who received prior platinum therapy resulted 
in objective responses of approximately 13% and stable disease in nearly 30% of 
patients [8, 9]. 
No added benefit of EGFR agents was found when combined with chemotherapy 
despite preclinical evidence suggesting otherwise [10, 11]. A recent review of molecular 
events that predict responses to erlotinib in a large clinical trial show that response rates 
were more than double in patients with tumors expressing EGFR (versus non-EGFR 
expressers).  Other factors which seem to predict response are EGFR amplification 
(versus no amplification), EGFR mutation (versus wild type), female gender (versus 
male), adenocarcinoma (versus 
all others), and non-smokers 
(versus current and former 
smokers) [12]. 
It appears none are 
mutually exclusive. Likewise, 
gefitinib, an FDA-restricted EGFR 
tyrosine kinase inhibitor has the 
same mechanism of action as 
erlotinib.  Studies evaluating 
gefitinib responders suggest that 
molecular analysis can identify 
patients with greater than a 90% 
chance of responding to treatment 
[13].  Patients that exhibit 
response to EGFR-targeted 
agents will frequently harbor a mutation in exon 19 or 21 of EGFR. The correlation of 
EGFR mutations with response and survival is controversial; the only method 
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demonstrated to predict response prospectively is to sequence exons 19 and 21 by 
standard methods from tumor tissue. However, efforts of our own using genomics 
approaches to select all responders provide an additional means for capturing the 
molecular signature of sensitivity in individual tumors [14].  
Treatment decisions based on single parameters alone encompass only a 
modest percentage of responders. Post-hoc analyses of clinical trial data identified 
substrata of patients (female gender, never-smokers, harboring EGFR mutations or 
EGFR amplification) who exhibited higher response rates to erlotinib therapy (15).  We 
hypothesized that a methodology that utilized a multi-gene molecular signature would be 
better suited than any single parameter in identifying responders to EGFR TKI. Our 
recent work identified a 180-gene expression signature of EGFR TKI response, which 
we have combined with predictive statistical analysis that can classify drug sensitivity in 
lung adenocarcinomas [14].  Data from our laboratory suggests that use of this 
classification tool can identify responding patients a priori more effectively than single 
parameters alone.   
Using DNA content analysis, we determined erlotinib sensitivity in NSCLC cell 
lines.  Using a genomic signature generated from a training set (5 of the 10 cell lines) 
and diagonal linear discriminant analysis, we correctly predicted sensitivity to first 
generation (reversible) EGFR TKIs in 90% of samples according to their sensitivity 
(Table 1).  Importantly, predicting on mutational status alone yields only 80% accuracy.  
Furthermore, the predictor identified cell lines sensitive to newer-generation irreversible 
inhibitors (i.e. EKB-569) with 100% accuracy.   These compounds are currently under 
clinical development. 
We have also applied this algorithm to genomic data from NSCLC tumors, and 
have found that approximately 70% of adenocarcinomas predict as sensitive.  In these 
datasets, however, the patients were not treated with erlotinib or gefitinib and therefore 
response cannot be ascertained. 
Thus, the approach has the potential to identify patients that are sensitive to 
EGFR TKI resulting in marked gains in overall survival, reductions in toxicity, and 
improved cost-benefit ratios in second line therapy of NSCLC. Further, those who are 
not predicted to respond to erlotinib therapy could be treated with alternative regimens to 
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Documented NSCLC recurrence and 
decision to treat with erlotinib 
 
 
Consent and enrollment 
 
 
Tumor biopsy/treatment with erlotinib 
 
Figure 1: Proposed study design 
which they may be more likely to see benefit.   A stepwise methodology that dissects the 
status of molecular targets of several commonly utilized and efficacious therapeutics 
provides a clinical tactic for prescribing the therapeutic most appropriate for the 
individual lung cancer patient.  Therefore, we propose the following pilot study to 
develop preliminary data to examine this hypothesis. 
2. Objectives  
The objectives for this investigator-initiated pilot study are as follows: (1) to 
ascertain if a sufficient amount of RNA, DNA, and tissue for molecular and histological 
analyses can be obtained through CT-guided biopsy, (2) to determine the whether 
biopsy and molecular analyses can be completed in an appropriate time frame for 
second-line therapy decisions to be 
initiated (goal: 2-week window), and 
(3) to develop preliminary data 
exploring the hypothesis that NSCLC 
patients possessing intra-tumoral 
EGFR-activated signals exhibit 
improved clinical responses.  
 Study Design   
The purpose of this study is 
to generate preliminary feasibility 
data in preparation for a randomized 
prospective trial to prove the benefits 
of individualized 2nd line therapy in 
NSCLC. We propose this pilot study be undertaken to test the potential for improved 
response to a single, second-agent therapy based on the molecular characteristics of 
the patient. The study design is outlined in Figure 1. 
Patient Consent and Tumor Biopsy  
We will enroll twenty patients for this feasibility study. The patients will be 
referred to the study at the time of recurrence or relapse by John J. Rinehart, M.D. or 
Susanne Arnold, M.D. at the University of Kentucky, Markey Cancer Center. The 
decision to treat with erlotinib, as this is an acceptable second-line or third line therapy 
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for progressing or relapsed NSCLC, will be made by the physician and patient prior to 
consent and enrollment. Following consent, a CT-guided biopsy of the lung tumor will be 
scheduled within a two-day window and obtained by Majid Maybody, M.D. The biopsy 
will be analyzed by pathology to determine if tumor tissue is present. If so, genetic, 
genomic and histological analyses can proceed. Therefore, we expect completion of 
analytical studies within a 10-14 day window. The resulting outcome data can then be 
compared with response rates in the literature and greater statistical confidence will be 
achieved. In cases where the oncologist feels it inappropriate to continue treatment with 
erlotinib, alternative second-line therapies or best supportive care will be initiated.  The 
patient response data will be removed from the analysis of objective 3 if they do not 
complete at least 30 days of erlotinib treatment. The Consent form (C) is attached. 
Tissue Handling and Assay Descriptions  
The molecular analyses will use the biopsied specimen for both DNA and RNA 
preparation. Prior to microarray analysis, RNA will be extracted from tumor tissue 
(RNeasy, Qiagen), quantified by absorbance, and a determination will be made whether 
there is enough RNA to assay gene expression by DNA microarray (1-5ug required of 
total RNA). 
The EGFR gene will be sequenced along exons 18-21, as described previously, 
using DNA extracted from tumor tissue [15]. Mutations, whether deletion in exon 19 or 
point mutants in exon 21, are considered ‘activating’ [16].  Point mutants in exon 20 
(T790M) confer resistance to erlotinib [17] 
Data from the microarray analysis will be imported into our predictive modeling 
software. In previous work (submitted for publication), we generated a gene expression 
predictor of EGFR-inhibitor sensitivity, and we will apply that predictive model to the 
gene expression data from each patient.  
Study Evaluation  
The feasibility study will be evaluated using the objectives stated earlier. 
Objective one assesses the amount of useful tumor tissue gathered from a CT-guided 
biopsy and will be gauged for each patient as DNA and RNA are prepared from the 
biopsied material. Objective two assesses time required for molecular analyses to be 
completed and provide information for therapeutic decisions and will be evaluated 
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following enrollment of the twenty patients. We hope that 18 of 20 patients can be 
evaluated within the 10-14 day window allowing assessment of molecular analyses prior 
to initiation of second-line therapy. To assess the effectiveness of using these molecular 
methods to determine second-line therapy, we will evaluate each patient following nine 
months of treatment by RECIST criteria or as the patient progresses or demonstrates 
toxicity to erlotinib. Objective three will assess response to therapy using Kaplan-Meier 
survival curves to compare patients who might be stratified by single molecular 
parameters alone (EGFR mutation/amplification) or by classification using the genomic 
predictor of response. We suspect that the genomic predictor will identify more 
responders than does the sequencing method for analyzing activation of EGFR. Thus, 
we believe many more responders to EGFR TKI can be treated with less toxic and more 
efficacious therapy than previously anticipated. The feasibility issues for molecular 
analysis can be resolved with this study and allow us to pursue a larger prospective 
study to utilize a decision tree algorithm testing two additional therapeutics. 
4. Study Population  
Inclusion Criteria 
We will enroll the first 20 NSCLC patients who meet eligibility criteria without regard to 
race, gender, or age.  All enrolled patients must meet each of the following inclusion 
criteria: 
• Prior decision by both the physician and patient to initiate erlotinib therapy 
• Previous treatment with front line systemic therapy (i.e. erlotinib will be used as 
2nd line or higher therapy) 
• Expected survival as determined by their oncologist of ≥ 3 months 
• Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 
• Patient must have a tumor which is capable of being biopsied by CT-guided CNB 
without evidence of excess risk, as determined by the interventional radiologist 
(Dr. Majid Maybody, MD) 
• Willing to undergo the CT-guided biopsy procedure, and assume risks associated 
with the procedure 
Exclusion Criteria 
Exclusion criteria include presence of any of the following: 
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• an ECOG performance status of ≥ 3 
• Patients at high risk for bleeding episodes, including thrombocytopenia 
(PLT<50,000) or pathologic bleeding disorders during the initial evaluation 
• Patients taking oral anticoagulants (i.e. warfarin), as these cannot be 
discontinued in a reasonable amount of time to allow for normalization of INR 
prior to undergoing the biopsy procedure 
5. Subject Recruitment Methods and Privacy 
Patients meeting recruitment criteria will be identified by John J. Rinehart, M.D. 
or Susanne Arnold M.D. at the time of their visit to the clinic. At that time, those patients 
will be referred to Esther P. Black, Ph.D., Assistant Professor in the College of 
Pharmacy, as potential participants in this study. Justin Balko, PharmD will be contacted 
to gain consent of the patient for participation in the study. We will not advertise this 
study to the general public. 
6. Informed Consent Process 
Informed consent will be carried out at time of evidence of recurrence or relapse 
by Justin Balko, PharmD, who will also serve as a witness. During administration of 
informed consent, the patient will be allowed to read or have read to them the document 
describing the study as a feasibility study to initiate the process for individualized care of 
recurrent lung cancer patients. Each patient will be informed that this is a genetic test 
that requires a biopsy sample of the tumor. The patient will be informed that they will be 
given a prescription for erlotinib and that their compliance will be monitored by routine 
calls to their designated pharmacy. If not used completely, the tumor sample will be 
banked for a defined period of time and then destroyed. The DNA and RNA samples will 
be stored in a locked sub-zero freezer and de-identified from the patient data. The 
patient will be asked to consent to secondary use of the genetic material for additional 
studies at this time. They may refuse to consent for secondary use, in which case 
excess sample will be destroyed. 
The patient will also be informed that they will not be notified of the results of the 
study nor will they receive compensation for their participation. Each patient in 
responsible for the cost of the erlotinib and any necessary follow-up care, as these are 
not study-related but are costs of standard of care. The study will be responsible for the 
costs of the biopsy and genetic testing of the biopsied material. 
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7. Research Procedures  
All procedures for this protocol are standard and have been previously completed 
by clinicians or scientific staff as outlined. If the patient has any medical issues during 
the study or does not comply with treatment parameters, they will be removed from 
study and standard of care will be initiated. 
Day 0:  Evidence of recurrence or relapse by Drs. Rinehart or Arnold. Referral to Dr. 
Black.  Dr. Balko will witness, consent, and schedule core biopsy. 
Day 1-3: CT-guided biopsy by Dr. Maybody. Prescription for erlotinib by Dr. Rinehart or 
Dr. Arnold.  Biopsy in RNAice (-20C), sample for H&E to Pathology (Balko). 
Day 4-7: Prepare RNA and DNA from biopsy and if remaining tissue, store at -20C 
(Balko).   RNA to microarray core facility (Dr. Kuey-Chu Chen, Director)  DNA to PCR 
amplification of EGFR exons for extraction and sequencing (Balko, AGTC core) 
Day 8-14: Collection of microarray and sequencing data (Balko)  Evaluation of molecular 
data ie. time to collection and analysis (Balko and Black) 
Month 1-12:  Evaluation of patient response by RECIST criteria (Rinehart or Arnold)  
Compliance follow-up every month (months 1-3), and every 3 months thereafter (Balko) 
All procedures for this protocol are standard and have been previously completed 
by clinicians or scientific staff as outlined. If the patient has any medical issues during 
the study or does not comply with treatment parameters, they will be removed from 
study and standard of care will be initiated. 
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Study Timetable: 
Procedure 
P
R
E 
Day Month 
0
1- 
3 4 5 6 7
8 - 
14 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
PRE-STUDY 
ASSESSMENTS                                       
Decision to Treat with 
Erlotinib X                        
STUDY-INITIATION 
ASSESSMENTS                                       
Eligibility Criteria   X                      
Consent   X                      
Concomitant Medication 
Record   X                      
Patient Compliance 
Record   X                      
Biopsy Scheduling   X                      
BIOPSY AND 
TREATMENT                                       
CT-guided Core Needle 
Biopsy     X                    
Patient Monitoring     X                    
Begin Erlotinib Treatment     X                    
LAB/STATISTICAL 
ASSESSMENTS                                       
RNA and DNA purification       X                   
EGFR Exon 18-21 
Amplification        X                  
Microarray hybridization 
(UK Core)        X                  
DNA Sequencing (UK 
Core)         X                 
Microarray Predictive 
Analysis           X              
DNA Mutational 
Assessment           X              
FOLLOW-UP 
ASSESSMENTS                                       
Pharmacy Compliance 
Follow-up                 X      X      X 
Response, Survival 
Follow-up (RECIST)                  X X     X     X     X 
 
8. Resources 
Markey Cancer Center has solicited funds from the Lexington Foundation for Dr. 
Esther P. Black to complete this feasibility study from November 2006 to October 2007. 
The funding will only pay the costs of the CT-guided biopsy, genetic tests, and the salary 
of the College of Pharmacy graduate student responsible for the study. There are no 
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additional costs for storage of samples. No funding in provided for counseling or ancillary 
care for the patients enrolled in the study. There is no funding available outside for 
outsourcing communication specialists for the patients. 
9. Potential Risks 
Physical risks include those associated with CT-guided biopsy.  The most 
common complications of percutaneous lung biopsy are pneumothorax (collapse of lung) 
and bleeding.  Pneumothorax occurs in up to 30% of cases the majority of which are self 
limited and need no interventions. Of all biopsy induced pneumothraces about 5-10% 
will continue to enlarge some of which will require chest tube placement. Chest tubes 
are small bore (8 french) plastic catheters placed under CT guidance on the same 
biopsy session. Patients who receive chest tube are required to be admitted to hospital 
for an overnight observation. The vast majority of chest tubes can be removed the next 
day if the hole in pleura created by biopsy is sealed (what is called absence of “air 
leake”). In an extremely small number of patients the chest tube has to remain in place 
for a few days till “air leake” is resolved. These patients are required to stay in hospital 
for as long as they carry a chest tube.  
It is recommended that patients who have undergone needle biopsy of lung not 
to fly for 48 hours post procedure. Pressurized cabin environment can potentially cause 
pneumothorax in these patients.  
Bleeding occurs in 2-4% of cases the majority of which are self limited and need 
no interventions. In extremely rare cases angiography and embolization may be 
required.  
Because the results of the study will not be shared with the patient, the 
physicians, or insurance providers there is likely no social or psychological risk to the 
patient. The genetic tests performed will not provide information about known hereditary 
disease and are therefore not a risk for the patient 
10. Safety Precautions 
The CT- guided biopsy provides only the necessary amount of tissue for the 
study with manageable risks for patient. The patient will be observed for several hours 
following the biopsy to monitor for adverse events, such as pneumothorax. Further 
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management of side effects or adverse events will be according to standard of care for 
each complication and may include hospitalization, chest tube insertion, monitoring in an 
intensive care unit, intubation, or other supportive care as deemed necessary by the 
treating physician.  
Stopping rules for adverse events: 
Anticipated complication rates for lung biopsy for this study include approximately 
30% with pneumothorax and 2% with bleeding; the majority of these being self-limited 
and requiring no intervention.  In the worst-case (conservative) scenario that these will 
occur independently, a stopping rule is designed using a composite complication rate of 
32%.  Patients will be closely monitored for these complication rates.  The protocol will 
be stopped if sufficient evidence exists suggesting that among patients receiving lung 
biopsy, the true incidence of pneumothorax or bleeding exceeds 32%.   Sufficient 
evidence will be taken to make an estimate whose lower limit to the corresponding one-
sided 90% confidence interval exceeds 32%, and these estimates will be made after 
every 5th enrolled patient that is evaluable for this phase of the protocol.  Operationally, 
any of the following observed ratios would lead to exceeding such a limit (ie. require 
stopping the study due to a safety concern):   This will occur if 3 or more of the first 5; 6 
or more of the first 10;  8 or more of the first 15; and 10 or more of the first 20 patients 
enrolled experience either pneumothorax or bleeding  complications as defined above.  
If the true probability of complication development is 32%, the probability of stopping the 
study under these rules is roughly 6% after enrollment of 10 or more patients on the 
study.  If the true probability is as high as 60%, the probability of stopping after 10 
patients is approximately 65% and after 20 patients approximately 74%.  Thus, this 
stopping rule has reasonable properties from a probabilistic viewpoint.   
Stopping rules for serious adverse events: 
If any patients experience Grade 2 pneumothorax or Grade 2 thoracic bleeding 
(symptomatic and/or requiring intervention) after lung biopsy, the study will be put on 
hold pending review by the safety committee.  
Stopping rules for appropriate collection techniques:  
In order to minimize undue patient risk associated with loss of study benefit, a 
stopping rule for assessment of appropriate tissue collection techniques will be used.  It 
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is anticipated that at least 80% of enrolled subjects will contribute “viable” biospecimen 
material.  Patients will be monitored and the protocol will be stopped and re-evaluated in 
regard to obtaining biospecimens if the true rate of obtaining a ‘viable’ specimen is 
smaller than 80%.  Sufficient evidence will be taken to make an estimate whose upper 
limit of the corresponding one-sided 90% confidence interval is lower than 80%.   
Monitoring will occur after every 5th patient is enrolled in the study.  Operationally, any of 
the following observed ratios would lead to stopping the study to re-evaluate the method 
for obtaining the biospecimens :  The upper 90% CI will be lower than 80% when no 
more than 2 (2 or less) out of the first 5; no more than 6 (6 or less) of the first 10;  no 
more than 9 (9 or less) of the first 15; or no more than 13 (13 or less) of the first 20 
enrolled contribute a ‘viable’ amount of lung biospecimen.  If the true rate of obtaining a 
‘viable’ biospecimen is as poor as 50%, then this rule will result in a 50% probability of 
stopping the study after 5 patients have been enrolled and an 83% probability of 
stopping after 10 patients have been enrolled.  If the true rate is 80%, then this rule will 
result in a 5.7% chance of stopping after 5 patients have been enrolled, and a 12% 
chance of stopping after 10 patients have been enrolled.  Thus, this stopping rule has 
reasonable properties from a simple probabilistic viewpoint. 
Protection of privacy: 
All sample information will be de-identified and the matching patient information 
will be kept in a separate password-protected document to be accessed only by the 
principle investigator, Dr. E. Penni Black, PhD. No data will be released to the patient, 
the physician or insurance providers to protect confidentiality. No treatment decision will 
be based on the results of the molecular tests. 
11. Benefit v. Risk 
There is no direct benefit to patient of the results of this study, but the information 
achieved in the study may lead to an advancement of knowledge in individualizing 
treatment of non-small cell lung cancer patients. 
The patient may risk injury due to the CT-guided biopsy and/or may have an 
adverse reaction to the erlotinib. 
12. Available Alternative Treatments 
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The only alternative treatment is for the patient to not participate in the study.  
Since the study design is observational and does not include treatment intervention, the 
patient will continue to receive erlotinib as determined by the patient and their oncologist 
until progression. 
13. Research Materials, Records, and Privacy 
Initially, medical records will be reviewed to obtain patient information (i.e. age, 
sex, race, smoking history, histology or previous treatment). Samples will be de-
identified such that only Dr. Black will retain a record of patient clinical information. 
The samples (DNA and RNA) will be stored in a locked sub-zero freezer in 
locked room in the College of Pharmacy. If patients consent to a secondary study, the 
de-identified samples may be used for further testing but there will be no need for 
additional patient data. 
For insuring privacy, neither patient, physician nor insurance provider will be 
informed of outcome of molecular testing. No treatment decision will be made with the 
molecular data and patients may withdraw from the study at any time. 
If the study is published, no identifying patient information will be published. 
14. Confidentiality 
As described above, de-identified patient data will be kept only by Dr. Black; 
samples will only be available to Drs. Black and Balko. Biopsy samples that are unused 
will be destroyed after 6 months. Nucleic acid samples (RNA and DNA) will be retained 
in a sub-zero freezer in lab of Dr. Black with no patient identifier. 
Data sharing may be arranged following publication of initial study as needed. No 
names or clinical data will be published. 
15. Payment 
CT- guided biopsy and genetic testing will be paid from the funds from the 
granting agency.  
16. Costs to Subject 
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The patient or the patient’s insurance provider will be responsible for the costs of 
the erlotinib and any necessary follow-up care. 
17. Data and Safety Monitoring  
The CT-guided biopsy is defined as greater-than-minimal risk. As such, each 
patient will be monitored by medical staff for several hours following the procedure. Each 
patient will be evaluated monthly by Dr. Rinehart or Arnold following prescription of 
erlotinib for assessment of compliance and safety. 
18. Subject Complaints 
The consent form contains phone numbers for Dr. Black and for the Office of 
Research Integrity for the purpose of monitoring complaints from the enrolled subjects 
19. Research Involving Non-English Speaking Subjects or Subjects from a Foreign 
Culture 
Given the small size of the study, we do not anticipate enrolling non-English 
speaking subjects.  Furthermore, since this study does not provide patient-specific 
benefit, and therefore no loss of benefit will occur by excluding non-English speaking 
patients. 
20. HIV/AIDs 
N/A 
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APPENDIX III: PROTOCOL FOR PROSPECTIVE CLINICAL TRIAL 
A Phase I Feasibility Study of a Multivariate Genomic Predictor of Erlotinib Benefit 
in 2nd or 3rd line Non-Small Cell Lung Cancer 
Principal Investigator: 
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1.0 INTRODUCTION 
The introduction of molecular profiling into medical practice has yet to be realized on a 
clinically useful basis.  The literature abounds with a number of basic science efforts to 
describe genome-wide expression patterns that characterize particular phenotypes.  
Oncology is an area of practice that could observe marked benefits in guiding therapies 
by such techniques.  While microarray technology remains an expensive tool, the 
extensive costs of new cancer treatments demand effective methods to predict patients 
who will benefit from such resources and to triage those not likely to respond to 
alternative empiric regimens.   
Erlotinib is a novel FDA-approved tyrosine kinase inhibitor which has been shown to 
offer survival advantages in 2nd and 3rd line non-small cell lung cancer therapy.  
However, there are substrata of the population which clearly exhibit improved responses 
and survival.  Our lab has conducted extensive in-vitro experiments to characterize a 
genomic expression pattern distinctive of sensitivity to inhibitors of EGFR.  We have 
combined this pattern with multivariate statistical methods with the ultimate goal of 
implementation in the clinical setting.  We hypothesize that use of this methodology 
(biopsy of lung tumor tissue, molecular analysis, and predictive analysis) will be a 
feasible approach to guiding 2nd line therapy in NSCLC.  In order for the approach to be 
useful, we will assay our ability to retrieve the appropriate amount of biological material 
(RNA and DNA) from CT-guided core needle biopsy.  We will also attempt to complete 
the methodology in a 2-week window following recurrence.  We have chosen a period of 
2 weeks as a reasonable amount of time to delay initiation of second-line care after 
consultation with UK oncologists.  Future studies will further confirm the usefulness of 
our genomic analysis in determining erlotinib candidates and improving survival in 2nd 
line NSCLC therapy. 
2.0 SPECIFIC AIMS 
To evaluate the feasibility of molecular profiling using genomic data in 2nd line NSCLC 
therapy, we will examine the following specific aims: 
Determine the amount of tissue and biological material (RNA and DNA) acquired by core 
needle biopsy of primary non-small cell lung cancer tumors 
Determine the length of time needed to perform computed tomography (CT) - guided 
core-needle biopsy, isolate biological material, and perform molecular analysis of 
erlotinib sensitivity in NSCLC patients 
Generate preliminary data on the usefulness of a genomic classifier of erlotinib response 
in predicting erlotinib response and/or survival. 
3.0 BACKGROUND AND PRELIMINARY DATA  
3.1 Current therapy paradigm in NSCLC 
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Lung cancers account for 30% of cancer-related deaths and are the most common 
cause of cancer-related mortality in the United States.  Unfortunately, the 
Commonwealth of Kentucky leads the nation in incidence and mortality due to lung 
cancer [1].  The majority of patients are diagnosed with NSCLC that is not surgically 
resectable, leaving systemic chemotherapy as their main treatment option. Platinum 
based doublets are utilized in front-line therapy with reasonable efficacy.  Recently, 
bevacizumab has been added to platinum-containing doublets and has shown a survival 
improvement compared to chemotherapy alone in non-squamous histologies [2]. 
Unfortunately, many patients do not respond to initial treatment or relapse soon after 
cessation of chemotherapy. For patients with a performance status > 2, treatment with a 
single agent is the standard of care for 2nd line therapy.  As single agents, docetaxel 
and erlotinib have all been shown to improve survival compared to best supportive care 
and pemetrexed has been proven to be equally effective as docetaxel. Gemcitabine, 
which is approved as a first line therapy, has significant activity as a single agent in 
second line therapy. As second line therapy, these agents have been shown to generate 
responses in approximately 10 percent of patients and prolong survival by approximately 
3 months [3-6].  As such, patients who respond to therapy have a longer survival than 
those who do not respond, and the median duration of response ranges from 4-6 months 
while less than 30% have responses that last more than a year.   
3.2 Erlotinib in 2nd or 3rd line therapy 
While many patients experience toxicity with commonly used chemotherapeutic agents, 
erlotinib, an orally available epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor (TKI), results in very low rates of grade 3-4 toxicity [7, 8].  Erlotinib represents a 
novel class of compounds shown in clinical studies to improve survival over best 
supportive care when used as single agent in second-line therapy for NSCLC.  
Erlotinib monotherapy in patients who received prior platinum therapy resulted in 
objective responses in only 13% and stable disease in approximately 30% of patients [8, 
9].   Importantly, the cost of erlotinib is exceedingly high.  The University of Kentucky is 
contracted to obtain a single month’s supply the typical daily dose (150mg daily) for 
approximately $1650 (~ $55/day).  The actual cost to patient would well exceed this 
mark.  This fact underscores the importance of developing efficacious strategies for 
identifying those who will benefit a priori. 
No added benefit of EGFR inhibiting agents was found when combined with 
chemotherapy despite preclinical evidence suggesting otherwise [10, 11]. A recent 
review analyzed clinical and molecular characteristics that predict responses to erlotinib 
in a large clinical trial show that response rates were more than double in EGFR 
expressing patients (versus non-EGFR expressers), EGFR amplification (versus no 
amplification), EGFR mutation (versus wild type), female gender (versus male), 
adenocarcinoma (versus all others), and non-smokers (versus current and former 
smokers) [12].  It appears none are mutually exclusive. Furthermore, treatment decisions 
based on single parameters alone encompass only a modest percentage of responders. 
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Likewise, gefitinib, an FDA-restricted EGFR tyrosine kinase inhibitor has the same 
mechanism of action as erlotinib.  Studies evaluating gefitinib responders suggest that 
molecular analysis can identify patients with greater than a 90% chance of responding to 
treatment [13].  Patients that exhibit response to EGFR-targeted agents will frequently 
harbour a mutation in exon 19 or 21 of EGFR [14, 15].  
3.3 Genomic microarray data and multivariate statistical methods as a 
predictor of response to erlotinib therapy 
Clinical and pre-clinical studies strongly suggest that a patient’s tumor bears a molecular 
signature that can be predictive of response to targeted therapies [16].  We 
hypothesized that a methodology that utilized a multi-gene molecular signature would be 
better suited than any single parameter in identifying responders to EGFR TKI. Our 
recent work identified a 180-gene expression signature of EGFR TKI response, which 
we have combined with predictive statistical analysis that can classify drug sensitivity in 
lung adenocarcinomas (Balko et al, in Submission).  Data from our laboratory suggests 
that use of this classification tool can identify responding patients a priori more 
effectively than single parameters alone.   
Using DNA content analysis, we determined erlotinib sensitivity in NSCLC cell lines.  
Using a genomic signature generated from a training set (5 of the 10 cell lines) and 
diagonal linear discriminant analysis, we correctly predicted sensitivity to first generation 
(reversible) EGFR TKIs in 90% of samples according to their sensitivity (Table 1).  
Importantly, predicting on mutational status alone yields only 80% accuracy.  
Furthermore, the predictor identified cell lines sensitive to newer-generation irreversible 
inhibitors (i.e. EKB-569) with 100% accuracy.   These compounds are currently under 
clinical development. 
We have also applied this algorithm to genomic data from NSCLC tumors, and have 
found that approximately 70% of adenocarcinomas predict as sensitive.  In these 
datasets, however, the patients were not treated with erlotinib or gefitinib and therefore 
response can not be ascertained. 
4.0 STUDY SIGNIFICANCE AND RATIONALE  
Using predictive measures of response, we can avoid patient exposure to toxic and 
ineffective chemotherapeutic agents. Thus, the approach has the potential to identify 
patients that are sensitive to EGFR TKI resulting in marked gains in overall survival, 
reductions in toxicity, and improved cost-benefit ratios in second line therapy of NSCLC. 
Further, those who are not predicted to respond to erlotinib therapy could be treated with 
alternative regimens to which they may be more likely to see benefit.   We anticipate that 
the use of genomic approaches to select all erlotinib responders, not just those 
harbouring EGFR mutations, will provide the most effective means for predicting 
sensitivity in individual tumors.  
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4.1 Use of an invasive procedure for research purposes 
The primary goal of this study is to determine if the biological analyses can be conducted 
and a test result can be achieved within 14 days of detection of recurrence. The 
secondary purpose of the study is to determine if the biological assay can predict 
sensitivity to erlotinib, and therefore further microarray and statistical analysis is only of 
benefit in cases where response data to erlotinib can be directly obtained, and will thus 
be conducted using tissue from recurrent lung cancer patients who have consented to 
erlotinib treatment.   The Markey Cancer Center banks frozen resected tumor specimens 
which we have previously utilized to determine minimum amounts of lung tissue 
necessary to obtain sufficient amounts of RNA and DNA (IRB # 05-1025-X1G) and to 
conduct microarray analysis.  The primary goal of this research, however, would 
preclude use of frozen specimens, since the test procedure will ultimately be conducted 
using biopsy core specimens following recurrence.  
Due to the infrequency of erlotinib use in the past at University of Kentucky, we have not 
been successful in identifying banked and frozen specimens from patients who were 
later treated with erlotinib and to whom response data is directly available.  Further, 
identification of patients who are to be treated with erlotinib and who have previously 
undergone surgical resection at UK with their tissues banked would result in a very low 
enrollment rate, and second, the molecular signature of the tumor would hypothetically 
be confounded by the effects of chemotherapy treatment between tissue extraction and 
erlotinib therapy.   These reasons are presented in justification of using an invasive 
biopsy procedure for the research protocol.   
4.2 Determination of RNA and DNA yield from core-needle biopsy of 
NSCLC tumors 
In order for our predictive approach to be feasible and useful in clinical situations where 
surgical biopsy of tumor specimens is not indicated, we will need to determine if non-
surgical biopsy (i.e. CT-guided core needle biopsy) will yield appropriate amounts of 
tumor RNA and DNA to perform molecular analyses.    
We have determined that gross tumor specimens yield approximately 250ng RNA / mg 
tissue.  In laboratory processed samples, the minimum yield was 150ng/mg tissue.  
Microarray analysis requires at least 1.5 ug of acceptable quality total RNA.  Based on 
these parameters we estimate a requirement of approximately 10 mg of tumor tissue 
from a core needle biopsy for RNA extraction to produce sufficient quantity in the 
majority of samples.   
Additionally, we will require 3-4 mg of tumor tissue for DNA extraction to perform 
sequencing of EGFR exons 18-21.  This brings the total tissue required to approximately 
14 mg tissue.  It will be necessary to assess our ability to achieve this goal in at least 
80% of cases to make the approach feasible.  We do not have estimated weights of core 
needle specimens, although we anticipate that 1-3 specimens will meet our tissue weight 
requirements. 
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4.3 Determination of time required to complete analyses 
As NSCLC patients are diagnosed with recurrence, time to initiate treatment is clearly an 
issue.  Delay of treatment can presumably lead to progression of malignancy and 
worsening of disease and outcome.  Thus, it is imperative that we assess our ability to 
perform the predictive analyses in as short of a period as possible.  The biopsy 
procedure presents a particular obstacle since the patient must schedule time for the 
procedure promptly and return within 2-3 days.  Based on communication with 
oncologists, we have determined that a 14 day window following recurrence detection is 
not deemed likely to affect patient outcome.  For the purposes of this study, since all 
included patients will already be decidedly placed on erlotinib therapy and we have not 
yet proven the value of the test, we will not delay treatment to perform analysis.  Instead 
we will assess our ability to schedule biopsy, isolate biological material, and perform 
predictive analyses within a simulated situation. 
4.4 Generation of preliminary data for efficacy of the predictive analysis 
in classifying patients by survival 
While this study is not statistically powered to detect improved survival between those 
patients predicted to respond and those patients predicted to be resistant, generation of 
preliminary data will allow us to evaluate trends in outcomes, and to determine whether it 
is useful to pursue our analysis in a larger interventional study. 
5.0 PATIENT SELECTION 
5.1 Inclusion Criteria 
We will enroll the first 20 NSCLC patients who meet eligibility criteria without regard to 
race, gender, or age.  All enrolled patients must meet each of the following inclusion 
criteria: 
• Prior decision by both the physician and patient to initiate erlotinib therapy 
• Previous treatment with front line systemic therapy (i.e. erlotinib will be used as 
2nd line or higher therapy) 
• Expected survival as determined by their oncologist of ≥ 3 months 
• Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 
• Patient must have a tumor which is capable of being biopsied by CT-guided core-
needle biopsy (CNB) without evidence of excess risk, as determined by the 
interventional radiologist (Dr. Majid Maybody, MD) 
• Willing to undergo the CT-guided biopsy procedure, and assume risks associated 
with the procedure 
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5.2 Exclusion Criteria 
Exclusion criteria include presence of any of the following: 
• an ECOG performance status of ≥ 3 
• Patients at high risk for bleeding episodes, including thrombocytopenia 
(PLT<50,000), prolonged prothrombin time, or known bleeding disorders 
• Patients taking oral anticoagulants (i.e. warfarin), as these cannot be 
discontinued in a reasonable amount of time to allow for normalization of INR prior to 
undergoing the biopsy procedure. 
6.0 OVERALL DESIGN AND ENDPOINTS 
6.1 Study Design 
This study will be performed as a pilot feasibility study evaluating the ability to achieve 
several criteria which are imperative to completion of a larger well-powered study 
evaluating the ability of predictive analyses to guide second line NSCLC therapy.   
All enrolled subjects will be patients about to initiate 2nd or 3rd line therapy with erlotinib 
for NSCLC recurrence.  We will assess our ability to perform a simulated intervention in 
an appropriate amount of time.  This intervention would require scheduling and 
performing CT-guided core needle biopsy, tissue procurement and extraction of 
biological material, DNA sequencing and microarray analysis, and prediction of 
sensitivity based on analyses outcomes. 
A secondary purpose of this study is to generate preliminary data on the accuracy of the 
molecular signature to predict response in a clinical situation. 
All patients will be treated with erlotinib per standard of care.  We will follow response 
and survival of patients and correlate these parameters with molecular predictions of 
sensitivity. 
6.2 Endpoints 
• The mass of RNA extracted from CT-guided core needle biopsy of primary or 
metastatic lung cancers 
• The mass of DNA extracted from CT-guided core-needle biopsy of primary or 
metastatic lung cancers 
• The time taken, in days, from enrollment of patient in the trial to completion of 
DNA sequence analysis as well as predictive genomic analysis 
• Response rate to erlotinib therapy, as measured by RECIST criteria 
• 1-year survival 
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7.0 METHODS 
7.1 Patient Consent 
Informed consent will be carried by Justin Balko, PharmD. During administration of 
informed consent, the patient will be allowed to read or have read to them the document 
describing the study as a feasibility study to initiate the process for individualized care of 
recurrent lung cancer patients. Each patient will be informed that this is a genetic test 
that requires a biopsy sample of the tumor. A concomitant medication form will be 
completed for the patient to ensure that the patient is not receiving any medications 
which may affect the efficacy of erlotinib (CYP450 3A4 substrates, inhibitors, inducers) 
and therefore represent a confounding variable.  The patient will be informed that their 
compliance will be monitored by routine calls to their designated pharmacy by Justin 
Balko.  Information regarding concomitant meds and pharmacy usage will be recorded 
and this information will be kept secured along with any other identifiable information by 
the PI as per the protocol.  If not used completely, the tumor sample will be banked for a 
6-month period of time and then destroyed. The DNA and RNA samples will be stored in 
a locked sub-zero freezer and de-identified from the patient data. The patient will be 
asked to consent to secondary use of the genetic material for additional studies at this 
time. They may refuse to consent for secondary use, in which case excess sample will 
be destroyed. 
7.2 CT-guided core needle biopsy 
At the time of consent, the patient will be referred to the radiology department in order to 
schedule a time for the core needle biopsy procedure.  The procedure will be preferably 
scheduled within 3 days of the consent process.   
All patients should have recent blood work for coagulation profile not older than two 
weeks including platelet count, INR and aPTT before the procedure. The minimal 
acceptable coagulation indices for core biopsy include a platelet count of at least 50,000, 
INR of less than 1.5 and aPTT of less than 34 seconds. Admission may be planned for 
those patients with laboratory values suggesting abnormal coagulation for corrective 
measures to be taken prior to procedure. The procedure is performed under conscious 
sedation with local anesthesia. Conscious sedation consists of intravenously 
administered fentanyl and midazolam. A sedation nurse constantly monitors patient’s 
vital signs during procedure.  For the purposes of sedation, all patients should be fasting 
for 8 hours before procedure. In each case, previous imaging studies are reviewed to 
determine the best approach for percutaneous biopsy. Patients are placed prone or 
supine in the CT scanner depending on the location of the lesion, and axial CT images 
are obtained through the thorax to localize the lesion. Intravenous contrast material is 
not routinely administered for this procedure. After an appropriate skin entry site is 
selected, a radiopaque marker is placed on the skin overlying the lesion with use of the 
axial laser light and confirmed by CT fluoroscopic imaging. The marker is removed and a 
mark is placed on the skin with an indelible pen. The depth of the lesion and the angle of 
the access trajectory are calculated on the scanner monitor in the plane of biopsy. The 
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skin site is prepared and draped in standard surgical fashion with povidone iodine. The 
skin access site is locally anesthetized with 1% lidocaine. A small dermatotomy is made 
with a no. 11 scalpel. A coaxial technique is used to reduce the number of pleural 
passes required thus minimizing the risk of pneumothorax. The lesion is accessed by a 
17 gauge calibrated introducer needle. Proper positioning of the introducer needle is 
confirmed by CT fluoroscopy. The core biopsy samples are taken by an18-gauge 
calibrated automated cutting device through the introducer needle. Upon completion of 
procedure, CT fluoroscopic images of the biopsy area are taken to evaluate the 
presence of pneumothorax and hemorrhage. All patients will also be evaluated by CT 
scan of chest or chest x-ray two hours post procedure. In this two hour period all patients 
are monitored by the sedation nurse. In case of complications proper action will be taken 
immediately. These may include manual aspiration of pneumothorax, chest tube 
placement or angiography. Patients may be admitted if they undergo chest tube 
placement or angiography. All patients will be fully recovered from conscious sedation 
prior to discharge. 
1-4 core specimens will be acquired.  One adjacent sample will be taken to 
histopathology under the care of Kim Absher, MD to be assessed for tumor content.   
The remaining samples will be deposited into 15 mL snap-cap Falcon tubes containing 
250uL RNA-later solution.  These tubes will be pre-weighed on a Fischer Scientific 
digital AccuSeries balance (room 441, College of Pharmacy.   The samples will be 
maintained at room temperature and taken to the laboratory of Esther Black, Ph.D in a 
sealed lockable container.  Tubes will be reweighed to determine the weight of the tissue 
specimens.   Total specimen weight and number of cores will be recorded.  Only 
samples in which the adjacent core was found the histopathologist to have 50% or more 
malignant tissue will be processed further.   
7.3 Patient safety measures 
7.3.1 Diagnostic labs 
All patients will have diagnostic labs drawn prior to undergoing core-needle biopsy.  
Prothrombin time, INR, and CBC will be determined to ensure minimal risk of bleeding 
during the procedure. 
7.3.2 Selection of biopsy site 
Biopsy site will be selected by the oncologist and/or diagnostic radiologist with the 
purpose of minimizing risk to the patient.  Sites within the lung which are considered to 
be sub-optimal for biopsy due to risk of complications will not be biopsied.  Pulmonary or 
extra-pulmonary sites will be used in such a scenario, provided the site is determined to 
carry less of a risk to the patient.  Good medical judgement will be used by the clinicians 
in determining the biopsy site. 
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7.3.3 Core needle biopsy good medical practices 
The most common complications of percutaneous lung biopsy are pneumothorax 
(collapse of lung) and bleeding.  However, not all patients on this protocol will receive 
biopsy of lung nodules, and may undergo biopsy of tissues with lower associated risk.  
Pneumothorax occurs in up to 30% of cases the majority of which are self limited and 
need no interventions. Of all biopsy induced pneumothoraces about 5-10% will continue 
to enlarge some of which will require chest tube placement. Chest tubes are small bore 
(8 french) plastic catheters placed under CT guidance on the same biopsy session. 
Patients who receive chest tube are required to be admitted to hospital for an overnight 
observation. The vast majority of chest tubes can be removed the next day if the hole in 
pleura created by biopsy is sealed (what is called absence of “air leake”). In an 
extremely small number of patients the chest tube has to remain in place for a few days 
till “air leake” is resolved. These patients are required to stay in hospital for as long as 
they carry a chest tube.  
It will be recommended that patients who have undergone needle biopsy of lung not to 
fly for 48 hours post procedure. Pressurized cabin environment can potentially cause 
pneumothorax in these patients.  
Bleeding occurs in 2-4% of cases the majority of which are self limited and need no 
interventions. In extremely rare cases angiography and embolization may be required.  
Because the results of the study will not be shared with the patient, the physicians, or 
insurance providers there is likely no social or psychological risk to the patient. The 
genetic tests performed will not provide information about known hereditary disease and 
are therefore not a risk for the patient 
The patient will be observed for several hours following the biopsy to monitor for adverse 
events, such as pneumothorax. Further management of side effects or adverse events 
will be according to standard of care for each complication and may include 
hospitalization, chest tube insertion, monitoring in an intensive care unit, intubation, or 
other supportive care as deemed necessary by the treating physician.   
7.3.4 Stopping rules 
7.3.4.1  Lung biopsy complications 
Anticipated complication rates for lung biopsy for this study include approximately 30% 
with pneumothorax and 2% with bleeding; the majority of these being self-limited and 
requiring no intervention.  In the worst-case (conservative) scenario that these will occur 
independently, a stopping rule is designed using a composite complication rate of 32%.  
Patients will be closely monitored for these complication rates.  The protocol will be 
stopped if sufficient evidence exists suggesting that among patients receiving lung 
biopsy, the true incidence of pneumothorax or bleeding exceeds 32%.   Sufficient 
evidence will be taken to make an estimate whose lower limit to the corresponding one-
sided 90% confidence interval exceeds 32%, and these estimates will be made after 
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every 5th enrolled patient that is evaluable for this phase of the protocol.  Operationally, 
any of the following observed ratios would lead to exceeding such a limit (ie. require 
stopping the study due to a safety concern):   This will occur if 3 or more of the first 5; 6 
or more of the first 10;  8 or more of the first 15; and 10 or more of the first 20 patients 
enrolled experience either pneumothorax or bleeding  complications as defined above.  
If the true probability of complication development is 32%, the probability of stopping the 
study under these rules is roughly 6% after enrollment of 10 or more patients on the 
study.  If the true probability is as high as 60%, the probability of stopping after 10 
patients is approximately 65% and after 20 patients approximately 74%.  Thus, this 
stopping rule has reasonable properties from a probabilistic viewpoint.   
7.3.4.2 Serious lung tumor complications  
If any patients experience Grade 2 pneumothorax or Grade 2 thoracic bleeding 
(symptomatic and/or requiring intervention) after lung biopsy, the study will be put on 
hold pending review by the safety committee.  
7.3.4.3 Collection of viable tumor tissue  
It is anticipated that at least 80% of enrolled subjects will contribute “viable” biospecimen 
material.  Patients will be monitored and the protocol will be stopped and re-evaluated in 
regard to obtaining biospecimens if the true rate of obtaining a ‘viable’ specimen is 
smaller than 80%.  Sufficient evidence will be taken to make an estimate whose upper 
limit of the corresponding one-sided 90% confidence interval is lower than 80%.   
Monitoring will occur after every 5th patient is enrolled in the study.  Operationally, any of 
the following observed ratios would lead to stopping the study to re-evaluate the method 
for obtaining the biospecimens :  The upper 90% CI will be lower than 80% when no 
more than 2 (2 or less) out of the first 5; no more than 6 (6 or less) of the first 10;  no 
more than 9 (9 or less) of the first 15; or no more than 13 (13 or less) of the first 20 
enrolled contribute a ‘viable’ amount of lung biospecimen.  If the true rate of obtaining a 
‘viable’ biospecimen is as poor as 50%, then this rule will result in a 50% probability of 
stopping the study after 5 patients have been enrolled and an 83% probability of 
stopping after 10 patients have been enrolled.  If the true rate is 80%, then this rule will 
result in a 5.7% chance of stopping after 5 patients have been enrolled, and a 12% 
chance of stopping after 10 patients have been enrolled.  Thus, this stopping rule has 
reasonable properties from a simple probabilistic viewpoint. 
7.4 Extraction of biological material 
7.4.1 RNA 
RNA will be purified by incubating the tumor tissue in RNA-later overnight, at least 16 
hours at 4 C.  Tissue will be cut and weighed on ice (30mg max) and placed in a 1.5 mL 
Kontes tube.  100uL RLT buffer (+β –mercaptoethanol, Qiagen) will be added to the 
sample and the tissue will be disrupted with a Kontes tissue grinder.  500uL RLT buffer 
will then be added and the sample will be ground again.  The sample will then be loaded 
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into a Qiashredder (Qiagen) column per directions and centrifuged to homogenize the 
sample.  The sample will then be loaded onto a micro RNEasy prep column (Ambion) 
and RNA will be eluted per manufacturer directions. 
7.4.2 DNA 
DNA will be purified by incubating the tumor tissue in RNA-later overnight, at least 16 
hours at 4 C.  Tissue will be cut and weighed on ice (10 mg max) and then digested at 
least 5 hours at 50 C in digestion buffer (100mM Tris, 5mM EDTA,0.2% SDS, 200mM 
NaCl, 100mcg/mL).  Tubes will be vortexed vigorously for 1 minute, then centrifuged for 
15 minutes at 13K RPM.  Supernatant will be transferred to a new tube and DNA will be 
precipitated with 500uL isopropanol.  DNA will be pelleted with high speed centrifugation 
and the pellet will be washed in 70% ethanol.  The washed pellet will be resuspended in 
EB buffer (Qiagen) and quantified by UV spectrophotometry.  DNA will be used as 
template for amplification reactions of exons 18-21 DNA.  PCR products will be resolved 
on a 1% agarose gel and the appropriate DNA fragment will be excised and purified 
used Qiaquick Gel Extraction Kit columns (Qiagen).  Amplified DNA fragments will then 
be provided to the AGTC core facility along with sequence-specific primers for exons 18-
21. 
7.5 Core facility procedures 
7.5.1 Microarray 
Confirmation of RNA integrity, probe generation, and hybridization to U133A microarrays 
will be completed by the UKMC core array facility as per standard protocols. 
7.5.2 Sequencing 
DNA sequencing of exon 18-21 will be completed by the UK AGTC core facility per 
standard protocols. 
7.6 Predictive analyses 
Affymetrix  MASv5.0 data will be imported into R and the diagonal linear discriminant 
analysis script will be run on the sample, as well as two control samples.  The result will 
be recorded. 
7.7 Patient follow-up 
All patients will be monitored via monthly (Months 1-3) and 3 month (Months 6, 9, and 
12) chart review by Justin Balko, PharmD, a study co-investigator.  Data to be collected 
will include severe adverse effects (Grade 3/4), objective response, patient survival, and 
disease state measures (recurrence, progression, etc).   
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8.0  STUDY CALENDAR/TIME TABLE   
Procedure 
P
R
E 
Day Month 
0
1- 
3 4 5 6 7
8 - 
14 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
PRE-STUDY 
ASSESSMENTS                                       
Decision to Treat with 
Erlotinib X                        
STUDY-INITIATION 
ASSESSMENTS                                       
Eligibility Criteria   X                      
Consent   X                      
Concomitant Medication 
Record   X                      
Patient Compliance 
Record   X                      
Biopsy Scheduling   X                      
BIOPSY AND 
TREATMENT                                       
CT-guided Core Needle 
Biopsy     X                    
Patient Monitoring     X                    
Begin Erlotinib Treatment     X                    
LAB/STATISTICAL 
ASSESSMENTS                                       
RNA and DNA purification       X                   
EGFR Exon 18-21 
Amplification        X                  
Microarray hybridization 
(UK Core)        X                  
DNA Sequencing (UK 
Core)         X                 
Microarray Predictive 
Analysis           X              
DNA Mutational 
Assessment           X              
FOLLOW-UP 
ASSESSMENTS                                       
Pharmacy Compliance 
Follow-up                 X      X      X 
Response, Survival 
Follow-up (RECIST)                  X X     X     X     X 
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9.0 STATISTICAL CONSIDERATIONS AND DATA MANAGEMENT  
Formal statistical analysis will not be undertaken in this pilot feasibility trial.  However, all 
data collected will be recorded and evaluated, including variability and trends of data. 
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APPENDIX IV: 180-GENE SIGNATURE OF EGFR SENSITIVITY 
 
Probeset  Gene  Description  p‐value 
205891_at  ADORA2B  adenosine A2b receptor  1.65347E‐12 
213434_at  EPIM  epimorphin  2.03526E‐12 
211475_s_at  BAG1  BCL2‐associated athanogene  1.2089E‐11 
201716_at  SNX1  sorting nexin 1  1.3942E‐11 
219933_at  GLRX2  glutaredoxin 2  2.82157E‐11 
204513_s_at  ELMO1  engulfment and cell motility 1   2.92588E‐11 
203011_at  IMPA1  inositol(myo)‐1(or 4)‐monophosphatase 1  4.20475E‐11 
202743_at  PIK3R3 
phosphoinositide‐3‐kinase, regulatory subunit 3 
(p55, gamma)  4.51605E‐11 
204491_at  PDE4D  Phosphodiesterase 4D, cAMP‐specific   8.05036E‐11 
204000_at  GNB5 
guanine nucleotide binding protein (G protein), 
beta 5  8.7681E‐11 
204115_at  GNG11 
guanine nucleotide binding protein (G protein), 
gamma 11  1.02678E‐10 
218913_s_at  GMIP  GEM interacting protein  2.64411E‐10 
200994_at  IPO7  importin 7  2.65447E‐10 
202286_s_at  TACSTD2  tumor‐associated calcium signal transducer 2  2.75325E‐10 
209035_at  MDK  midkine (neurite growth‐promoting factor 2)  7.31553E‐10 
218995_s_at  EDN1  endothelin 1  7.75626E‐10 
219855_at  NUDT11 
nudix (nucleoside diphosphate linked moiety X)‐
type motif 11  8.77697E‐10 
209678_s_at  PRKCI  protein kinase C, iota  1.04253E‐09 
202501_at  MAPRE2 
microtubule‐associated protein, RP/EB family, 
member 2  2.31343E‐09 
212117_at  RHOQ  ras homolog gene family, member Q  3.22134E‐09 
206277_at  P2RY2  purinergic receptor P2Y, G‐protein coupled, 2  3.92313E‐09 
209295_at 
TNFRSF10
B 
tumor necrosis factor receptor superfamily, 
member 10b  4.33798E‐09 
205376_at  INPP4B 
inositol polyphosphate‐4‐phosphatase, type II, 
105kDa  4.50987E‐09 
206722_s_at  EDG4 
endothelial differentiation, lysophosphatidic 
acid GPCR,4  7.96715E‐09 
205673_s_at  ASB9  ankyrin repeat and SOCS box‐containing 9  1.24878E‐08 
201471_s_at  SQSTM1  sequestosome 1  1.34231E‐08 
204352_at  TRAF5  TNF receptor‐associated factor 5  1.46887E‐08 
206907_at  TNFSF9 
tumor necrosis factor (ligand) superfamily, 
member 9  1.57771E‐08 
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218150_at  ARL5  ADP‐ribosylation factor‐like 5  2.04888E‐08 
205459_s_at  NPAS2  neuronal PAS domain protein 2  2.22961E‐08 
205455_at  MST1R 
macrophage stimulating 1 receptor (c‐met‐
related tyrosine kinase)  2.45512E‐08 
202641_at  ARL3  ADP‐ribosylation factor‐like 3  2.78193E‐08 
201667_at  GJA1 
gap junction protein, alpha 1, 43kDa (connexin 
43)  2.86113E‐08 
210512_s_at  VEGF  vascular endothelial growth factor  2.90316E‐08 
212104_s_at  RBM9  RNA binding motif protein 9  5.42805E‐08 
200762_at  DPYSL2  dihydropyrimidinase‐like 2  5.43168E‐08 
221235_s_at  TGFBRAP1 
transforming growth factor, beta receptor 
associated protein 1  5.51367E‐08 
211302_s_at  PDE4B  phosphodiesterase 4B, cAMP‐specific   5.51731E‐08 
205080_at  RARB  retinoic acid receptor, beta  7.03586E‐08 
202266_at  TTRAP  TRAF and TNF receptor associated protein  7.2889E‐08 
205240_at  GPSM2 
G‐protein signalling modulator 2 (AGS3‐like, C. 
elegans)  8.30858E‐08 
213798_s_at  CAP1 
CAP, adenylate cyclase‐associated protein 1 
(yeast)  8.61121E‐08 
221819_at  RAB35  RAB35, member RAS oncogene family  8.9216E‐08 
207011_s_at  PTK7  PTK7 protein tyrosine kinase 7  9.78716E‐08 
204255_s_at  VDR  vitamin D (1,25‐ dihydroxyvitamin D3) receptor  1.1087E‐07 
208864_s_at  TXN  thioredoxin  1.34274E‐07 
209885_at  RHOD  ras homolog gene family, member D  1.50021E‐07 
201923_at  PRDX4  peroxiredoxin 4  1.6148E‐07 
204392_at  CAMK1  calcium/calmodulin‐dependent protein kinase I  2.24378E‐07 
203269_at  NSMAF 
neutral sphingomyelinase (N‐SMase) activation 
associated factor  2.59238E‐07 
205924_at  RAB3B  RAB3B, member RAS oncogene family  2.77173E‐07 
202853_s_at  RYK  RYK receptor‐like tyrosine kinase  3.45502E‐07 
202530_at  MAPK14  mitogen‐activated protein kinase 14  3.53556E‐07 
219936_s_at  GPR87  G protein‐coupled receptor 87  4.06845E‐07 
203665_at  HMOX1  heme oxygenase (decycling) 1  4.37988E‐07 
205926_at  IL27RA  interleukin 27 receptor, alpha  5.33484E‐07 
202105_at  IGBP1  immunoglobulin (CD79A) binding protein 1  6.14358E‐07 
213324_at  SRC 
v‐src sarcoma (Schmidt‐Ruppin A‐2) viral 
oncogene homolog (avian)  8.2585E‐07 
205709_s_at  CDS1 
CDP‐diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1  8.69007E‐07 
207303_at  PDE1C 
phosphodiesterase 1C, calmodulin‐dependent 
70kDa  9.11398E‐07 
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204484_at  PIK3C2B 
phosphoinositide‐3‐kinase, class 2, beta 
polypeptide  9.23963E‐07 
38269_at  PRKD2  protein kinase D2  9.25184E‐07 
211171_s_at  PDE10A  phosphodiesterase 10A  1.0636E‐06 
212757_s_at  CAMK2G 
calcium/calmodulin‐dependent protein kinase 
(CaM kinase) II gamma  1.08937E‐06 
202167_s_at  MMS19L  MMS19‐like (MET18 homolog, S. cerevisiae)  1.18954E‐06 
202932_at  YES1 
v‐yes‐1 Yamaguchi sarcoma viral oncogene 
homolog 1  1.24119E‐06 
209110_s_at  RGL2 
ral guanine nucleotide dissociation stimulator‐
like 2  1.343E‐06 
205055_at  ITGAE  integrin, alpha E   1.48098E‐06 
203910_at  PARG1  PTPL1‐associated RhoGAP 1  1.52987E‐06 
203388_at  ARRB2  arrestin, beta 2  1.59381E‐06 
212099_at  RHOB  ras homolog gene family, member B  1.76917E‐06 
204497_at  ADCY9  adenylate cyclase 9  1.78932E‐06 
208091_s_at 
DKFZP564
K0822  hypothetical protein DKFZp564K0822  1.81223E‐06 
213135_at  TIAM1  T‐cell lymphoma invasion and metastasis 1  1.84133E‐06 
203837_at  MAP3K5  mitogen‐activated protein kinase kinase kinase 5  1.89236E‐06 
206549_at  INSL4  insulin‐like 4 (placenta)  2.17123E‐06 
205880_at  PRKD1  protein kinase D1  2.29581E‐06 
211471_s_at  RAB36  RAB36, member RAS oncogene family  2.29859E‐06 
210058_at  MAPK13  mitogen‐activated protein kinase 13  2.44208E‐06 
40850_at  FKBP8  FK506 binding protein 8, 38kDa  2.88345E‐06 
208819_at  RAB8A  RAB8A, member RAS oncogene family  3.20502E‐06 
202203_s_at  AMFR  autocrine motility factor receptor  3.36339E‐06 
201431_s_at  DPYSL3  dihydropyrimidinase‐like 3  3.54374E‐06 
217976_s_at  DNCLI1 
dynein, cytoplasmic, light intermediate 
polypeptide 1  3.62385E‐06 
201097_s_at  ARF4  ADP‐ribosylation factor 4  3.81095E‐06 
203077_s_at  SMAD2 
SMAD, mothers against DPP homolog 2 
(Drosophila)  3.81843E‐06 
203081_at  CTNNBIP1  catenin, beta interacting protein 1  3.83717E‐06 
219357_at  GTPBP1  GTP binding protein 1  3.95215E‐06 
212255_s_at  ATP2C1  ATPase, Ca++ transporting, type 2C, member 1  4.40768E‐06 
218360_at  RAB22A  RAB22A, member RAS oncogene family  4.52284E‐06 
202545_at  PRKCD  protein kinase C, delta  4.62498E‐06 
203679_at  TMED1 
transmembrane emp24 protein transport 
domain containing 1  4.8425E‐06 
212070_at  GPR56  G protein‐coupled receptor 56  5.80992E‐06 
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204622_x_at  NR4A2 
nuclear receptor subfamily 4, group A, member 
2  5.98479E‐06 
202844_s_at  RALBP1  ralA binding protein 1  6.56314E‐06 
204547_at  RAB40B  RAB40B, member RAS oncogene family  6.59316E‐06 
219032_x_at  OPN3  opsin 3 (encephalopsin, panopsin)  7.0888E‐06 
212422_at  PDCD11  programmed cell death 11  7.19593E‐06 
203266_s_at  MAP2K4  mitogen‐activated protein kinase kinase 4  7.43037E‐06 
205220_at  GPR109B 
G protein‐coupled receptor 109B /// G protein‐
coupled receptor 109B  7.59026E‐06 
212181_s_at  NUDT4 
nudix (nucleoside diphosphate linked moiety X)‐
type motif 4  8.07236E‐06 
208072_s_at  DGKD  diacylglycerol kinase, delta 130kDa  8.08474E‐06 
218329_at  PRDM4  PR domain containing 4  8.32807E‐06 
210288_at  KLRG1 
killer cell lectin‐like receptor subfamily G, 
member 1  8.456E‐06 
206099_at  PRKCH  protein kinase C, eta  9.06238E‐06 
205481_at  ADORA1  adenosine A1 receptor  1.02958E‐05 
217839_at  TFG  TRK‐fused gene  1.04379E‐05 
202340_x_at  NR4A1 
nuclear receptor subfamily 4, group A, member 
1  1.11601E‐05 
212873_at  HA‐1  minor histocompatibility antigen HA‐1  1.24958E‐05 
202020_s_at  LANCL1 
LanC lantibiotic synthetase component C‐like 1 
(bacterial)  1.31667E‐05 
209666_s_at  CHUK  conserved helix‐loop‐helix ubiquitous kinase  1.3401E‐05 
200651_at  GNB2L1 
guanine nucleotide binding protein (G protein), 
beta polypeptide 2‐like 1  1.41049E‐05 
201401_s_at  ADRBK1  adrenergic, beta, receptor kinase 1  1.43031E‐05 
203185_at  RASSF2  Ras association (RalGDS/AF‐6) domain family 2  1.51579E‐05 
202401_s_at  SRF  serum response factor   1.58311E‐05 
203726_s_at  LAMA3  laminin, alpha 3  1.62925E‐05 
217496_s_at  IDE  insulin‐degrading enzyme  1.74448E‐05 
206118_at  STAT4  signal transducer and activator of transcription 4  1.80022E‐05 
208641_s_at  RAC1  ras‐related C3 botulinum toxin substrate 1   1.92909E‐05 
206044_s_at  BRAF 
v‐raf murine sarcoma viral oncogene homolog 
B1  1.98244E‐05 
205349_at  GNA15 
guanine nucleotide binding protein (G protein), 
alpha 15 (Gq class)  2.02216E‐05 
1007_s_at  DDR1  discoidin domain receptor family, member 1  2.03771E‐05 
58994_at  FLJ20241  putative NFkB activating protein  2.12741E‐05 
201895_at  ARAF 
v‐raf murine sarcoma 3611 viral oncogene 
homolog  2.13489E‐05 
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211499_s_at  MAPK11  mitogen‐activated protein kinase 11  2.17506E‐05 
203567_s_at  TRIM38  tripartite motif‐containing 38  2.2332E‐05 
210621_s_at  RASA1 
RAS p21 protein activator (GTPase activating 
protein) 1  2.24105E‐05 
219646_at  FLJ20186  hypothetical protein FLJ20186  2.24905E‐05 
218856_at  TNFRSF21 
tumor necrosis factor receptor superfamily, 
member 21  2.28896E‐05 
205147_x_at  NCF4  neutrophil cytosolic factor 4, 40kDa  2.44098E‐05 
215177_s_at  ITGA6  integrin, alpha 6  2.57288E‐05 
202564_x_at  ARL2  ADP‐ribosylation factor‐like 2  2.63409E‐05 
207630_s_at  CREM  cAMP responsive element modulator  2.73227E‐05 
212629_s_at  PKN2  protein kinase N2  2.80355E‐05 
201181_at  GNAI3  G protein alpha inhibiting activity polypeptide 3  2.8689E‐05 
207375_s_at  IL15RA  interleukin 15 receptor, alpha  2.91388E‐05 
201983_s_at  EGFR  epidermal growth factor receptor   2.95162E‐05 
205263_at  BCL10  B‐cell CLL/lymphoma 10  3.07237E‐05 
218186_at  RAB25  RAB25, member RAS oncogene family  3.17395E‐05 
207111_at  EMR1 
egf‐like module containing, mucin‐like, hormone 
receptor‐like 1  3.39972E‐05 
219290_x_at  DAPP1 
dual adaptor of phosphotyrosine and 3‐
phosphoinositides  3.51493E‐05 
206456_at  GABRA5 
gamma‐aminobutyric acid (GABA) A receptor, 
alpha 5  3.61634E‐05 
219537_x_at  DLL3  delta‐like 3 (Drosophila)  4.0124E‐05 
200923_at  LGALS3BP 
lectin, galactoside‐binding, soluble, 3 binding 
protein  4.18435E‐05 
201390_s_at  CSNK2B  casein kinase 2, beta polypeptide  4.2931E‐05 
211992_at  WNK1  WNK lysine deficient protein kinase 1  4.54378E‐05 
205992_s_at  IL15  interleukin 15  4.58957E‐05 
200991_s_at  SNX17  sorting nexin 17  4.73166E‐05 
221610_s_at  STAP2  signal‐transducing adaptor protein‐2  4.76896E‐05 
201508_at  IGFBP4  insulin‐like growth factor binding protein 4  4.83857E‐05 
219327_s_at  GPRC5C 
G protein‐coupled receptor, family C, group 5, 
member C  6.06081E‐05 
200985_s_at  CD59  CD59 antigen p18‐20   6.20756E‐05 
202315_s_at  BCR  breakpoint cluster region  6.45513E‐05 
200627_at  TEBP  unactive progesterone receptor  6.4762E‐05 
201288_at  ARHGDIB  Rho GDP dissociation inhibitor (GDI) beta  6.49524E‐05 
205854_at  TULP3  tubby like protein 3  7.0941E‐05 
204369_at  PIK3CA 
phosphoinositide‐3‐kinase, catalytic, alpha 
polypeptide  7.12144E‐05 
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202012_s_at  EXT2  exostoses (multiple) 2  7.25418E‐05 
206204_at  GRB14  growth factor receptor‐bound protein 14  7.62668E‐05 
201980_s_at  RSU1  Ras suppressor protein 1  7.72429E‐05 
210105_s_at  FYN  FYN oncogene related to SRC, FGR, YES  7.73012E‐05 
218589_at  P2RY5  purinergic receptor P2Y, G‐protein coupled, 5  8.07908E‐05 
202150_s_at  NEDD9 
neural precursor cell expressed, 
developmentally down‐regulated 9  8.37333E‐05 
212273_x_at  GNAS  GNAS complex locus  8.74661E‐05 
200833_s_at  RAP1B  RAP1B, member of RAS oncogene family  8.96348E‐05 
214724_at  DIXDC1  DIX domain containing 1  9.31294E‐05 
207643_s_at  TNFRSF1A 
tumor necrosis factor receptor superfamily, 
member 1A  9.56597E‐05 
219020_at  FLJ14249  HS1‐binding protein 3  9.74361E‐05 
203895_at  PLCB4  phospholipase C, beta 4  0.000101184 
204336_s_at  RGS19  regulator of G‐protein signalling 19  0.000106767 
217792_at  SNX5  sorting nexin 5  0.000113975 
210056_at  RND1  Rho family GTPase 1  0.000121576 
32137_at  JAG2  jagged 2  0.000123516 
205596_s_at  SMURF2  SMAD specific E3 ubiquitin protein ligase 2  0.000126851 
205698_s_at  MAP2K6  mitogen‐activated protein kinase kinase 6  0.000143749 
218931_at  RAB17  RAB17, member RAS oncogene family  0.000144453 
217763_s_at  RAB31  RAB31, member RAS oncogene family  0.000179924 
214875_x_at  APLP2  amyloid beta (A4) precursor‐like protein 2  0.000185475 
209184_s_at  IRS2  insulin receptor substrate 2  0.000193615 
204602_at  DKK1  dickkopf homolog 1 (Xenopus laevis)  0.000260573 
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APPENDIX V: SUPPLEMENTARY FIGURES FOR CHAPTER 4 
Figure V1: MEK inhibition reduces growth in EGFR-dependent NSCLC cell lines  
EGFR-dependent NSCLC were cultured in low-serum media for 24 hr before 
replacement with-full serum media (10% FBS) plus 10µM U0126 (grey).  An equal 
volume of DMSO was used as control (black).  Cell proliferation was measured by trypan 
blue exclusion at 0, 24, 48, and 72 hr after treatment.  Data were normalized to the 0 hr 
cell counts and is expressed as percent viable cells +/- standard deviation.   
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Figure V2: MEK inhibition reduces cell survival in EGFR-dependent NSCLC cell 
lines  
EGFR-dependent non-small cell lung cancer cell lines were cultured for 24 hr in low 
serum media (0.1% FBS) and subsequently treated with 10 µM U0126 (grey) or DMSO 
control (black) in fresh low serum media or full serum media (10% FBS).  Cell 
proliferation was measured by trypan blue exclusion at 0, 24, 48, and 72 hr after 
treatment.  The percent viable cells in each group were determined as described in 
‘Methods’.  Data represent mean +/- standard deviation. Data were analyzed by ANOVA 
for repeated measures, and p-values are reported in the inset. 
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